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   Foreword 
This thesis dissertation represents four years of research undertaken at 
the Animal Cell Technology Unit of the Instituto de Tecnologia Química e 
Biológica from the Universidade Nova de Lisboa/Instituto de Biologia 
Experimental e Tecnológica under the supervision of Dr. Paula Alves.  
This thesis intends to explore efficient and scalable bioprocesses for 
expansion and neuronal differentiation of stem cells in order to ensure 
the robust production of challenging cell-based products, namely human 
embryonic stem cells, for clinical application.  
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 ABSTRACT 
Over the last decade, human embryonic stem cells (hESCs) have 
garnered a lot of attention owing to their inherent self-renewal ability and 
pluripotency. These characteristics have opened opportunities for 
potential stem cell-based regenerative medicines, for development of 
drug discovery platforms and as unique in vitro models for the study of 
early human development.  
With “large-scale” applications of hESCs in the horizon, the 
establishment of scalable and well defined culture methods that must 
preserve their proliferation capacity and differentiation potential is still a 
challenge. Currently, 2-D culture systems are well established for routine 
hESC cultivation. However, the inherent variability, lack of environment 
control and the low productions yields associated with these 2-D culturing 
approaches are the main drawbacks limiting their use in clinical or 
industrial scale.  
The main focus of this thesis was the development of robust and scalable 
systems for the efficient production of cell-based products, capable of 
generating relevant numbers of well characterized cells for therapeutic 
and/or pharmacological applications. More specifically, novel culture 
strategies were explored aiming to enhance stem cell expansion and/or 
neuronal differentiation. On a first approach, two distinct stem cell lines 
were used, namely adult and teratocarcinoma stem cells, as both share 
important characteristics and similar bioprocessing challenges with 
hESCs. The preliminary knowledge gained with these stem cell systems 
contributed to cope with the complexity of hESC culture and fulfill the 
final goal of this thesis which was the implementation of robust 
bioprocesses for the production of pluripotent hESCs. To achieve these 
aims, an integrated approach was developed by combining different 3-D 
culturing strategies (such as cell aggregates and cell immobilized on 
 x 
 
microcarriers) with stirred tank bioreactor technology and by addressing 
critical bioprocess variables.  
In Chapter 1 the recent advances in stem cell bioprocessing are 
reviewed, with particular relevance given to specific environmental 
factors impacting on stem cell fate decisions and culture outcome. A 
special focus is given to the current drawbacks of standard protocols for 
hESC cultivation and the potential of novel culture strategies and 
bioreactor systems to overcome them. 
In Chapter 2, a scalable and controlled strategy was developed for the 
expansion of undifferentiated rat pancreatic stem cells (rPSCs) which are 
anchorage-dependent cells that present high proliferation capacity and 
differentiation potential. This was done by combining microcarrier 
technology with environmentally controlled stirred tank bioreactors. The 
use of microcarrier supports overcame the main drawbacks of aggregate 
culture namely by avoiding the cell clumping that prevented pluriferation. 
Although the two microcarriers tested were suitable for PSC culture, 
Cytodex 3 provided a better matrix to promote cell attachment and 
growth. At the end, the controlled bioprocess allows the efficient 
expansion of rPSCs, without compromising stem cell characteristics and 
differentiation potential, representing an efficient starting point towards 
the development of novel protocols for other stem cell lines including 
hESCs. 
The main focus of Chapters 3 and 4 was the development of a robust 
platform for the production of human neurons derived from stem cells. 
The rationale behind the selection of the teratocarcinoma stem cell line 
(NT2 cell) was based, not only on the important characteristics that these 
cells share with hESCs (expression of stem cell markers, high self-
renewal ability and pluripotency), but also because they are a valuable 
model for human neuronal differentiation in vitro; the neurons derived 
 xi 
from this cell line, NT2-N, have been used as a promising biological 
source both for cell therapy and for drug screening investigations. The 
cultivation of NT2 cells as 3-D cell aggregates (“neurospheres”) in stirred 
tank bioreactors was the strategy adopted aiming to accomplish three 
main objectives: i) up-scale ii) accelerate and iii) enhance neuronal 
differentiation of stem cells. 
Chapter 3 describes in detail the three-step protocol developed for NT2 
differentiation. It was shown that, both cell-cell interactions and retinoic 
acid treatment presented in the 3-D neurosphere system contributed to a 
more efficient (4-fold) and rapid (approximately 50%) neuronal 
differentiation process than in the conventional cell monolayer cultures. 
Efforts were also directed in the optimization of cell harvesting 
procedures. The highest percentage of recovered neurons was achieved 
when intact neurospheres were transferred directly to treated surfaces, 
indicating that both 3-D neurosphere dynamics and the extracellular 
matrix surfaces are sufficient to provide an optimal system for the 
harvesting of NT2-N neurons.  
The expansion step of NT2 aggregates was further investigated in 
Chapter 4. Different bioprocess variables were tested and the best 
compromise was obtained using an inoculum concentration of 4x105 
cell/mL and the media exchange operation mode, ensuring the fast 
production of high cell numbers without compromising their phenotype 
and differentiation potential. By incorporating both expansion and 
differentiation steps in an integrated bioprocess, the strategy allows for 
obtaining well differentiated neurons after 2 weeks of differentiation, as 
well as higher yields of neurons for a later culture time (10-fold 
improvement when compared to static culture protocols). Importantly, the 
bioprocess was reproduced and validated in controlled stirred tank 
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bioreactors, conferring process automation, scalability and reproducibility, 
important requirements in stem cell bioprocessing. 
In Chapters 5 and 6, we step into the complexity of hESC cultivation. 
The potential of bioreactor technology was explored in Chapter 5 to 
improve the expansion of pluripotent hESC on microcarriers. The 
importance of controlling dissolved oxygen at 30% air saturation and the 
impact of incorporating an automated continuous perfusion system on 
cell growth and metabolism were discussed, demonstrating to be critical 
for the production of relevant cell numbers without compromising their 
pluripotency. At the end an improvement of 12-fold in the final cell yield 
was obtained when compared to static 2-D cultures, yielding almost 
7×108 of pluripotent hESCs per 300mL bioreactor run.  
Cell microencapsulation in alginate was investigated in Chapter 6 as the 
main strategy to improve further hESC expansion and facilitate 
bioprocess integration with cryopreservation protocols. For this purpose 
three different 3-D culture strategies were evaluated and compared: 
microencapsulation of hESCs as single cells, aggregates and 
immobilized on microcarriers. The combination of cell microencapsulation 
and microcarrier technology resulted in an optimum protocol for the 
production and storage of pluripotent hESCs. This strategy ensures high 
expansion ratios (approximately 19-fold increase in cell concentration) 
and high cell recovery yields after cryopreservation. hESCs-
microcapsules were cultured in stirred tank bioreactors and, after 
expansion, cryopreserved in cryovials, aiming to implement a scalable 
and straightforward integrated bioprocess. 
Chapter 7 consists of a general discussion, where main achievements 
and conclusions of the work are presented and future perspectives 
outlined. 
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This thesis contributes substantially to the establishment of effective 
methodologies for the production of challenging cell-based products such 
as hESCs. We believe that the 3-D culture strategies developed herein 
will provide a new way to streamline robust protocols for stem cell 
expansion and directed differentiation and potentiate the translation of 
stem cells and their derivatives towards a broad spectrum of applications 
in regenerative medicine, tissue engineering and in vitro toxicology. 
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RESUMO 
Durante a última década, as células estaminais embrionárias humanas 
(hESCs) despertaram muita atenção devido à sua capacidade de auto-
renovação e pluripotência. Estas propriedades conferem às hESCs uma 
enorme aplicabilidade em medicina regenerativa, no rastreio de novos 
fármacos e em investigação científica por constituírem modelos celulares 
únicos para o estudo e compreensão dos processos de desenvolvimento 
embrionário inicial.     
Contudo, a aplicação crescente das hESCs requer ainda o 
desenvolvimento de metodologias de cultura bem definidas e 
reproduzíveis em maior escala, que garantam a manutenção das 
propriedades de auto-renovação e diferenciação das células após o 
processo. Os métodos mais correntemente utilizados para cultura de 
hESCs são as monocamadas bi-dimensionais (2-D). No entanto, a baixa 
reprodutibilidade, a falta de controlo ambiental e os baixos rendimentos 
celulares associados a estas abordagens de cultura 2-D limitam a 
utilização destes sistemas numa escala clínica ou industrial.  
O principal objectivo desta tese consistiu em estabelecer sistemas de 
cultura para a produção eficiente de células estaminais, que permitam o 
redimensionamento e robustez do processo e que sejam capazes de 
gerar elevados números de células bem caracterizadas para terapia e/ou 
para aplicações farmacêuticas. Especificamente, foram exploradas 
estratégias de cultura de células de forma a melhorar os processos de 
expansão e de diferenciação neuronal. Numa primeira abordagem, 
foram usadas duas linhas de células estaminais, nomeadamente células 
estaminais adultas e células estaminais de um teratocarcinoma, que 
apresentam características biológicas e de cultura muito semelhantes às 
hESCs.    
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O conhecimento preliminar adquirido com esses sistemas celulares 
permitiu compreender a complexidade da cultura de hESC e 
implementar bioprocessos robustos para a produção de hESCs 
pluripotentes. Foi desenvolvida uma abordagem integrada através da 
combinação de diferentes estratégias de cultura tri-dimensionais (3-D) 
(tais como agregados celulares e células imobilizadas em microsuportes) 
com a tecnologia de bioreactores de tanque agitado, e através da 
manipulação de diversas variáveis críticas ao bioprocesso. 
No Capítulo 1, é apresentada uma introdução geral ao tema de 
bioprocessamento de células estaminais, incidindo no impacto de 
determinados factores ambientais na cultura de células estaminais. É 
dada particular relevância ao estado da arte relativamente às limitações 
dos sistemas tradicionais de cultura em 2-D, bem como ao potencial de 
novas estratégias de cultura 3-D e à tecnologia de  biorreatores para 
ultrapassar essas limitações.  
No Capítulo 2, foi desenvolvida uma estratégia escalonável e robusta 
para a expansão de células estaminais pancreáticas de rato (rPSCs), 
que são células que apresentam uma grande capacidade de proliferação 
e diferenciação e cuja cultura é dependente de uma matriz/suporte. Para 
tal, as rPSCs foram cultivadas em microsuportes num ambiente 
controlado, usando bioreactores de tanque agitado. O uso de 
microsuportes superou as principais desvantagens da cultura de 
agregados celulares, onde as células se agruparam e não proliferaram. 
Embora os dois tipos de microsuportes testados tenham sido eficientes 
na cultura de rPSC, os microsuportes Cytodex 3 proporcionaram melhor 
aderência e crescimento às células. No final, o bioprocesso controlado 
permitiu a expansão eficiente de rPSCs, sem comprometer as 
características biológicas das células nem o seu potencial de 
diferenciação, o que representa um ponto de partida relevante para a 
 xvii 
implementação de protocolos promissores para outras linhas de células 
estaminais, incluindo hESCs. 
O principal objectivo dos Capítulos 3 e 4 foi o desenvolvimento de uma 
plataforma robusta para produção de neurónios humanos derivados de 
células estaminais. O racional por detrás da selecção da linha celular de 
células estaminais de um teratocarcinoma (NT2) baseou-se, não só pelo 
facto destas células apresentarem características importantes e 
semelhantes às hESCs (expressão de marcadores de células 
estaminais, capacidade de auto-renovação e pluripotência), mas 
também por constituírem um bom modelo celular para a diferenciação 
neuronal in vitro; os neurónios derivados desta linha celular, NT2-N, têm 
sido usados em ensaios de terapia celular e no desenvolvimento de 
novos fármacos. Nestes capítulos, as células NT2 foram cultivadas como 
agregados 3-D de células ("neurosferas") em biorreatores de tanque 
agitado com o objectivo de: i) aumentar a escala ii) acelerar e iii) 
melhorar o processo de diferenciação neuronal de células estaminais. 
O Capítulo 3 descreve em pormenor o protocolo 3-D estabelecido para 
a diferenciação neuronal de células NT2. Verifiou-se que, as interacções 
célula-célula e o tratamento com ácido retinóico presentes no sistema 3-
D contribuíram para um processo de diferenciação mais eficiente (4 
vezes) e mais rápido (cerca de 50%) comparativamente com as culturas 
convencionais em sistema estático. Neste capítulo foram ainda 
optimizados métodos de recolha e selecção de neurónios com o intuito 
de obter elevadas percentagens de recuperação. O método mais eficaz 
correspondeu ao processo de transferência directa das neurosferas 
intactas para superfícies tratadas com proteínas da matriz extracelular, 
indicando que, tanto a dinâmica celular das neurosferas como as 
propriedades da matriz são suficientes para fornecer um sistema ideal 
para recolha e selecção de neurónios NT2-N. 
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No Capítulo 4 foi investigada a etapa de expansão de células NT2 na 
forma de agregados. Diferentes variáveis de processo foram estudas e o 
melhor compromisso foi obtido utilizando uma concentração de inóculo 
de 4x105 célula/mL e a mudança de meio como modo de operação da 
cultura. Estas condições garantiram a produção rápida de números 
elevados de células sem comprometer o seu fenótipo e potencial de 
diferenciação. Ao integrar as etapas de expansão e diferenciação, o 
bioprocesso desenvolvido permitiu obter neurónios diferenciados em 
apenas duas semanas de diferenciação. Para além disso, no final da 
terceira semana, o número de neurónios produzidos foi 
significativamente superior quando comparado com o protocolo de 
cultura em sistema estático (aumento de 10 vezes da eficiência de 
diferenciação). No fim, o bioprocesso foi reproduzido e validado em 
bioreactores de tanque agitado e em ambiente controlado, conferindo ao 
processo automatização, escalabilidade e reprodutibilidade, requisitos 
importantes no bioprocessamento de células estaminais.  
Os Capítulos 5 e 6, descrevem já um nível de complexidade superior, 
utilizando culturas de hESCs. O potencial da tecnologia de bioreactores, 
adquirido nos Capítulos 3 e 4, foi explorado no Capítulo 5 com o 
objectivo de melhorar a expansão de hESCs pluripotentes em 
microsuportes. A importância do controlo de oxigénio dissolvido (30% de 
ar saturado) e o impacto da perfusão contínua da cultura no crescimento 
celular e no metabolismo foram estudados, e demonstraram ser 
parâmetros fundamentais para a produção de hESCs em elevadas 
quantidades sem comprometer a sua pluripotência. No final, o 
rendimento celular foi melhorado 12 vezes relativamente aos métodos 
de culturas 2-D em sistema estático, garantindo cerca de 7×108 hESCs 
pluripotentes por cada ensaio em biorreactor de 300mL. 
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No Capítulo 6 foi explorada a tecnologia de microencapsulação de 
células em alginato com o objectivo de melhorar o processo de 
expansão de hESCs e desenvolver um bioprocesso integrado com 
protocolos de criopreservação. Para este efeito, foram avaliadas e 
comparadas diferentes estratégias de cultura 3-D, nomeadamente a 
microencapsulação de hESCs como: células individualizadas, agregados 
de células e células imobilizadas em microsuportes. A combinação da 
microencapsulação de células com a tecnologia microsuportes resultou 
num protocolo eficiente para a produção e armazenamento de hESCs 
pluripotentes. Esta estratégia garantiu rendimentos de expansão celular 
elevados (aumento de cerca de 19 vezes na concentração de células) e 
percentagens de viabilidade celular altas após a criopreservação. As 
culturas de hESCs microencapsuladas foram cultivadas em 
biorreactores de tanque agitado e, após a expansão, criopreservadas em 
criotubos, visando a implementação de um bioprocesso simples 
integrado e possível de aumento de escala.  
O Capítulo 7 consiste numa discussão geral, onde são apresentadas os 
principais resultados, conclusões e as perspectivas futuras do trabalho. 
Em resumo, esta tese contribui significativamente para o 
estabelecimento de metodologias eficazes para a produção de sistemas 
celulares complexos, tais como as hESCs. As estratégias inovadoras de 
cultura 3-D aqui apresentadas poderão acelerar o desenvolvimento de 
protocolos robustos para a expansão e diferenciação dirigida de células 
estaminais e consequentemente potenciar a transição destas células e 
seus derivados para um amplo espectro de aplicações em medicina 
regenerativa, engenharia de tecidos e no desenvolvimento de novos 
fármacos. 
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ABBREVIATIONS 
Abbreviation Full form 
µ apparent growth rate 
2-D two-dimensional 
3-D three-dimensional 
ANOVA analysis of variance (statistics) 
AP alkaline phosphatase 
AraC cytosine arabinoside 
ASCs adult stem cell 
BDNF brain-derived neurotrophic factor   
bFGF basic fibroblast growth facto 
BSA bovine serum albumin 
cDNA complementary deoxyribonucleic acid 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco's modified Eagle medium 
DMEM-HG Dulbecco's modified Eagle medium with high glucose concentration 
EBs embryoid body 
EC embryonal carcinoma 
ECM extracellular matrix 
ELISA enzyme linked immuno sorbent assay 
ESC embryonic stem cell 
FBS foetal bovine serum 
FDA Food and Drug Administration 
FI fold increase in cell expansion 
FOX A2 forkheadbox A2 
FSG fish skin gelatin 
Fudr fluorodeoxyuridine 
GFAP glial fibrillary acidic protein 
GLC glucose 
GLN glutamine 
GMP good manufacturing practices 
GRNOPC1 geron’s oligodendrocyte progenitor cells derived from hESCs 
HARV high aspect rotating vessel 
hESC human embryonic stem cell 
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hESCellect
TM
 antibody with high specificity against surface epitopes in 
undifferentiated hESCs 
hFF human foreskin fibroblasts  
hFFCellect
TM
 antibody with high specificity against surface epitopes in 
undifferentiated hFFs 
HGF hepatocyte growth factors 
ICM inner cell mass 
IgG immunoglobulin G 
IgM immunoglobulin M 
IPATIMUP Instituto de Patologia e Imunologia Molecular da Universidade do 
Porto 
iPSC induced pluripotent stem cell 
kd apparent death rate 
Ki67 protein that is encoded by the MKI67 gene (antigen identified by 
monoclonal antibody Ki-67); marker to determine the growth fraction 
of a given cell population 
KO-DMEM knock out Dulbecco's modified Eagle medium 
KO-SR knock out serum replacement 
LAC Lactate 
LDH lactate dehydrogenase 
MAP2a&b microtubule associated protein-2 
mESC mouse embryonic stem cell 
MG Matrigel 
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1. INTRODUCTION  
Human embryonic stem cells (hESCs) constitute an exciting emerging field. 
The inherent capacity of these cells to grow indefinitely (self-renewal) and 
their ability to differentiate into all mature cells of the human body 
(pluripotency), have made them an extremely attractive tool for 
regenerative medicine and tissue engineering (Nirmalanandhan and 
Sittampalam, 2009). Indeed, for many years, they are considered the great 
promise for treating degenerative disorders such as Parkinson diseases, 
type I diabetes and heart failure, hoped to provide a new source of 
neurons, insulin producing cells or cardiomyocytes to replace the 
degenerating tissues and/or impaired cells.   
The first clinical trial with hESCs was approved by the US Food and Drug 
Administration (FDA) in January 2009 but only initiated in October 2010. 
The goal of this first study is to assess the safety and tolerability of 
oligodendrocyte progenitor cells derived from hESCs (GRNOPC1, Geron 
Comp.) in patients with neurologically complete spinal cord injuries, i.e. 
patients with complete loss of locomotor and sensory activity below the site 
of injury. The second endpoint is efficacy; it will use similar testing for 
evidence of any return of sensory function or lower extremity locomotion for 
one year after injection of GRNOPC1. This clinical trial holds high 
expectations as in previous experiments with rats these cells revealed to be 
safe and efficient in restoring some function (Zhang et al., 2006).  
Recently, another hESC clinical trial was approved (November 2010) by the 
US FDA. Advanced Cell Technology, Inc. announced a Phase I/II 
multicenter clinical trial using retinal cells derived from hESCs to treat 
patients with Stargardt’s Macular Dystrophy (SMD), one of the most 
common forms of juvenile macular degeneration in the world. 
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Today an increasing number of biotechnology industries have focused their 
interest on the development of both adult and embryonic stem cells as 
therapies; some examples are listed in Table 1.1. 
In addition to clinical applications, hESCs have enormous prospective for 
the development of novel technologies in drug screening (Davila et al., 
2004; Ebert and Svendsen, 2010; Jensen et al., 2009).  In fact, given the 
high costs spent by pharmaceutical R&D to bring a new drug to market, 
there is ongoing effort to introduce new cell models which are practicable 
(robust, reproducible, etc.) and have improved throughput and predictivity. 
hESCs and their derivatives have all the potential to be used here as “bio-
tools”, also contributing to the reduction of animal experimentation (Davila 
et al., 2004; Jensen et al., 2009). For example, pure cultures of 
hepatocytes, cardiomyocytes and neuronal cells derived from hESCs would 
provide robust cell-based in vitro assays for toxicity measurements and for 
drugs being development for cardiovascular or neurodegenerative 
disorders, respectively.     
hESCs are also valuable models for scientific research. They can lead to a 
better understanding of the basic biology of the human body, embryonic 
development, pathogenesis of congenital defects and cancer formation 
(Bongso et al., 2008). In fact, it is possible to derive disease-specific hESCs 
from embryos with diagnosed mutations by preimplantation genetic 
diagnosis (Galat et al., 2010). As an example, hESC lines derived from 
embryos with Fanconi anemia-A mutation and fragile X mutation have 
already been established (Galat et al., 2010). These hESC lines will provide 
in vitro models for study the phenotype of these mutations, allowing the 
faster identification of new treatments for these diseases. 
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Table 1.1.  Summary of some biotechnology industries that have focused their research on 
the development of both adult and embryonic stem cells as therapies. The main 
technologies developed and ongoing actions are presented.  
Company  Technology Indications Action and Clinical Status 
Aastrom 
Biosciences Inc 
(Minnesota,USA)  
Autologous therapy 
(patient´s own cells) 
Tissue repair cells 
Limb ischemia, bone, 
cardiac regeneration  
Phase II, III, I clinical trial 
Advanced Cell 
Technology Inc 
(California, USA) 
Multiple technologies  
based on ESC 
Heart failure, macular 
degeneration , 
vascular ischemia 
Received U.S. FDA approval for 
use retinal stem cells to treat 
Stargardt's Macular Dystrophy 
Phase I/II 
Aldagen Inc 
(North Carolina, USA) 
ALD-201 Heart failure Phase I clinical trial  
AmStem, Histostem 
(California, USA) 
Human umbilical cord blood 
stem cells 
Buerger´s disease 
Hair loss treatment 
Phase I and II clinical trial 
completed 
Received Korea FDS approval 
Phase II and III clinical trials  
Athersys (ATHX) 
(Ohio, USA) 
MultiStem Myocardial infarction, 
bone marrow 
transplantation 
Phase I clinical trial 
Celgene Corp 
(New Jersey, USA) 
Blood cancer treatments  Phase I clinical trials 
Cytori Therapeutics 
Inc (California, USA) 
Adipose tissue derived 
stem cells 
Tissue regeneration 
after breast surgery, 
cardiac ischemia, 
hear attack 
In planning, pilot study 
Its StemSource product line is sold 
globally for cell banking and 
research applications. 
Geron Corp. 
(California, USA) 
hESCs derived  
oligodendrocytes 
Spinal cord injury Received U.S. FDA approval  
Phase I 
Neuralstem Inc                           
(Maryland, USA) 
Neural Stem cells CNS injury (chronic 
spinal cord injury, 
amyotrophic lateral 
sclerosis) 
Recently filed a new drug 
application with the FDA to begin a 
Phase I safety clinical trial for 
chronic spinal cord injury  
NovoCell                                    
(California, USA) 
Stem cell engineering, cell 
encapsulation  
Type I diabetes Proof of concept phase I/II 
Osiris Therapeutics 
Inc. (Maryland, USA) 
Autologous therapy 
(patient´s own cells taken 
from the bone marrow) 
Crohn's disease Phase III clinical trial 
ReNeuron Group Plc 
(Guildford,UK) 
REN009 stem cell therapy peripheral arterial 
disease in diabetes 
Starting trials in 2011. 
StemCells Inc.                            
(California, USA) 
Human neural stem cells 
(HuCNS-SC
®
 product) 
Batten disease Starting human trials in 2011 
 Technology   
Apceth 
(München,Germany) 
Development of GMP-grade protocols for mesenchymal stem cell production and gene 
transfer for cancer therapy applications 
International Stem 
Cell Corporation            
(California, USA) 
Establishment of  human stem cells via parthenogenesis (hpSC lines) to provide potential 
products as alternatives to ESCs. ISCO plans to create a bank of these hpSC lines  
(UniStemCell™) 
Lonza Bioscience 
(Basel, Switzerland) 
Establishment of Poietics® Human Adipose-Derived Stem Cells for use in adult stem cell 
research 
Thermogenesis Corp               
(California, USA) 
Supply of products and services that process and store adult stem cells 
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2. TRANSFERRING STEM CELLS TO THE CLINIC: WHAT IS NEEDED?  
The successful translation of stem cells to the clinical and/or industrial fields 
will require contributions from fundamental research (from the 
developmental biology to the “omics” technologies and advances in 
immunology) and from existing industrial practice (biologics), especially on 
automation, quality assurance and regulation. 
Attention is shifting also to the development of bioprocesses to produce 
hESCs or their derivatives in high purity, consistent quality and relevant 
quantity.  
2.1. Purity 
The tumorigenic potential of pluripotent stem cells is one of the important 
hurdles in the safety utilization of these cells. At present, protocols for the 
directed differentiation of stem cells are generally inefficient, resulting in low 
differentiated cell yields and contamination by other cell types. Of greater 
concern is the persistence of undifferentiated stem cells and the possibility 
of these cells form malignant tumors when transplanted in the host 
(Fujikawa et al., 2005). Therefore the use of efficient  methods for 
differentiation and selection of pure populations of specialized cells will be 
essential before these cells being used clinically (Brignier and Gewirtz, 
2010). 
2.2. Quality 
To develop cell-based products with clinical quality, procedures (e.g. 
isolation, propagation, differentiation, cryopreservation) and compounds 
(e.g. matrices, culture and cryopreservation media, supplements) have to 
minutely follow the FDA regulations (Holm et al., 2010). Importantly, cell 
phenotype and function should be characterized and evaluated during 
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culture. Undifferentiated stem cells have to maintain their pluripotency and 
genetic and epigenetic stability after expansion while stem cell derivatives 
must express markers of the specific cell lineage and be fully functional 
after differentiation. 
2.3. Quantity 
Another important challenge is to achieve sufficient numbers of stem cell 
for an effective therapy. In general, these numbers fall in the range of 
millions to a few billion. For example, in Geron´s first clinical trial, patients 
will be injected in the spinal cord with small doses of GRNOPC1 (2x106 
cells, www.geron.com), but for the replacement of damage cardiac tissue 
after myocardial infarction 1-2x109 cardiomyocytes are required (Jing et al., 
2008). To achieve these high cell numbers robust, affordable and scalable 
bioprocesses need to be developed.  
 
3. STEM CELL BIOPROCESSING  
The successful production of stem cell-based products relies on robust 
bioprocesses that should be designed following pertinent principles (Figure 
1.1, Placzek et al., 2009).   
 
Figure 1.1. Design principles for stem cell bioprocessing (Adapted from Placzek et al. 
2009).  
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Herein, the cell source and the signals that govern stem cell fate decisions 
are essential bioprocessing components. Next, the integration of a 
controlled culturing strategy for 3-D cell organization via cell self-assembly, 
cell immobilization to biomaterials/supports with a bioreactor-based system 
where the necessary conditions for cells to guide their fate are “perfectly 
tuned”, is a key factor to move stem cells from lab scale to clinical trials and 
large scale industrial applications. In this chapter, the importance of these 
process components on the design of stem cell bioprocesses will be 
presented, highlighting the main requirements needed to fulfil the end 
product’s purity, quality and quantity. 
3.1. Stem cell sources 
There are several classes of stem cells including embryonic and adult stem 
cells, and the new type of induced stem cells, each one presenting its own 
benefits, limitations and challenges in bioprocess development (Figure 1.2). 
All of them share as common features the ability to proliferate indefinitely 
(unlimited self-renewal capacity) and vary in their differentiation potential. 
hESCs are isolated from the inner cell mass (ICM) of blastocysts at day five 
of embryonic development. The first reports of hESCs were published in 
1984 (SB Fishel et al., 1984) and 1994 (Bongso et al., 1994), but it was 
only in 1998 that Thomson and co-workers described the isolation of 
hESCs and the establishment of the firsts permanent and characterized 
hESC lines for research (Thomson et al., 1998). Today, more than 1000 
hESC lines are reported in the literature (Löser et al., 2010). Some of these 
cell lines are well characterized and organized in international stem cell 
banks, for example, hESCreg (www.hescreg.eu), UK stem cell bank 
(www.ukstemcellbank.org.uk), and National stem cell bank 
(www.nationalstemcellbank.org).  
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Figure 1.2. Stem cell sources and characteristics. (Adapted from (Placzek et al., 2009)).  
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Substantial efforts have been made towards the identification of 
phenotypic/genomic markers to characterize, validate and distinguish 
hESCs from other cell types. hESC lines can be identify by the presence of 
surface marker antigens (Tra series, SSEA series, GCT series, HLA, and 
CD markers) and transcriptional factors (Oct4, Nanog), by the 
chromossomal stability with serial culture, alkaline phosphatase 
positiveness and high telomerase activity (Allegrucci and Young, 2007; 
Bongso et al., 2008). As described above, these cells present a high 
proliferation capacity and are pluripotent, i.e., they possess the potential to 
differentiate into all cell types that compose an adult body, derived from the 
three germ layers (e.g. cardiomyocytes, neurons, pancreatic islets, 
hepatocytes, chondrocytes,) (Hay et al., 2007; Kroon et al., 2008; 
Mummery et al., 2003; Toh et al., 2009; Zhang et al., 2001). However, 
hESCs are still difficult to control with respect to their stem cell fate, and 
elicit ethical considerations, requiring the manipulation of human embryos. 
For clinical applications, these cells still present limitations related with 
immune rejection and the possibility of teratoma formation. On the other 
hand, adult stem cells (ASCs) do not present immunogenic complications 
on implantation since they can be isolated directly from the patient.  ASCs 
exist  in  specific  niches  in  the different organs (e.g. bone marrow, 
peripheral blood, pancreas, lung, brain, liver) (Lanza et al., 2004) 
contributing to the regeneration/repair of the tissue/organ where they 
reside. Depending on the source, ASCs can be isolated relatively easy, 
however they present as major limitations the difficulty in obtaining pure 
populations, the limited expansion capacity and the restricted differentiation 
potential, as they are often committed to their original cell lineage 
(multipotent cells).    
One of the most important and promising achievements in the stem cell 
field was the reversion of somatic cells (e.g. fibroblasts, keratinocytes) to a 
Process engineering of stem cells for clinical application 
11 
state of pluripotency using defined reprogramming strategies including 
overexpression of a core transcription factors known to be required for 
maintenance of ESC pluripotence and proliferation (Oct4, Sox2, and either 
c-Myc and Klf4 or Nanog and Lin28) (Takahashi et al., 2007; Takahashi 
and Yamanaka, 2006; Yu et al., 2007). The creation of these induced 
pluripotent stem cells (iPSCs) elicited an explosion of scientific curiosity 
and industrial interest. This is mainly because iPSCs are similar to ESCs 
(namely  cell morphology, cell-surface markers, self-renewal ability, 
potential to differentiate in vitro and in vivo into cells derived from all three 
germ layers)   (Takahashi et al., 2007; Takahashi and Yamanaka, 2006) 
and thereby could potentially replace ESCs for clinical applications, 
circumventing the ethical concerns regarding the use of embryos. 
Additionally, iPSCs present the benefit of being patient-derived cells, 
avoiding immune rejection in cell therapy applications. iPSC research is 
expanding rapidly, including modeling complex diseases in vitro and 
pursuing novel therapeuticals (Selvaraj et al., 2010). However, generation 
of iPSCs still suffers from low efficiency and high costs revised in (Brignier 
and Gewirtz, 2010). Furthermore the viral expression vectors used to obtain 
iPSCs (Fenno et al., 2008), the potential for insertional mutagenesis 
(Yamanaka and Blau, 2010) and the recent knowledge that hiPSCs 
expresses cancer hallmarks (Malchenko et al., 2010) have raised additional 
concerns regarding the safety of these cells. Currently, the possibility of 
reprogramming somatic cells into less immature developmental stages that 
could be more directly applicable to therapeutic applications is being 
intensely explored (Jang et al., 2010; Vierbuchen et al., 2010; Zhu et al., 
2010). 
 
 
Chapter 1. Introduction 
12 
3.2. Environmental factors that determine stem cell fate decisions 
Stem cells develop their behaviour from cues that lie in the extracellular 
environment. These cues operate on different temporal and spatial scales, 
driving specific cellular behaviours and ultimately promoting/controlling 
cells’ self-renewal, differentiation or apoptosis (Figure 1.3).  
 
Figure 1.3. Environmental factors and bioprocessing parameters impacting stem cell fate 
decisions (quiescence, self-renewal, differentiation and apoptosis).   
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Substantial efforts have been made to identify such stimuli. The 
extracellular matrix (ECM), soluble factors, cell-cell interactions, physical 
forces and physiochemical factors have been suggested as the most 
relevant cues governing stem cell fate.  
3.2.1. Extracellular matrix 
Extracellular matrix (ECM) is a key component of the stem cell niche in vivo 
and can influence stem cell fate via mediating cell attachment and 
migration, presenting chemical and physical cues, as well as binding 
soluble factors. In a natural setting, this environment encloses a complex 
and dynamic network of proteins, polysaccharides, proteoglycans and 
water that provide structural and organizational guides for tissue 
development. The activation of these signalling pathways through the 
adhesion of specific components of the ECM to cells via 
integrins/cadherins/cell surface receptors is not trivial as it is highly 
dependent on the composition, orientation and structure of the ECM 
(Lukashev and Werb, 1998). 
A wide range of animal and human-derived and recombinant protein 
matrices are normally used to support self-renewal or direct differentiation 
of hESCs (Table 1.2). hESCs are typically cultured directly of feeder cells 
(mouse embryonic fibroblasts, human foreskin fibroblasts) or on Matrigel, a 
basement membrane matrix extracted from Engellbreth-Holm-Swarm 
mouse tumors. However, these substrates are complex, poorly-defined  
and xenogenic and thus, large efforts have been done in developing 
defined matrixes for hESCs cultivation (Hakala et al., 2009). At least one 
cell subtract material composed by relatively well defined components is 
commercially available (CELLstart™ from Invitrogen, www.invitrogen.com). 
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Table 1.2. Summary of substrates used for propagation and/or differentiation of hESCs. 
(Adapted from (Abraham et al., 2009)) 
Substrate 
Expansion 
(timeline) 
Differentiation 
(cell lineage) 
Ref. 
Feeder layer based    
Human foreskin fibroblasts >70 passages - 
(Amit et al., 2003; Choo et al., 
2004; Hovatta et al., 2003) 
Fetal skin cells 20 passages - 
(Richards et al., 2002; 
Richards et al., 2003) 
Adult marrow cells 13 passages - (Cheng et al., 2003) 
Human adult uterin endonmetrial 
cells  
90 passages - (Lee et al., 2004) 
Human placental fibroblasts >25 passages - 
(Genbacev et al., 2005; Kim et 
al., 2007) 
hESCs-derived fibroblasts  30-52 passages - 
(Stojkovic et al., 2005b; Wang 
et al., 2005) 
Mouse bone marrow cell line S17 - Hematopoietic (Kaufman et al., 2001) 
Yolk sac endothelial line C166 - Hematopoietic (Kaufman et al., 2001) 
Human periodontal ligament 
fibroblasts  
- Osteogenic (Inanc et al., 2007) 
Natural substrates    
Matrigel 
TM
 130 passages - (Xu et al., 2001) 
Human serum >27 passages - (Stojkovic et al., 2005a) 
Collagen IV + vitronectin+ laminin+ 
fibronectin  
Derivation of hESCs  (Ludwig et al., 2006) 
Mouse embryonic fibroblasts ECM >30 passages - (Klimanskaya et al., 2005) 
Hyaluronic acid 20 days - (Gerecht et al., 2007a) 
Collagen scaffolds - Hepatic (Baharvand et al., 2006) 
Alginate scaffolds - Hematopoietic (Gerecht-Nir et al., 2004b) 
Synthetic substrates    
Poly- (glycerolcosebacate)- acrylate 1 week - (Gerecht et al., 2007b) 
Polyurethane microwells >21 days - (Mohr et al., 2006) 
Poly (N-isopropyl acrylamide-co-
acrilic acid) SIPN 
5 days - (Li et al., 2006) 
Dextran-based hydrogels with 
immobilized RGD peptide and VEGF 
- Vascular differentiation (Ferreira et al., 2007) 
Poly (D,L-lactide) scaffolds - Osteogenic (Bielby et al., 2004) 
Poly (L-lactic acide) and poly(lactic-
co-glycolic acid) 
                   + retinoic acid 
                   + TGF-beta 
                   + activin A and IGF  
 
- 
- 
- 
 
 
Neuronal 
Chondrogenic 
Pancreatic 
(Levenberg et al., 2003) 
Poly[2-(methacryloyloxy)ethyl 
dimethyl-(3-sulfopropyl)ammonium 
hydroxide] PMEDSAH 
25 passages - (Villa-Diaz et al., 2010) 
High-affinity disulphide-bridgedRGD 
peptide, CRGDC  
10 passages - (Kolhar et al., 2010) 
Peptide-acrylate surfaces PAS 10 passages Cardiomyocytes (Melkoumian et al., 2010) 
Recombinant proteins    
Human recombinant laminin-511 20 passages - (Rodin et al., 2010) 
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From clinical and industrial perspectives, the use of synthetic matrices may 
offer greater advantages in terms of reproducibility, quality control and 
costs (Kolhar et al., 2010; Melkoumian et al., 2010; Villa-Diaz et al., 2010). 
These matrices have wide diversity in properties that may be obtained and 
tailored with respect to mechanics, chemistry and degradation according to 
the case study. However, potential limitations to the use of synthetic 
materials include toxicity and limited repertoire of cellular interactions, 
unless they are modified with adhesion peptides or designed to release 
biological molecules. 
3.2.2. Soluble factors 
The outcome of stem cell culture depends also on the 
presence/concentration of growth/differentiation factors which provide 
survival, proliferation, differentiation signals to the cells. These regulatory 
molecules can be either added to the culture or secreted by the cells. Upon 
diffusion through the medium, these factors are sequestered by the ECM 
and bind to the cell surface receptors thus activating cellular functions. In 
alternative, to achieve a better control of the cellular microenvironment and 
ultimately enhance stem cell proliferation and/or differentiation, they can be 
immobilized on the surface of biomaterials (Ferreira et al., 2007). 
Substantial efforts have been made to identify the factors regulating stem 
cell proliferation and/or differentiation. As an example, the basic fibroblast 
growth factor (bFGF) and several members of the transforming growth 
factor beta (TGFβ) superfamily of ligands have been reported as vital 
components for the self-renewal of hESCs (revised in Azarin and Palecek, 
2010), while brain-derived neurotrophic factor  (BDNF), hepatocyte growth 
factors (HGF) and vascular endothelial growth factor (VEGF) have been 
used to direct stem cell differentiation into specialized cell types (revised in 
Ulloa-Montoya et al., 2005). Some concerns regarding the use of growth 
Chapter 1. Introduction 
16 
and differentiation factors in scalable culture systems is their high costs and 
low stability in medium. The engineering of more stable molecules or the 
development of appropriated perfusion systems would be potential 
strategies to reduce the concentration of these compounds without 
compromising the culture outcome.   
In parallel, attempts have been made to minimize the use of these factors, 
for example, by including natural and/or synthetic small molecules that can 
be isolated/synthesized economically. Small molecules have been shown 
to target specific signal transduction pathways (e.g. Wnt, Hedgehog, 
retinoid, NF-κB), which either alone or in concert dictate the fate of stem 
cells, including the maintenance of undifferentiated phenotype (Sato et al., 
2004) and pluripotency (Miyabayashi et al., 2007), improve cell viabilities 
(Watanabe et al., 2009) and promote differentiation of stem cells to cardiac 
(Tseng et al., 2006), hematopoietic (Naito et al., 2006), neuronal (Ding et 
al., 2003), and bone (Wu et al., 2004) cell phenotypes. With the advent of 
high-throughput screening technologies, small molecule libraries have been 
analyzed to identify molecular interactions leading to particular stem cell 
responses (revised in Ding and Schultz, 2004; McNeish, 2007).  
3.2.3. Cell-cell interactions 
Cell-to-cell communication, either in vivo or in vitro, can be established via 
direct contact (juxtacrine communication) or over distance via the diffusion 
of soluble signals secreted from closer (paracrine signalling) or distant 
(endocrine signalling) neighbouring cells. While juxtacrine cell-cell 
communication provides a persistent morphogenic cue, allowing the 
precise control of cellular responses, paracrine signaling is normally time-
constrained. The extent of such limitation is dependent on the spatial 
distance between proximal population of cells. This occurs because 
signalling molecules may: 1) degrade very quickly, limiting their 
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effectiveness; 2) be taken by the cells very quickly, leaving few to travel 
further, thus creating a heterogeneous environment where cells are 
exposed to different concentration gradients; 3) have their movement 
hindered by the ECM.  These different cell-cell interactions drive a set of 
stem cell responses, from the induction of programs of differentiation (Tsai 
and McKay, 2000) to promote proliferation and self-renewal properties 
(Purpura et al., 2004). In particular, hESCs are standard cultivated as flat 
colonies in static adherent conditions. Typically, these colonies are 
maintained at an appropriate size to assure controlled self-renewal. It is 
well established that individual cells or small clumps do not grow efficiently 
while large colonies exhibit substantial levels of spontaneous differentiation 
(Azarin and Palecek, 2010; Bauwens et al., 2008).   
In addition, the spatial distribution of the ECM within the stem cell niche in 
combination with these cell-cell interactions physically affects stem cell 
behaviour. Using soft lithography techniques, researches have investigated 
the influence of spatially patterned adhesion molecules on cell 
differentiation (McBeath et al., 2004). These patterning tools have been 
used to investigate cell spreading and shape on mesenchymal stem cell 
(MSC) differentiation, through control of the cellular cytoskeleton. MSCs 
patterned on larger islands of adhesion ligands, which allowed for cell 
spreading tended to differentiate into osteoblasts, whereas cells on smaller 
islands, where cells stayed rounded, differentiated into adipocytes 
(McBeath et al., 2004). Therefore, specific culture parameters such as the 
cell inoculum concentration, co-cultivation with other cell types and surface 
patterning/topography require optimization so that bioprocess performance 
can be tightly controlled, improving the robustness and reproducibility of the 
cultures (Figure 1.3, page 12).  
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3.2.4. Physical forces 
A number of in vivo and in vitro studies have demonstrated that physical 
forces (e.g. hydrodynamic/hydrostatic, mechanical and electrical) play a 
key role in the development of tissues and organs during embryogenesis as 
well as their remodelling and growth in postnatal life. Moreover, it has been 
found that stem cells are sensitive to fluid flow-induced shear stress 
(Glossop and Cartmell, 2009), compressive and tensional strains 
(Haudenschild et al., 2009), cyclical stretching (Shimizu et al., 2008) and 
hydrostatic pressures (Liu et al., 2009). In particular, Sargent et al 
demonstrated that manipulation of hydrodynamic environments modulates 
the kinetic profile of gene expression and relative percentages of ESC 
differentiation (Sargent et al., 2010). In another study, Veraitch et al 
reported that excessive centrifugal forces up to 1000 g cause shifts in 
phenotype and proliferation during expansion and differentiation of ESCs 
(Veraitch et al., 2008).  
However, relatively few information is known about the impact of these 
physical forces on physiological mechanisms. Recently, Stolberg et al 
proposed potential mechanisms for shear stress signalling that may play a 
role in endothelial differentiation trough the VEGF signalling pathway 
(Stolberg and McCloskey, 2009). Since scalable culture systems often 
employ perfusion or mixing that can apply mechanical forces to the cells, 
this kind of information will be extremely important to design efficient 
bioreactor-based strategies. The effect of shear-protection additives on 
hESC proliferation, viability and pluripotency will be important information 
for the establishment of scalable bioprocesses. 
3.2.5. Physiochemical environment 
The propagation and differentiation of stem cell cultures are highly 
dependent on the physiochemical conditions. The concentration of nutrients 
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and metabolites affects cell growth, viability and differentiation. In order to 
mimic the in vivo physiological environment and further improve culture 
performance, different operation modes can be adopted, including fed-
batch and perfusion. The fed-batch strategy is often considered the most 
suitable for tuning cell metabolism; by providing nutrients in a rational 
manner, their uptake and consumption are energetically more efficient 
leading to reduced accumulation of metabolites in culture supernatant (Xie 
and Wang, 1994). However, as described above, growth factors play a 
crucial role in regulation of stem cell behavior. Thus perfusion mode has 
been preferentially adopted in the majority of stem cell bioprocesses aimed 
to control culture outcome, since it assures the continuous renewal of 
nutrients and other factors as well as the continuous removal of metabolic 
byproducts (Bauwens et al., 2005). Within this context, more knowledge 
regarding the in vivo stem cells microenvironment is needed, i.e. the 
concentration gradients existed in stem cell niches in order to understand 
their impact on stem cells’ fate decisions. 
Although typically cultivated inside of incubators operated at standard 
conditions of temperature (37ºC), dissolved oxygen tension (20%) and pH 
(7.4), stem cell expansion and differentiation potential can be enhanced at 
different conditions. Up to now few studies have been conducted on the 
effect of temperature and pH in stem cell culture. For instance, it has been 
shown that mesenchymal stem cell differentiation is enhanced at lower 
temperatures (32ºC) than in 37ºC conditions (Stolzing and Scutt, 2006) 
while high temperatures (39ºC) demonstrated to enhance 
megakaryopoiesis in CD34- enriched cord blood cells (Proulx et al., 2004). 
Concerning pH, it was demonstrated that high values (pH 7.60) enhance 
differentiation and maturation of megakaryocyte progenitors (McAdams et 
al., 1998) whereas low pH values (7.1) increase their expansion capacity 
(Yang et al., 2002). Recently, Veraitch et al. reported that extended 
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exposure of ESC cultures for 1-3 h to ambient conditions during passaging 
procedures (which resulted in a rapid drop in temperature and rise in pH) 
inhibits cell proliferation and reduces the expression levels of Oct-4 
(Veraitch et al., 2008).    
Stem cell niches are often located in regions of low oxygen tension (pO2) 
and low pO2 typically decreases the rate of stem cell differentiation and 
enhances stem cell proliferative potential (King and Miller, 2007; Millman et 
al., 2009). Regarding hESC culture, there is emerging evidence that 
reducing oxygen concentration towards physiological levels, i.e. low levels 
of oxygen (hypoxia – 1.5-8%) is beneficial for in vitro maintenance of their 
pluripotent status: stem cells self-renewal is supported, spontaneous 
(uncontrolled) differentiation is reduced and karyotypic integrity is 
maintained (Ezashi et al., 2005; Prasad et al., 2009), contrasting to 
normoxia conditions (20% oxygen). The hypothesis is that these hypoxic 
environments protect the ESCs from oxygen toxicity while inducing the up-
regulation of an array of genes orchestrating the earliest steps of embryonic 
development. Nonetheless, further investigation is required to support such 
assumption. 
Based on these findings and in an attempt to unlock the full potential of 
stem cells, bioprocess engineers are focused on recreating in vitro the 
dynamic environments experienced by cells in vivo. However, the design of 
such complex microenvironments is not trivial. The degree of complexity 
involving the incorporation of various ECM proteins, soluble factors and cell 
populations into different physical stimuli and physiochemical conditions, 
within a heterogeneous spatial and temporal pattern, generates a large 
space of solutions from which the development of new cell-based products 
should be initiated. From a bioprocess perspective, these 
microenvironments can be engineered by combining 3-D culturing 
approaches with bioreactor technology.  
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3.3. Moving stem cells from 2-D monolayers to 3-D culturing 
approaches  
Stem cells are traditionally cultured in 2-D systems (e.g. Petri dishes, 
culture flasks and well plates). In particular, hESCs are propagated as 
colonies on top of a feeder layer of inactivated fibroblasts (Figure 1.4).  
Over the last years, constant inadequacy of conventional 2-D culture 
systems in resembling the in vivo developmental microenvironment has 
been observed in both basic biology and tissue engineering studies. In fact, 
tissue-specific architecture, mechanical and biochemical cues, cell-cell and 
cell-matrix communications are lost under such simplified and highly biased 
conditions. In addition, the inherent uncontrollability, heterogeneity and low 
production yields associated with these systems have made them 
unattractive and unsuitable for clinical and industrial applications. 
 
Figure 1.4. Two-dimensional (2-D) and three-dimensional (3-D) strategies for 
cultivation of human embryonic stem cells (hESCs). 
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Moving stem cells from 2-D cell monolayers to 3-D culturing strategies is 
imperative to enhance cells’ performance and fully exploit cells’ potential. 
The general recognition that spatial arrangement and directional cues have 
an important role in stem cells behaviour contributed for the acceptance of 
3-D cultures as the most suitable system to mimic stem cells’ native 
microenvironment. By providing a cellular context closer to what actually 
occurs in native microenvironment, these strategies can significantly 
improve cell’s viability, identity and function (Cukierman et al., 2002; Lund 
et al., 2009; Pampaloni et al., 2007). In summary, engineered 3-D 
microstructures have the potential to provide a higher degree of efficiency, 
robustness, consistency and predictability to the cultures. 
This section will address current 3-D culture strategies that could be used 
to generate large numbers of pluripotent hESCs and/or their derivatives 
with potential application in regenerative medicine and drug discovery. It is 
important to highlight that, an optimal hESC based bioprocess capable of 
embracing all the applications of these cells does not exist so far. 
Nonetheless, the knowledge gained during the last decades with murine 
ESCs (mESCs) and other stem cell model systems (e.g. human 
teratocarcinoma stem cells), in which the quantitative characterization of 
expansion and differentiation processes is included, have been providing 
important insights for the development of robust hESC production 
platforms.  
A variety of 3-D microstructures are currently established for stem cell 
expansion and/or differentiation. Self-aggregated spheroids (3-D cell 
aggregates), cell immobilization on microcarrier and cell encapsulation in 
biomaterials, are some examples. The main benefits and disadvantages of 
2-D and 3-D strategies for stem cell cultivation are listed in Table 1.3.  
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Table 1.3. List of advantages and disadvantages of different culture systems for stem cell 
bioprocessing. 
Culture Strategy Advantages Disadvantages 
2-D Culture 
Static Cultures 
 easy visualization and cell morphology 
monitorization 
 easy handling 
 affordable system 
 ideal for small scale studies 
 low reproducibility 
 low scalability 
difficult to control specific culture 
parameters and diffusion gradients 
 low cell production yields 
 limitation in resembling in vitro tissues 
Cell aggregates  easy handling 
 scalable system 
 high reproducibility 
 3- D cell-cell contact is preserved 
 can mimic stem cells’ native 
microenvironment 
 high differentiation efficiency 
 high cell production yields 
 difficult to control culture outcome due 
to the occurrence of 
uncontrolled/spontaneous  differentiation 
(EB formation) 
 aggregate size (important to avoid 
diffusion gradients inside the aggregate 
structure that lead to necrotic centres 
and/or spontaneous differentiation) 
 single cell harvesting (difficult to 
dissociate aggregates without 
compromising cell viability) 
 cell damage due to physical forces 
(hydrodynamic shear, perfusion flow)  
Microcarriers  
      Non-porous  
 easy handling 
 scalable system 
 high reproducibility 
 easy visualization and cell morphology 
monitorization 
 No limitations in mass and gas diffusion 
 high surface to volume ratio (able to 
support high cell densities, reduce the 
process cost) 
 high cell production yields 
 microcarrier agglomeration (important 
to avoid diffusion gradients inside the 
cell-microcarrier aggregate structure that 
lead to necrotic centres and/or 
spontaneous differentiation) 
 cell-bead separation step required 
 cell damage due to physical forces 
(hydrodynamic shear, perfusion flow) 
 costs associated to material 
(microcarrier) 
      Porous   easy handling 
 scalable system 
 high reproducibility 
 high surface to volume ratio (able to 
support high cell densities, reduce the 
process cost) 
 high cell production yields 
 protection from  physical forces 
(hydrodynamic shear, perfusion flow) 
 difficulty in culture visualization and cell 
morphology monitorization 
 Limitations in mass and gas diffusion 
inside the pores that lead to necrotic 
centres and/or spontaneous 
differentiation 
 cell harvesting limitation (except for 
biodegradable supports)  
 cell-bead separation step required 
 costs associated to material 
(microcarrier) 
Cell 
Microencapsulation 
 easy handling 
 scalable system 
 high reproducibility 
 high surface to volume ratio (able to 
support high cell densities, reduce the 
process cost) 
 high cell production yields 
 protection from  physical forces 
(hydrodynamic shear, perfusion flow) 
 3- D cell-cell and cell-matrix contacts 
are preserved, mimicking stem cells’ 
native microenvironment 
 biomaterial can be engineered to 
improve cell culture performance 
 process can be integrated in 
transplantation studies 
 difficulty in culture visualization and cell 
morphology monitorization 
 Limitations in mass and gas diffusion 
inside the pores that lead to necrotic 
centres and/or spontaneous 
differentiation 
 cell harvesting (decapsulation protocol 
could compromise cell viability)  
 costs associated to encapsulation 
equipment/process and biomaterials 
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3.3.1. Cell aggregates 
By aggregation into spheroids, cells can re-establish mutual contacts and 
specific microenvironments that allow them to express a tissue-like 
structure. Within this context, the cultivation of stem cells as 3-D 
aggregates has been extremely explored during the last decades proving to 
be an efficient system for expansion/differentiation of progenitor cells, such 
as human neural precursor cells (Baghbaderani et al., 2008; Baghbaderani 
et al., 2010), pancreatic cells (Chawla et al., 2006) and  hepatocyte 
progenitors (Gerlach et al., 2003; Miranda et al., 2009). 
For ESCs, the 3-D aggregate culture strategy is usually associated with 
differentiation; the most robust method for generating differentiated cells 
from ESCs is through the formation of embryoid bodies (EBs), where ESC 
cultured in suspension self-aggregate and spontaneously differentiate into 
multiple tissues (Dang et al., 2004). EB differentiation has been shown to 
recapitulate aspects of early embryogenesis, including the formation of a 
complex 3-D arrangement where cell-cell and cell-matrix interactions are 
thought to support the development of three embryonic germ layers and 
their derivatives (Itskovitz-Eldor et al., 2000; Keller, 1995). 
The main limitation of this system is, in fact, the inefficient control of stem 
cell expansion or in directing stem cell differentiation towards a specific 
lineage, thus resulting in a mixture of different cell types. This drawback 
demands the need of efficient integrative downstream approaches to 
further purify the culture outcome into a desired cell type population.  
Cormier et al. were the firsts who developed a system for the expansion of 
undifferentiated mESCs as aggregates in stirred bioreactors, achieving 31-
fold expansion during 5 days without compromising stem cell 
characteristics (Cormier et al., 2006). These results were very encouraging, 
contributing for the implementation of improved and scalable protocols for 
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expansion of pluripotent stem cells. One year later, zur Nieden 
demonstrated that mESCs could be maintained for a total of 28 days in 
these culture systems by repeated aggregate dissociation (zur Nieden et 
al., 2007).    
Besides propagation, many studies have been performed in directing 
differentiation of mESCs aggregates into a specific cell lineage (revised in 
(Jensen et al., 2009; King and Miller, 2007; Ulloa-Montoya et al., 2005).The 
knowledge gained with these model systems combined with developments 
in fundamental cell biology contributed to the design of controlled 
bioprocesses for hESCs. During the last 2 years, significant efforts have 
been made in 3-D aggregate culture systems for controlled expansion of 
undifferentiated hESCs and their directed differentiation into functional cell 
types (summarized in Table 1.4). 
3.3.2. Cell immobilized in microcarriers 
A microcarrier is a support matrix that allows the growth of anchorage-
dependent cells in suspension systems. Microcarrier cultures are 
characterized by high surface-to-volume ratio, accommodating higher cell 
densities than those obtained in static cultures; the area available for cell 
growth can be adjusted easily by changing the amount of microcarriers, 
which further facilitates the process scale-up. From industrial/ commercial/ 
clinical perspectives, this feature has a tremendous impact in reducing the 
costs of cell manufacturing by reducing the amount of media, growth 
factors and other expensive supplements required in stem cell cultivation. 
For each stem cell type and bioprocess it is important to optimize specific 
parameters including microcarrier type, concentration and inoculum 
density.  
 
 
Chapter 1. Introduction 
26 
Table 1.4.  Summary of the studies involving the cultivation of hESCs as aggregates.  
(STLV: slow turning lateral vessel; DMEM-KO: knockout Dulbecco's modified Eagle's medium; KO-SR: knockout 
serum replacement; FBS: foetal bovine serum; EB: embryoid body; IL6RIL6: interleukin-6 receptor fused to interleukin-
6.; RI: Rock inhibitor)   
Culture Conditions Results Ref. 
Expansion Differentiation 
System: STLV  
Medium: DMEM-KO, FBS and 
supplements  
Strategy: EB culture 
70-fold in 28 days 
(max: 36x10
6
 cell/mL) 
EB formation –No specific 
cell lineage differentiation 
(Gerecht-Nir 
et al., 
2004a) 
System: spinner flasks  
Medium: DMEM, FBS and supplements 
Strategy: EB culture 
15-fold in 21 days 
(max: 2-3  x10
5
 cell/mL) 
hematopoietic progenitors  
5-6% at day 14  
(Cameron 
et al., 2006) 
System: perfused and dialyzed STLV 
bioreactors 
Medium: DMEM-KO ,KO-SR and 
supplements  
Strategy: EB culture 
- 
Efficient EB formation and 
rapid EB differentiation into 
neural cells 
(Come et 
al., 2008) 
System: 
STLV  
spinner flask ball impeller 
spinner flask with paddle impeller 
Medium: DMEM-KO ,KO-SR and 
supplements  
Strategy: EB culture 
 
1.2-fold in 10 days 
6.4-fold in 10 days 
2.2-fold in 10 days 
 
 
 
EB formation –No specific 
cell lineage differentiation 
 
 
(Yirme et 
al., 2008)   
System: spinner flask with triangle 
impeller and glass-etched baffles  
Medium: mEFs conditioned medium 
Strategy: hESC aggregates in 10% 
matrigel 
5.6-fold in 10 days 
(max: 3.4 x10
6
 cell/mL) 
- 
(Kehoe et 
al., 2009) 
System: 
spinner flasks uncontrolled conditions 
stirred bioreactor 21% oxygen 
stirred bioreactor 4% oxygen 
Medium: DMEM-KO, FBS and 
supplements  
Strategy: patterned hESC colonies-EBs 
Max cell concentration:  
2.2 x10
5
 cell/mL day 16 
4.0 x10
5 
cell/mL day 16 
5.2 x10
5
 cell/mL day 16 
 
 
 
Cardiomyocyte (day 16) 
23.7%  
48.3%  
48.8%  
 
 
 
(Niebruegge 
et al., 2009) 
System: spinner flasks 
System: mTeSR, 0,1nM Rapamycin ,10 
µM Rocki 
Strategy: Treatment with RI after single 
cell dissociation 
25-fold in 6 days 
(max: 4.5 x10
5
 cell/mL) 
- 
(Krawetz et 
al., 2009) 
System: spinner flasks  with a bulb-
shaped pendulum  
Medium:  mTeSR medium with 10µM 
Rocki 
Strategy:Heat shock and RI  treatment 
after single  cell dissociation  
2-fold in 7 days 
 (>2x10
6 
cells/mL) 
- 
(Singh et 
al., 2010) 
System:Erlenmeyer flask 
Medium: mTeSR, 10 µM ROCKi  
Strategy: Treatment with Rocki after single 
cell dissociation 
21.6-fold in 4 days 
(max: 7-8 x10
5
 cell/mL) EB formation 
(Olmer et 
al., 2010) 
System:Erlenmayer flasks 
Medium: DMEM-KO , 100 pg/ml IL6RIL6 
chimera  
Strategy: inoculation of hESC clumps 
25-folds in 10-11 days 
(max: 9 x10
5
 cell/mL) 
- 
(Amit et al., 
2010) 
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A wide range of microcarrier types are commercially available today; 
supports can be porous or non-porous, composed by gelatin, glass, 
collagen, cellulose, presenting dimensions within the range of 10 to 6000 
µm. In addition, these microcarriers can be functionalized with different 
coating materials (ECM proteins, small molecules) in order to further 
improve cell culture performance (attachment and growth). Thus, 
microcarrier technology allows the flexibility of culturing the cells in different 
conformations and on different matrices.  
Cells cultured in macroporous beads (e.g. Cytopore2, CultisphereS) are 
cultured in a 3-D system, protected from the shear stress, although the 
diffusion of oxygen and nutrients within the bead could be limited. These 
systems have been used for the expansion and differentiation of mouse 
embryonic stem cells (Akasha et al., 2008; Fernandes et al., 2007; Storm et 
al., 2010) and for propagation of MSCs (Eibes et al., 2010).  
In non-porous microcarriers (e.g. Cytodex 1 and Cytodex 3, Hillex II), cells 
are attached to the surface of the beads, assuming a similar configuration 
to that of 2-D monolayers. Adult stem cells, such as mesenchymal stem 
cells, demonstrated higher expansion yields while keeping their phenotype 
and differentiation potential on non-porous microcarriers (Sart et al., 2009).  
One of the challenges that still need to be addressed is the optimization of 
cell harvesting protocols after expansion/differentiation process, to 
guarantee efficient cell-bead separation and high cell recovery yields 
without compromising their viability, potential and/or functionality. 
Recent results have shown that hESCs exhibit improved cell growth and 
retain their differentiation potential when cultured on dextran or cellulose-
based microcarrier supports, coated with matrigel or denatured collagen 
(Lock and Tzanakakis, 2009; Nie et al., 2009; Oh et al., 2009; Phillips et al., 
2008). Seeding hESC as single cells into microcarriers avoided formation of 
EBs and the consequent uncontrolled differentiation. Noteworthy is the 
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generation of 3-D hESC-microcarriers aggregates in culture upon 
microcarrier colonization (Figure 1.4). This 3-D cell growth results in 
additional increase in cell yields, when compared to 2-D culture systems. In 
this particular case, the control of microcarrier clumping will be critical to 
avoid the formation of larger aggregates that could lead to diffusion 
limitations. A summary of the studies performed using microcarrier 
technology for the production of hESC-based products as well as the main 
results obtained are indicated in Table 1.5. 
Table 1.5.  Summary of the studies involving the cultivation of hESCs immobilized in 
microcarriers. (mEFs: mouse embryonic fibroblasts; DMEM-KO: knock out Dulbecco's modified Eagle's medium; 
KO-SR: knock out serum replacement;)   
Culture Conditions Results Ref. 
Expansion Differentiation 
Microcarriers: trimethylamonium-coated 
polydtyrene microcarriers (Hillex II) 
Medium: mEFs conditioned medium 
System: ultralow attachment plates 
2.5-fold in 5 days 
 (0.2x10
6 
cell/mL) 
- 
(Phillips et 
al., 2008) 
Microcarriers: Cytodex
TM
3 microcarriers 
coated with Matrigel   
Medium: mEFs conditioned medium 
System: ultra low well plates  
3.4-fold in 2.5 days  
(Nie et al., 
2009) 
Microcarriers: Hyclone microcarriers 
coated with matrigel  
Medium: mEFs conditioned 
medium/Differentiation medium 
System: 50 mL spinner flasks 
34- to 45- fold in 8 days 
(1x10
6
 cell/mL) 
Differentiation to definitive 
endoderm  
>80% efficiency 
(Lock and 
Tzanakakis, 
2009) 
Microcarriers: Cytodex
TM
3 microcarriers 
Medium: mEFs conditioned medium  
System: spinner flasks 
6.8-fold in 14 days  
(1.5 x10
6
 cell/mL) 
- 
(Fernandes 
et al., 2009)  
Microcarriers: Matrigel-coated cellulose 
microgranular cylindrical  
Medium: mEFs conditioned medium 
System: spinner flasks 
5.8-fold in 5 days 
(3.5x10
6
 cell/mL)  
- 
(Oh et al., 
2009)   
Microcarriers: Cultisphere S  
Medium: DMEM-KO, KO-SR and 
supplements 
System: spinner flasks 
10- fold in 7 days  
(3.5x10
6
 cell/mL) 
 
(Storm et 
al., 2010) 
Microcarriers: TSKgel Tresyl-5PW 
(TOSOH-10) coated with laminin 
Medium: Differentiation medium 
System: spinner flasks 
- 
20% cardiomyocytes day 16 
 3-fold expansion in 16 days 
(2.14x10
5 
cardiomyocyte/mL) 
(Chen et 
al., 2010) 
 
Process engineering of stem cells for clinical application 
29 
To overcome certain problems encountered in cell therapy, particularly cell 
survival, lack of cell differentiation and integration in the host tissue, the use 
of pharmacologically active microcarriers (PAM) has been explored 
(revised in Delcroix et al., 2010; Hernandez et al., 2010). These 
biodegradable particles made with poly(D,L-lactic-co-glycolic acid) (PLGA) 
and coated with specific adhesion molecules serve as a support for survival 
and differentiation of the transported cells as well as their 
microenvironment, ultimately enhancing graft integration.   
3.3.3. Encapsulated cells 
The main benefit of cell encapsulation technology is the possibility of 
designing the scaffold environment with specific biomaterials that exhibit a 
wide range of mechanical/chemical properties, correlating to the properties 
of native tissues. Such tailored microenvironments may be more suitable 
for the self-renewal of stem cells, for directing their differentiation into 
specialized cell types, for promoting the organization of cells in 3-D 
configurations similar to those established in vivo.  
Within this context, several scaffolds/biomaterials have been used to 
enhance the culture of hESCs including alginate (Siti-Ismail et al., 2008), 
poly (lactic-co-glycolic acid)/poly(l-lactic acid) scaffolds (Levenberg et al., 
2003) and hydrogels of agarose (Dang et al., 2004), chitosan (Li et al., 
2010), synthetic semi-interpenetrating polymers (Li et al., 2006), hyaluronic 
acid (Gerecht et al., 2007a) and a natural components from the ECM (Yang 
et al., 2010) (also described above, Table 1.2).  
Many different kinds of encapsulation systems have been studied. The 
entrapment of cells in microcapsules has demonstrated several advantages 
in stem cell bioprocessing since the small size and spherical capsules offer 
an optimal surface to volume ratio and appropriate diffusion capacity of 
nutrients, growth factors and gases. Cell microencapsulation technology is 
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also a valuable tool for improving cell yields since it protect cells from the 
harmful effects associated to shear stress and avoid excessive 
agglomeration of cell aggregates. Therefore, this approach has been 
adopted and combined with bioreactor systems (stirred vessels, HARV, 
perfusion bioreactors) to enhance the formation of tissues and the 
differentiation of stem/progenitor cells to myocardium (Bauwens et al., 
2005), hepatocytes (Maguire et al., 2007; Maguire et al., 2006), pancreatic 
islets (Lee et al., 2009; Wang et al., 2009), bone (Goldstein et al., 2001), 
cartilage (Kuo et al., 2006), hematopoietic cells (Liu and Roy, 2005), 
neuronal cells (Delcroix et al., 2010) and vascular grafts (Nieponice et al., 
2008). Up to now, there are just three studies that explored the use o 
microencapsulated technology in hESC cultivation (Table 1.6).  
Table 1.6.  Summary of the studies involving the cultivation of microencapsulated hESCs.  
(PLL: poly-L-lysine ; EB: embryoid body)   
Culture Conditions Results Ref. 
Expansion Differentiation 
Microcapsules: 1,1% calcium alginate; 
(diameter: 1mm) 
System: static culture 
Efficient proliferation 
hESCs maintained 
their undifferentiated 
state up to 260 days 
- 
(Siti-Ismail et 
al., 2008) 
Microcapsules: 1,1% calcium alginate 
and 0,1 % gelatin; (diameter: 400-600 
µm) 
System: static culture 
70-80% cell viability 
Cluster formation  
Cell growth in 8 days 
Directed differentiation to 
definitive endoderm cells 
(Chayosumrit 
et al., 2010) 
Microcapsules: 1.5% calcium alginate 
coated with PLL; liquid core capsules 
(diameter: 500-600 µm)  
System: static  culture and spinner 
vessels 
 9-fold in 15 days 
(16x10
4
 cells/mL)  
>85% viability 
Differentiation into 
cardiomyocytes via EB culture 
(Jing et al., 
2010) 
 
It is important to highlight that microencapsulation technology will also 
contribute for the success of transplantation experiments. In contrast to 
cells in suspension, encapsulated tissue constructs are less susceptible to 
immune rejection, their delivery is better target and the in vivo degradation 
kinetics can be tuned permitting a more efficient and functional integration 
of cells in the host organ (Delcroix et al., 2010; Murua et al., 2008). 
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3.4. Bioreactors for stem cell cultivation 
Bioreactors have been, and still are, extensively used in chemical/biological 
industries for the production of enzymes, antibodies, viruses, recombinant 
proteins amongst many other products. The knowledge accumulated from 
the years facilitated their transition to stem cell bioengineering, in which the 
cells are the main products. At present, there is a large range of designs 
available, which ranges from fluidized and packed bed bioreactors to airlift, 
hollow fibre and disposable wave bioreactors (Table 1.7). In the particular 
field of stem cell research, microfluidic devices, rotary cell culture (RCC) 
systems and stirred culture vessels have been the main bioreactors 
explored till the moment (Figure 1.5). 
Bioreactors for stem cells are designed to accurately control/regulate the 
cellular microenvironment that supports cell viability and provides spatial 
and temporal control of signalling. These fully controlled bioreactors should 
allow a rapid and controlled cell expansion and/or differentiation, an 
efficient local exchange of gases (e.g. oxygen), nutrients, metabolites and 
growth factors as well as the provision of physiological stimuli.  
In order to successfully translate stem cell technologies from bench to 
bedside, the clinical efficacy of a stem cell-based product needs to be 
accompanied by a scalable and cost effective manufacturing process. In 
addition, it must comply to the evolving regulatory framework in terms of 
quality control and good manufacturing practices (GMP) requirements. In 
the end, by generating and maintaining a controlled culture environment, 
stem cells bioreactors represent a key element for the development of 
automated, standardized, traceable, cost-effective, and safe manufacturing 
processes for stem cell-based products. 
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Figure 1.5. Bioreactors used for stem cell cultivation. (A-C) Micro-bioreactor 
developed within the scope of CellPROM European project (www.cellprom.net): 
(A) MagnaLab central unit, (B) chip compartment, (C) cell carrier; (D-F) Rotary cell 
culture system (www.synthecon.com): (D) bioreactor unit, (E) high aspect rotating 
vessels, (F) slow turning lateral vessels. (G-H) Fully controlled stirred tank 
bioreactor (BIOSTAT® Qplus): (G) bioreactor unit, (H) stirred vessels. 
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3.4.1. Microfluidic culture systems 
Microfluidic devices, or micro-bioreactors, are efficient small-scale systems 
mainly used for the optimization of culture conditions for cell expansion and 
differentiation while also providing the precise control over the cell 
microenvironment (Azarin and Palecek, 2010; Placzek et al., 2009) (Figure 
1.5A-C). Arrays of micro-bioreactors have been developed to study growth 
and differentiation of hESC and ASC in a 3-D perfusion system (Cimetta et 
al., 2009; Fong et al., 2005; Gottwald et al., 2008; Zhao et al., 2009). The 
microenvironment can be controlled by adjusting specific operating 
parameters such as the perfusion rate, resulting in a high-throughput 
system for evaluating the effects of concentration gradients of soluble 
factors on various cell processes. However, the main limitations of these 
culture systems are low scalability and the high shear stress associated to 
perfusion as well as and the continuous removal of important factors 
secreted by the cells that could ultimately compromise stem cell 
performance.  
3.4.2 Rotary cell culture systems 
Developed by NASA, RCC bioreactors (which includes STLV- slow turning 
lateral vessel and HARV- high aspect rotating vessel) are composed by a 
rotating 3-D chamber in which cells remain suspended in near free-fall, 
simulating microgravity conditions (Figure 1.5D-F). These low shear stress 
bioreactors can provide a well mixed environment for cell growth as well as 
efficient gas transfer through a silicon membrane. Rotary cell culture 
systems have been used for expansion of cells as of human EBs, and for 
multiple ASC using scaffolds (Come et al., 2008; Gerecht-Nir et al., 2004a; 
King and Miller, 2007).  
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Amongst the main disadvantages of RCC are the limited control of 
aggregate size and nutrient/gas concentrations throughout the vessel. This 
may result in the formation of necrotic centers, leading to cell death inside 
the aggregates, and uncontrolled microenvironments, caused by the 
concentration gradients resulted from mass transfer limitations. In addition 
the working volume of these bioreactors is still low, thus limiting their use in 
a clinical and/or larger scale. 
3.4.3. Stirred culture vessels 
Stirred culture vessels, including spinner vessels and stirred tank 
bioreactors (Figure 1.5G-H), are scalable and hydrodynamically well 
characterized systems with simple design and operation. The main 
characteristic of these bioreactors is the possibility of culturing cells in a 
dynamic stirred environment, overcoming the mass transport and gas 
transfer limitations of static and other bioreactor systems (Table 1.7).  Here, 
the impeller design and ranges of stirring rate should be delineated 
carefully for each case study since each stem cell type has different 
sensitivities/necessities in terms of the shear stress. Another important 
feature of these bioreactors is the feasibility to perform non-invasive 
sampling thus enabling the continuous monitorization/characterization of 
the stem cell culture status/performance which is critical for process 
optimization (Figure 1.6). 
In particular, fully controlled stirred tank bioreactors provide an automated 
control of the environment, allowing the on-line monitoring and control of  
specific culture variables (temperature, pH, dissolved oxygen, nutrients) 
that can affect stem cell self-renewal and directed differentiation, ultimately 
improving culture outcome and ensuring reproducibility (Figure 1.6).  
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These bioreactors are highly flexible as they can operate in different culture 
operation modes (batch, perfusion), can be adapted to different type of 
bioprocesses (stem cell expansion and/or differentiation) and can be 
accommodated to different 3-D culture strategies (cell aggregates, 
microcarriers, microencapsulated cells), presenting widespread potential in 
stem cell bioengineering (Jang et al., 2010; Niebruegge et al., 2009).  
The key studies reporting the use of stirred culture bioreactors in hESC 
expansion and differentiation are listed above in Tables 1.4, 1.5 and 1.6. 
One of the main limitations of stirred culture vessels is the hydrodynamic 
stress promoted by stirring, as described above. In addition, the minimal 
volume required to set up the experiments is very high (approximately 50 
mL), demanding higher starting cell numbers, increasing the costs 
associated to optimization studies and compromising the use of stirred 
bioreactors for high-throughput applications. 
 
4. SCOPE OF THE THESIS  
This thesis focused on the development of robust and scalable systems for 
the efficient production of cell-based products, capable of generating 
relevant numbers of well characterized cells for therapeutical and/or 
pharmacological applications. More specifically, the cultivation of stem cells 
in a 3-D culturing approach using stirred tank bioreactors was explored. 
The overall goal was to obtain robust protocols for the expansion of hESCs 
which can ensure the production of pluripotent stem cells in high quality 
and relevant quantities. 
To achieve this, an integrated approach was developed by evaluating 
different 3-D culturing strategies (cell aggregates and cells immobilized to 
microcarriers) and addressing specific bioprocessing parameters namely 
inoculum concentration, microcarrier type and culture operation mode. On a 
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first step, two model systems were used to establish preliminary strategies 
for the production of (i) undifferentiated stem cells as well as (ii) neuron 
derived-stem cells, namely 
(i) rat pancreatic stem cells (rPSCs), due to their great potential for self-
renewal and multilineage differentiation. In addition, rPSCs showed 
spontaneous differentiation into lineages of the three germ layers 
(Kruse et al., 2004). This plasticity potential makes them an appealing 
source for cell replacement therapies and tissue engineering 
applications;  
(ii) human embryonal carcinoma stem cell line NTera-2/cl.D1 (NT2), 
since it presents similar characteristics with undifferentiated hESCs 
including the expression of stem cell markers, high self-renewal ability 
and pluripotency. Moreover, NT2 cells are also a valuable model for 
human neuronal differentiation in vitro, showing patterns of 
morphological differentiation similar to the ones present in vivo 
neurogenesis. The neurons derived from this cell line have been 
successfully used in transplantation and toxicology studies 
(Kondziolka and Wechsler, 2008), providing a promising material for 
cell therapy and drug screening investigations.  
The knowledge gained from these systems contributed for understanding 
better the complexity of hESC culture and fulfill the final aim of this thesis 
which was the implementation of robust bioprocesses for the production of 
hESCs with high cell viabilities and expansion yields and without 
compromising their undifferentiated phenotype and pluripotency. 
Taking into account that oxygen and medium perfusion have shown to be  
essential parameters in hESC culture (Placzek et al., 2009), the possibility 
of cultivating hESCs in environmentally controlled stirred tank bioreactors, 
where process automation and tight monitorization/control of the culture 
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environment are strictly ensured, was evaluated aiming to improve the 
expansion yields of pluripotent hESCs. 
One of the drawbacks associated to the combination of these 3-D 
approaches with stirred tank bioreactors in hESC cultivation is the 
hydrodynamic stress caused by stirring. Therefore the effect of alginate 
microencapsulation technology was investigated not only to protect cells 
from the shear stress and to avoid the commonly observed aggregate 
clumping or microcarrier agglomeration but also as a main strategy to 
facilitate bioprocess integration with cryopreservation protocols.   
A schematic representation of the main aims proposed for this thesis as 
well as the strategies that will be employed to address them are 
summarized on Figure 1.7. 
The development of robust strategies for the scalable production of 
complex stem cell systems addressed in this thesis will facilitate the 
transition of stem cell-based products for a broad spectrum of applications 
in regenerative medicine, tissue engineering and in vitro toxicology. 
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EXPANSION OF ADULT PANCREATIC STEM 
CELLS IN STIRRED TANK BIOREACTORS 
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ABSTRACT  
Adult pluripotent stem cells are a cellular resource providing unprecedented 
potential for cell therapy and tissue engineering. Complementary to this 
promise, there is a need for efficient bioprocesses for their large expansion 
and/or differentiation.   
Within this goal, our work was focused on the development of 3-D culture 
systems for the controlled expansion of rat pancreatic stem cells (rPSCs). 
For this purpose, two different culturing strategies were evaluated, using 
spinner vessels: cell aggregated cultures versus microcarrier technology. 
The use of microcarrier supports (Cytodex 1 and Cytodex 3) rendered 
expanded cell populations that retained their self-renewal ability, cell 
marker, and the potential to differentiate into adipocytes. This strategy 
overcame the drawbacks faced by aggregates in culture, revealed 
unfeasible as cells clumped together, did not proliferate and lost rPSC 
marker expression. Furthermore, the results obtained showed that, 
although both microcarriers tested herein were suitable to sustain cell 
expansion, Cytodex 3 provided a better substrate to promote cell 
adherence and growth.  
For the last approach, the potential of bioreactor technology was combined 
with the efficient Cytodex 3 strategy; under controlled environment, cell 
growth was more efficient, as shown by faster doubling time, higher growth 
rate and higher fold increase in cell concentration, when compared to 
spinner cultures. This study describes a robust bioprocess for the controlled 
expansion of adult rPSC, representing an efficient starting point for the 
development of novel technologies for cell therapy. 
 
 
 
Process engineering of stem cells for clinical application 
 53 
TABLE OF CONTENTS 
 
1. Introduction........................................................................................................ 54 
2. Material and Methods ........................................................................................ 55 
2.1. Cell line ..................................................................................................................... 55 
2.2. Cell culture in static adherent conditions .................................................................. 55 
2.3. Cell culture in stirred conditions ................................................................................ 56 
2.4. Cell counts and viability ............................................................................................ 58 
2.5. Growth rate, doubling time and fold increase in cell expansion ................................ 58 
2.6. Metabolite analysis ................................................................................................... 59 
2.7. Telomerase activity ................................................................................................... 59 
2.8. Immunocytochemistry ............................................................................................... 59 
2.9. Adipocyte differentiation ........................................................................................... 60 
3. Results ................................................................................................................ 61 
3.1. Culture of PSCs as aggregates ................................................................................ 61 
3.2. Cell growth and viability of PSCs cultured in microcarriers ....................................... 62 
3.3. Metabolic characterization of PSCs cultured in microcarrires ................................... 65 
3.4. PSCs expansion in a fully controlled bioreactor ........................................................ 67 
3.5. Characterization of PSCs expanded in microcarriers ............................................... 69 
4. Discussion ......................................................................................................... 71 
5. Acknowledgments ............................................................................................. 74 
6. References ......................................................................................................... 74 
 
 
 
Chapter 2. Expansion of pancreatic stem cells in bioreactors 
 54 
1. INTRODUCTION  
The potential of adult stem cells (ASCs) to differentiate was thought to be 
restricted to cell types related to the tissues in which they reside, as their 
primary role is in tissue homeostasis and regeneration  (Gokhale and 
Andrews, 2006). However, this concept has been challenged by the 
isolation of new lineage classes of uncommitted pluripotent stem cells, with 
a remarkable versatility in their differentiation potential, including pancreatic 
stem cells (PSCs) (Kruse et al., 2004, 2006). PSCs were able to growth for 
more than 140 passages maintaining the expression of typical stem cell 
markers (alkaline phosphatase, SSEA-1, Oct-4 and Nestin), as 
demonstrated by immunocytochemistry and RT-PCR (Kruse et al., 2006). 
PSCs were shown to possess great potential for self-renewal and 
multilineage differentiation. These cells showed spontaneous differentiation 
into lineages of the three germ layers; when cultured in hanging drops, 
PSCs formed organoid bodies, three-dimensional aggregates that 
contained cells of different lineages (Kruse et al., 2004, 2006). This PSC 
plasticity makes them an appealing source for cell replacement therapies 
and tissue engineering.  
Complementary to the promising potential of pluripotent stem cells, there is 
a need for efficient culture systems for their large expansion and/or 
differentiation. The past years have witnessed an increased number of 
studies geared towards this goal. In particular, stirred suspension 
bioreactors have gained special interest due to their advantageous 
characteristics: they are hydrodynamically well characterized, easy to 
scale-up, enable culture homogeneity and continuous monitoring and 
control of the culture parameters (Ulloa-Montoya et al., 2005; King and 
Miller, 2007). So far, these systems have been used for a wide range of 
applications: (i) to culture embryoid bodies derived from mouse and human 
embryonic stem cells (ESCs) and differentiate them into hematopoietic and 
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cardiac lineages (Dang et al., 2002; Cameron et al., 2006); (ii) to expand 
undifferentiated murine ES cells as aggregates (Cormier et al., 2006, zur-
Nieden et al., 2007); (iii) to enhance expansion and neuronal differentiation 
of human teratocarcinoma stem cells (Serra et al., 2007); (iv) to culture 
several types of tissue-specific ASCs as 3-D aggregates (Gilbertson et al., 
2006; Youn et al., 2006; Chawla et al., 2006). Several research groups 
have also employed stirred bioreactors to culture ESCs using microcarriers 
as substrate to support attachment and growth (Abranches et al., 2007; Fok 
and Zandstra, 2005). However, many challenges remain as no studies 
focused on large expansion of pluripotent ASCs have been reported so far.  
Herein, the feasibility of scaling-up adult PSCs expansion was assessed by 
testing two different approaches: cell aggregated cultures versus 
microcarrier technology.  
The present work describes, for the first time, an efficient bioprocess for the 
controlled expansion of rat PSCs using stirred bioreactors, overcoming one 
of the drawbacks of stem cell technology. 
 
2. MATERIAL AND METHODS 
2.1. Cell line 
The rPSC cell line (RSAPank) was derived from rat exocrine pancreas: 
acini from male Sprague Dawley rats were isolated at Fraunhofer Institute 
of Biomedical Engineering-University of Lübeck and purified as described 
previously (Kruse et al, 2004, 2006).  
2.2. Cell culture in static adherent conditions 
Rat PSCs were routinely cultured in Dulbecco's modified Eagle medium 
(DMEM, Invitrogen) supplemented with 10% of foetal bovine serum (FBS-
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Gold, PAA) and 100 U/mL penicillin-streptomycin (P/S, Invitrogen), at 37ºC, 
in a humidified atmosphere of 5% CO2. Cells from passage 21 to passage 
24 were used for all stirred culture experiments. 
2.3. Cell culture in stirred conditions 
Suspension studies were performed in spinner vessels (Wheaton, USA) of 
125 mL volume (working volume - 100mL) incubated at 37ºC in a 
humidified atmosphere of 5% CO2. Two different cultivation strategies were 
carried out - cells cultured as aggregates (Strategy 1) and immobilized in 
microcarrier supports (Strategy 2).  
Strategy 1- Aggregates: Spinner vessels equipped with ball or paddle 
impellers were tested. rPSCs were inoculated at a concentration of 
4x105cell/mL, in 70 mL of DMEM supplemented with 15% of FBS-Gold and 
100 U/mL P/S, and stirred at 50 rpm.  After 6 h, culture medium was added 
to yield a final volume of 100 mL and the percentage of serum adjusted to 
10%. During cultivation time, the agitation rate was changed from 60 to 120 
rpm to avoid cell damage or aggregate clumping. 
Strategy 2- Microcarriers: Two types of microcarriers were tested, Cytodex 
1 and Cytodex 3 (GE Healthcare), both at a concentration of 3 g/L (dry 
weight). The microcarriers were prepared and sterilized according to the 
manufacturer's recommendations. Cell inocula (1x105cell/mL) were 
obtained from adherent rPSCs routinely cultured in static adherent 
conditions, harvested by trypsinization, collected by centrifugation, 
resuspended in 5 mL culture medium (DMEM supplemented with 10% 
FBS-Gold and 100 U/mL P/S), and immediately transferred to spinner 
vessels. Immobilization in the microcarriers was carried out for 4-5 h:   cells 
were allowed to attach to the beads with intermittent stirring (1 min of 
stirring every 20 min), in order to obtain a homogeneous cell distribution. 
The culture volume was then adjusted to 75 mL by addition of culture 
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medium, and continuous agitation was set to 45-50 rpm. Twenty four h after 
inoculation, culture medium was added to obtain the final culture volume 
(100 mL) and the agitation rate was increased over time (up to 80 rpm). 
 In all stirred experiments, culture medium was partially replaced (50%) 
every 3 days. This was done by stopping agitation withdrawing spent 
medium and refeeding fresh medium immediately after sedimentation of 
microcarriers/aggregates.   
Cell Culture in Bioreactor: A 250 mL bioreactor vessel, designed in house, 
was used to culture rPSCs in a fully controlled environment. The internal 
geometry of the vessel is similar to the commercially available spinner 
vessels but is equipped with pH and pO2 meters (from Mettler-Toledo, 
Urdorf, Switzerland) which allow online measuring and control of these 
parameters. The pH was kept at 7.2 by injection of CO2 and addition of 
base (NaOH, 0.2M). The dissolved oxygen concentration was maintained 
at 30% via surface aeration. The temperature was kept at 37ºC by water 
recirculation in the vessel jacket controlled by a thermocirculator module. 
This vessel was adapted to a commercially available bioreactor control unit 
(B-DCU, B-Braun Biotech International GmbH, Sartorius, Germany) that 
controls pH, pO2 and temperature. Data acquisition and process control 
were performed using MFCS/Win Supervisory Control and Data Acquisition 
(SCADA) software (B-Braun Biotech International GmbH, Sartorius, 
Germany).   
rPSCs were immobilized in Cytodex 3 microcarries (3 g/L) and directly 
inoculated in the bioreactor (1x105 cell/mL) in a working volume of 250 mL. 
The agitation rate was kept at 50 rpm during the first 24 h and then 
increased throughout the culture time up to 80 rpm. Culture medium was 
partially replaced (50%) every 3 days, as described above for the spinner 
experiments. 
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2.4. Cell counts and viability 
Cell culture samples collected daily were visualized using an inverted 
microscope with phase contrast (DM IRB, Leica, Germany). Total cell 
number was determined by counting cell nuclei using a Fuchs-Rosenthal 
hemacytometer, after digestion with 0.1 M citric acid/1% Triton X-100 
(wt/wt) /0.1% crystal violet (wt/v) (Alves et al., 1996).  
Cellular viability was assessed by measuring lactate dehydrogenase (LDH) 
activity from the culture supernatant. LDH activity was determined by 
following spectrophotometrically (at 340 nm) the rate of oxidation of NADH 
to NAD+ coupled with the reduction of pyruvate to lactate. The specific rate 
of LDH release (qLDH) was calculated for every time interval using the 
following equation: qLDH = LDH/(t x X),  where LDH is the change in 
LDH activity over the time period t, and Xv is the average of total cells 
during the same time period. 
2.5. Growth rate, doubling time and fold increase in cell expansion 
Growth rates, doubling times and fold increase parameters were also 
calculated for all cultures in microcarrier systems. Growth rates () were 
calculated using a simple first order kinetic model for cell expansion: dX/dt 
= X, where t (day) is the culture time and X (cell) is the value of viable 
cells for a specific t. was estimated using this model applied to the slope 
of the curves during the exponential phase. Doubling time (td) was 
calculated using the equation td = [Ln(2)]/ The fold increase in cell 
expansion (FI) was evaluated based on the ratio XMAX/X0, where XMAX is the 
peak cell density (cell/mL) and X0 is the lowest cell density (cell/mL).  
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2.6. Metabolite analysis  
Glucose (GLC) and lactate (LAC) concentrations in the culture were 
analyzed using a Bioprofile 100 plus Analyzer (Nova Biomedical, USA). 
The specific metabolic rates (qMet., mol/(day cell)) were calculated for the 
two periods between the first two refeeds, using the equation: 
qMet. = ΔMet/(Δt ΔXv), where ΔMet is the variation in metabolite concentration 
during the time period Δt and ΔXv the average of adherent cells during the 
same time period. The apparent lactate from glucose yield (YLAC/GLC) was 
calculated as the ratio between qLAC/qGLC.  
2.7. Telomerase activity 
The telomerase is responsible for the maintenance of chromosome length 
and a significant telomerase activity in cells is fundamental for their infinite 
replication capacity (Masters 2000). Telomerase activity was determined 
using the Telo TAGGG Telomerase PCR ELISA PLUS kit (Roche, Basel, 
Switzerland) according to the manufacturer’s instructions. The assay uses 
the telomeric repeat amplification protocol (TRAP), in which the telomerase-
mediated elongation products are amplified by PCR and detected with an 
enzyme-linked immunosorbent assay. 
2.8. Immunocytochemistry 
Cell cultured in microcarriers: Microcarrier cultures were transferred to 1.5 
mL tubes and sedimented by gravity. The medium was removed and cells 
were rinsed with 0.5mM MgCl2 solution in phosphate-buffered saline (PBS), 
fixed, for 20 min, in 4% (w/v) paraformaldehyde (PFA, Sigma) solution in 
PBS and permeabilized with Triton X-100 (TX-100, Sigma), 0.3% (w/v) 
diluted in PBS, during 20 min.  After 1 h in blocking solution (bovine serum 
albumin, BSA, 1% (w/v), and TX-100 0.1% (w/v) in PBS), cells were 
incubated with primary antibody, for 2 h; washed 3 times with PBS and 
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incubated with secondary antibody, for 1 h. Microcarriers were transferred 
to glass slides and covered with a drop of ProLong mounting medium 
containing DAPI (Molecular Probes). For sample observation, slides were 
covered with glass coverslips.  
Cell Aggregates: After sampling, PBS-washed aggregates were transferred 
to a tissue protecting compound (Tissue Teck, OCT™ Compound, Sakura) 
and frozen. Samples were kept at -80ºC until cryosectioning in a Leica 
Cryostat. For the immunofluorescence assay, 10 m sections were 
rehydrated with PBS and fixed in methanol, at -20ºC, during 10 min. After 1 
h in a solution of 2% (w/v) BSA and 0.1% (v/v) TX-100 in PBS, the slides 
were incubated with the primary antibody, for 1 h. After 2 washing steps 
with PBS, the slides were incubated an additional 45 min with the 
secondary antibody. At the end, a drop of ProLong mounting medium 
(Molecular Probes) was added to the slide, that was then covered with a 
coverslip. 
Incubations were done at room temperature. Primary and secondary 
antibodies used were: monoclonal mouse anti-Nestin (Chemicon) and anti-
mouse AlexaFluor 488 (Molecular Probes), respectively, diluted in blocking 
solution. 
All samples were visualized under a fluorescence microscope (DMRB, 
Leica, Germany).  
2.9. Adipocyte differentiation 
Cell samples were transferred to static cultures (Tissue culture flasks 
75cm2) and cultured until reaching 100% confluency. At this time, cultures 
were induced to differentiate into adipocytes by replacing the growth 
medium with differentiation medium (DMEM containing 10% FBS Gold heat 
inactivated, 100 U/mL P/S, 10 nM dexamethasone, 0.5 mM 
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isobutylmethylxantine, 60 M indomethacin and 100 ng/mL insulin, all from 
Sigma). Control cultures were run in parallel in medium without additives. 
The medium was replaced 3 times per week and adipogenesis was 
observed over a period of 14 days. Differentiation was assessed by 
morphological characteristics and lipid staining by Oil Red O. Briefly, 
adipocyte differentiated cultures were washed with PBS and fixed with 
formalin 10% (Biorad), at room temperature, for 30 min. Cells were then 
washed twice with sterile water and incubated with 60% isopropanol 
(Sigma) during 2 min. After that, cultures were stained with fresh solution of 
Oil red O (1:3 v/v) and counterstained with hematoxylin.  
 
3. RESULTS  
3.1. Culture of rPSCs as aggregates  
The hypothesis of culturing rPSCs as cell aggregates (Strategy 1) in stirred 
suspension systems was evaluated using 125 mL spinner vessels. With 
this strategy, the effect of impeller geometry on cell aggregation and growth 
was assessed; two impellers configurations were tested: ball (SP-AB) and 
paddle (SP-AP). Initially, the agitation was kept at low rate (50 rpm), in 
medium supplemented with 15% of FBS, in order to promote cell 
aggregation (Masters 2000). One day after inoculation, small cell 
aggregates (70-90 m) were observed in both cultures by phase contrast 
microscopy (Figure 2.1A, C). Although cells were able to assemble, single 
cells were also detected in the culture supernatant. This was particularly 
observed in SP-AP (Figure 2.1A), confirming previous reports that show that 
the ball impeller geometry favors cell aggregation (Moreira et al 1995; 
Santos et al 2007). From day 1 onwards, SP-AP aggregates loosed their 
integrity (Figure 2.1B) and culture viability had a pronounced decrease 
(data not shown). 
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In SP-AB, cell aggregates increased in size, with diameters ranging from 90 
to 120 m upon 3 days of cell cultivation (Figure 2.1D). However, no cell 
proliferation occurred, suggesting that the increase in size was a result of 
cell assembling and aggregate clumping. At day 13 (Figure 2.1E), SP-AB 
aggregates samples were collected and analyzed for the presence of nestin 
positive cells, a marker of adult pancreatic stem cells (Kruse 2006), was 
evaluated by immunofluorescence microscopy in cryosections. Figure 2.1F 
shows that only a small percentage of cells stained positive for nestin. 
3.2. Cell growth and viability of rPSCs cultured in microcarriers 
For the second strategy, CytodexTM1 microcarriers, based on a cross-linked 
dextran matrix positively charged, and CytodexTM3, where the dextran 
matrix is covered with a layer of collagen, were tested for their ability to 
support the growth of rPSCs in spinner vessels (SP-Cyt1 and SP-Cyt3 
experiments). In both studies, cells were inoculated at 1 × 105 cells/mL, 
corresponding to 5 and 8 cells per microcarrier in SP-Cyt1 and SP-Cyt3, 
respectively. For all experiments, the microcarrier concentration was 3 g/L, 
the agitation rate was increased during the culture time from 50 to 80 rpm, 
and medium replacement was performed every 3 days. Four hours after 
inoculation, the majority of cells (87.5% of the cell inoculum) were already 
attached to the microcarriers in SP-Cyt3 (Figure 2.2A), which were able to 
support cell growth until day 4 (Figure 2.2B). A similar behavior was 
observed in SP-Cyt1 culture (data not shown), except that, herein, a lower 
amount of cells adhered to the supports (76.3% of the cell inoculum).  
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Figure 2.1. Phase contrast photomicrographs of rPSCs cultured as small aggregates in 
spinner vessels equipped with  paddle (A, B) and  ball impeller (C, D, E, F). Cells were 
visualized by day 1 (A, C), day 3 (B, D) and day 13 (E). Immunofluorescence 
photomicrographs of cell aggregates cryosections at day 13 of ball spinner culture (F). 
rPSCs were identified by nestin (green) labelling and nuclei were stained with DAPI 
(blue) Scale bars: (A-E) 100 m, (F) 50 m.   
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Figure 2.2. Phase contrast photomicrographs of rPSCs cultured in Cytodex 3 
microcarriers under stirred suspension conditions. Cells were visualized 4 h after 
inoculation (A) and by day 4 (B). Scale bar: 100 m. 
 
Figure 2.3A shows the total cell concentration profile of adherent rPSCs in 
SP-Cyt1 and SP-Cyt3 experiments. In both cultures, the exponential growth 
phase lasted until day 4, where the maximum cell concentrations were 
reached: 1.7 × 105 cell/mL and 1.9 × 105 cell/mL for SP-Cyt1 and SP-Cyt3, 
respectively (Figure 2.3A). These values correspond to a 2.2 fold increase 
in cell concentration for both experiments (Table 2.1), considering the 
percentage of inoculated cells that attached to the supports. 
 
 
Figure 2.3. rPSCs cultured in microcarriers using stirred suspension systems.              
(A) Growth curves in terms of total adherent cells per millilitre and (B) viability 
expressed by the cumulative values of specific LDH release rates. 
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Growth rates () and doubling times (td) were calculated and compared 
(Table 2.1). A higher growth rate was achieved for SP-Cyt3 (0.26 day-1) 
than for SP-Cyt1 (0.21 day-1), since the exponential phase period was 
shorter (3 days) in the first culture. For the same reason, td was lower in 
SP-Cyt3 (2.6 days). Culture viability was analyzed by measuring the 
cumulative values of specific LDH release rates (qLDH) in the culture 
supernatant. Figure 2.3B shows that, from day 4 onwards, a significant 
increase in cumulative qLDH was observed for both experiments (more 
pronounced in SP-Cyt1). Simultaneously, a decline in total cell number was 
detected, indicating that cultures had reached the death phase (Figure 
2.3A).      
 
Table 2.1. Growth rate (), doubling time (td) and fold increase (FI) values of 
rPSCs cultured in cytodex 1 and cytodex 3 microcarriers, using spinner 
vessels and a 250 mL bioreactor. 
 Spinner 
Cytodex 1 
Spinner 
Cytodex 3 
Bioreactor 
Cytodex 3 
 (day
-1
) 0.21 0.26 0.35 
td (day; h) 3.2; 78 2.6; 63 2.0; 47 
FI 2.2 2.2 4.7 
 
3.3. Metabolic characterization of rPSCs cultured in microcarrires 
Partial medium exchange was performed every 3 days in order to: i) assure 
supply of nutrients, ii) partially remove metabolic waste products and, more 
importantly, iii) avoid accumulation of growth/differentiation factors or other 
secreted molecules capable of inducing rPSC differentiation. Cell 
metabolism was compared in Cytodex 1 and Cytodex 3 microcarriers 
cultures to ensure that nutrient consumption and waste production were not 
limiting rPSC growth. Measurement of metabolite concentrations in the 
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medium (namely glucose and lactate) were performed daily and are 
presented in Figure 2.4. The results showed that for both cultures and up to 
9 days, there was no depletion of glucose levels. Concerning metabolic 
product, the levels of lactate never reached 20 mM, except in SP-Cyt1 at 
the last 2 days of cultivation (Figure 2.4).  
Figure 2.4. Glucose uptake and lactate release of rPSC cultured in Cytodex 1 and 
Cytodex 3 microcarriers, using spinner vessels and a 250 mL bioreactor. Metabolite 
concentrations are shown over 9 days of culture. 
 
In order to better characterize and compare the cell metabolism pattern of 
the two microcarrier cultures, the specific rates of nutrient consumption 
(qGLC) and metabolite production (qLAC) were calculated. Two phases were 
considered: one until the first reefed (Phase 1, from day 0 to day 3) and the 
other between the first and second refeeds (Phase 2, from day 3 to day 6) 
(Table 2.2). 
The values obtained for both cultures were similar. Overall, the specific 
consumption and production rates were higher within Phase 1, which is 
consistent with the high activity of cells at the beginning of the exponential 
phase in cell growth. In Phase 2, a decrease on all specific rates (qGLC and 
qLAC) was detected; at this time, cells were at the end of the exponential 
phase and entering into the death period, usually associated with a 
slowdown of their metabolic activity. The yields of lactate production from 
glucose consumption (YLAC/GLC) were also calculated in order to evaluate 
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the efficiency of glucose metabolism (Table 2.2).  The results showed that 
overall, YLAC/GLC were higher than 2, suggesting that glucose was totally 
converted to lactate via glycolysis and that other carbon sources are 
eventually being canalized to generate lactate. These findings indicate the 
occurrence of oxygen limitation in both spinner experiments. 
 
Table 2.2. Metabolic characterization of rPSCs cultured in Cytodex 1 and Cytodex 3 
microcarriers, using spinner vessels and a 250 mL bioreactor. The specific rates of glucose 
consumption (qGLC) and lactate production (qLAC) were calculated from day 0 to day 3 
(Phase 1) and from day 3 to day 6 (Phase 2). The apparent lactate from glucose (YLAC/GLC) 
yields was calculated for the two phases.   
 Spinner 
Cytodex 1 
Spinner 
Cytodex 3 
Bioreactor 
Cytodex 3 
 
Phase 1 Phase 2 Phase 1 Phase 2 Phase 1 Phase 2 
qGLC 
mol/(10
6
cells.days) 
15.1 10.6 13.0 8.0 12.7 9.5 
qLAC 
mol/(10
6
cells.days) 
32.5 23.5 29.0 17.9 20.3 11.4 
YLAC/GLC 2.1 2.2 2.2 2.2 1.6 1.2 
 
3.4. rPSCs expansion in a fully controlled bioreactor 
Since Cytodex 3 microcarriers have been shown to preferentially support 
PSCs growth on stirred suspension systems (best cell adherence and 
faster cell growth), the next challenge was to scale-up and control rPSCs 
growth by culturing cells in a 250 mL controlled bioreactor (BR-Cyt3). In this 
vessel, cells were cultured in the same conditions used for SP-Cyt3 
(agitation rate- 50 to 80 rpm, inoculum concentration- 1 x 105 cell/mL, bead 
concentration- 3g/L), except that, herein, cells previously attached to 
Cytodex 3 microcarriers were directly inoculated in the bioreactor. 
Furthermore, cultivation was performed in a fully controlled environment 
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(temperature-37ºC, pH-7.2, and pO2-30%), in order to overcome the 
oxygen limitation observed in the spinner culture (described above).   
Total cell concentrations of adherent cells are represented in Figure 2.3A, 
as well as the cumulative qLDH values achieved throughout culture time in 
Figure 2.3B. The first 4 h were characterized by a pronounced decrease in 
cell number; 50% of the total starting cells were detached from the beads. 
Simultaneously, qLDH was significantly higher at this time point than in 
spinner culture, confirming that increased cell lysis was taking place. Phase 
contrast photomicrograph showed that a smaller amount of cells remained 
attached to microcarriers in BR-Cyt3 than in SP-Cyt3 (Figures 2.5A and 
2.2A, respectively), confirming that the inoculation process was somehow 
aggressive for the cells. After 24 h, cells started to divide with a growth 
pattern similar to that obtained for SP-Cyt3, except that the exponential 
phase was extended until day 5 (Figure 2.3A). At this time, a high 
percentage of supports were totally covered by rPSC (Figure 2.5B); cell 
concentration reached the maximum value (2.3 x 105 cell/mL), yielding a 
two times higher fold increase in cell concentration than in SP-Cyt3 (4.6 
versus 2.2) (Table 2.1). From day 5 onwards, cells reached the death 
phase and detached from the beads (Figure 2.5C), resulting in increasing 
qLDH levels (Figure 2.3B). Growth characteristics were also compared for 
both culture systems (Table 2.1). The results obtained showed  the 
apparent growth rate was higher (0.35 day -1) and the doubling time was 
lower (47 h or 2 days) in BR-Cyt3 than in SP-Cyt3, confirming that cell 
growth was faster in the bioreactor culture. Overall these results can be 
justified by the metabolic performance of cells when cultured in a fully 
controlled environment. Neither depletion of nutrients nor accumulation of 
inhibitory waste concentrations was detected over culture time (Figure 2.4). 
The specific rates of metabolites consumption and production were 
estimated (Table 2.2). Furthermore no changes were detected in glucose 
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consumptions, while the levels of lactate production were significantly 
lower, resulting in yields of YLAC/GLC lower than 2 (1.6 and 1.2 for phase 1 
and phase 2, respectively); due to the higher oxygen availability to the cells, 
there was a more efficient use of glucose, thus resulting in a higher 
production of biomass  
 
Figure 2.5. Phase contrast photomicrographs of rPSCs cultured in Cytodex 3 
microcarriers in a 250 mL bioreactor. Cells were visualized after inoculation (A), by day 4 
(B) and at the end of cell cultivation, i.e., by day 9 (C). Scale bar: 100 m.  
 
3.5. Characterization of rPSCs expanded in microcarriers 
The distribution of rPSCs on the microcarriers surface was visualized by 
nestin staining using immunofluorescence microscopy. In the experiments 
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using the Cytodex supports, adherent cells, identified by nuclear DAPI 
staining, stained positive for nestin (Figure 2.6A).  
To evaluate the efficiency of each microcarrier culture system in expanding 
rPSCs, all populations were characterized in terms of self-renewal capacity 
and differentiation potential; this was done by evaluating telomerase activity 
and inducing adipocyte differentiation, respectively. The telomerase activity 
was analyzed for rPSCs derived from both static and microcarrier cultures 
(Figure 2.6C). In all cases, the absorbance readings of samples (A450nm-
A690nm) were higher than two-fold the value of the respective negative 
control (heat-treated samples), confirming that all samples were telomerase 
positive. In microcarrier cultures, the levels of telomerase activity were 
similar to the control, showing that expanded PSCs maintained the capacity 
to proliferate extensively in vitro. To examine the differentiation potential, 
rPSCs were cultured in adipocyte differentiation medium for 2 weeks. The 
presence of lipid deposits stained with Oil Red O (Figures 2.6B) 
demonstrated that these cells were able to differentiate into adipocytes.  In 
conclusion, all these findings demonstrate that after expansion in 
microcarriers, cells maintained the expression of rPSC marker, their self-
renewal ability and differentiation potential, confirming that they retained 
their stem cell behavior. 
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Figure 2.6. Characterization of rPSCs cultured in Cytodex 3 microcarriers.  By day 7, 
rPSCs growing adherent to the carriers were identified by nestin labelling (green), 
using immunofluorescence microscopy (A). Adipogenic differentiation was evaluated 
by lipid staining by Oil Red O (B). Scale bars: (A) 50 m and (B) 100 m. Telomerase 
activity of rPSCs was analyzed by day 7 of culture using a Telo TAGGG Telomerase 
PCR ELISA 
PLUS
 kit (C). The white bars show the results obtained for the rPSCs 
expanded in static (Static) and stirred (SP-Cyt1, SP-Cyt3 and BR-Cyt3) conditions. 
Negative controls (black bars) represent telomerase activity following inactivation by 
heat.  
 
4. DISCUSSION 
The first purpose of stem cell cultivation is to expand cells while maintaining 
their pluripotent potential, in order to produce large numbers of highly pure 
populations, adequate for controlled differentiation. In the present study, we 
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successfully developed an efficient strategy for the expansion of rPSC 
cultures in Cytodex 3 microcarriers using fully controlled bioreactors.  
A vast range of microcarriers is currently available, employing different 
materials and surface types, in order to allow the culture of different 
anchorage-dependent cell types in stirred conditions. This strategy has 
been widely used by our group in the development of scalable 
bioprocesses to grow mammalian cells in suspension bioreactors (Alves et 
al., 1996; Sa Santos et al., 2005).  In this work, the two microcarriers tested 
(Cytodex 1 and Cytodex 3), provided a suitable matrix for the expansion of 
PSCs under stirred conditions. A more efficient and robust cell adherence 
and proliferation was obtained using Cytodex 3 beads (Figure 2.3), which 
may be explained by the better adhesion of rPSCs to the collagen layer that 
covers the surface of the carriers. Cytodex 3 is specially designed for 
culturing sensitive cells and has been reported to be suitable for culture of 
primary brain cells (Santos et al., 2005), as well as for the expansion of 
mouse ESCs in suspension stirred systems (Fok and Zandstra, 2005; 
Abranches et al. 2007).  
Expanding rPSCs adherent to Cytodex 3 microcarriers resulted in stem cell 
population that retained their characteristics: rPSC marker, self-renewal 
ability and differentiation potential (Figure 2.6), proving to be of great 
advantage over culturing the cells as aggregates, where cells clumped 
together, did not proliferate and lost their nestin labeling (Figure 2.1). 
Although cell aggregates have been used in previous reports to expand 
undifferentiated murine embryonic stem cells (Cornier et al., 2007; zur 
Nieden et al., 2007), neural stem cells (Gilbertson et al., 2006) and 
carcinoma stem cells (Youn et al 2006), this approach revealed to be 
unfeasible for culturing PSCs (Figure 2.1). These differences in cell 
behavior may reflect the distinct tissue origins, as rPSCs are pluripotent 
adult stem cells derived from pancreas (Kruse et al 2004, 2006). Our 
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results suggest that rPSCs are anchorage-dependent and that adherence 
plays a role in the control of cell fate decisions.  
The potential of bioreactor technology was combined with the efficient 
Cytodex 3 strategy, resulting in a robust bioprocess for the expansion of 
PSCs. Under controlled environment (pH, pO2 and temperature), cell 
growth was more efficient, as shown by faster doubling time, higher growth 
rate and higher fold increase, when compared to spinner cultures (Table 
2.1). This improvement may be explained by the higher availability of 
oxygen (supplied by the bioreactor controller) to the cells. Comparison of 
apparent lactate from glucose yields obtained in stirred bioreactor and 
spinner vessels (YLAC/GLC = 1.6-1.2 and 2.2, respectively, Table 2.2) 
indicates that cells metabolized glucose more efficiently in the bioreactor, 
with lower production of lactate. Thus, the oxygen limitation observed in the 
spinners was successfully overcome in the bioreactor experimental setup, 
leading to an increased level of cell proliferation.  
The fold increase in cell concentration obtained in the bioreactor was not as 
high as those achieved for mESC cultured in Cytodex-3 microcarriers in 
spinner vessels (Fernandes et al, 2007) and neonatal porcine pancreatic 
cells cultured as spherical-islets (Chawla et al, 2006). PSCs are fusiform 
cells, with sizes up to 50 -100 µm, which limited the cell expansion ratio in 
microcarriers to the approximately 5-fold increase obtained in this study.  
Thus, in order to obtain higher expansion ratios, serial passaging with 
addition of fresh microcarriers can be incorporated. Moreover, alternative 
strategies, such as perfusion or fed-batch culture mode allowing the 
microcarrier feeding may be considered.  
In summary, this controlled and robust culture system for expansion of 
multipotent adult rPSCs, using stirred bioreactors, has proven to be a 
strong starting point for the development of novel technologies for cell 
therapy. 
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ABSTRACT  
Embryonal carcinoma (EC) stem cells derived from germ cell tumours 
closely resemble embryonic stem (ES) cells and are valuable tools for the 
study of embryogenesis. Human pluripotent NT2 cell line, derived from a 
teratocarcinoma, can be induced to differentiate into neurons (NT2-N) after 
retinoic acid treatment. To realize the full potential of stem cells, in vitro 
methods for stem cell proliferation and differentiation constitute a key 
challenge.  
Herein, a novel culture strategy for NT2 neuronal differentiation was 
developed to expand NT2-N neurons, reduce the time required for the 
differentiation process and increase the final yields of NT2-N neurons. NT2 
cells were cultured as 3D cell aggregates (“neurospheres”) in the presence 
of retinoic acid, using small scale stirred bioreactors; it was possible to 
obtain a homogeneous neurosphere population, which can be transferred 
for further neuronal selection into coated surfaces. This culturing strategy 
yields higher amounts of NT2-N neurons with increased purity, as 
compared with those routinely obtained for static cultures. Moreover, 
mechanical and enzymatic methods for neurosphere dissociation were 
evaluated in their ability to recover neurons, trypsin digestion yielding the 
best results. Nevertheless, highest recoveries were obtained when 
neurospheres were collected directly to treated surfaces without 
dissociation steps. 
This novel culture strategy allows improving drastically the neuronal 
differentiation efficiency of NT2 cells as a 4-fold increase was obtained, 
reducing simultaneously the time needed for the differentiation process. 
The culture method described herein ensures efficient, reproducible and 
scaleable ES cell proliferation and differentiation, contributing for the 
usefulness of stem cells bioengineering. 
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1. INTRODUCTION  
Human embryonic stem cells (hESCs) have been the focus of intense 
research since the first successful isolation of human inner cell mass (ICM) 
in 1994 (Bongso et al., 1994) and the establishment of the first hESC line 
nearly 4 years later (Thomson et al., 1998). These cells can be propagated 
in culture for extended periods and can differentiate into all somatic cell 
types (pluripotent cells), thus holding enormous prospect for the 
development of novel approaches for improving processes in cell therapy, 
tissue engineering, drug discovery and in vitro toxicology (Jones and 
Thomson, 2000; Davila et al., 2004; McNeish 2004). However, assessing 
and characterizing hESC lines can be difficult, time consuming and 
expensive due to demanding cell culture procedures and requirements 
under existing patents. To overcome this, hESC model systems are very 
valuable for predicting cellular behaviour and elucidating mechanisms 
involved in self-renewal and differentiation. Within this, several groups have 
proposed using embryonal carcinoma (EC) cell lines based on earlier 
observations that germ cells are pluripotent (Pal and Ravindran, 2006) and 
share characteristics with ESCs (Andrews, 2002). 
Pluripotent EC cells are derived from tumours known as teratocarcinomas 
that are understood to arise from transformed germ cells (Przyborski et al., 
2004). It is generally accepted that EC cells closely resemble ES cells and 
are often considered to be the malignant counterparts of ES cells (Andrews 
et al., 2001). In fact, EC stem cell lines provide a useful alternative to 
embryos for the study of mammalian cell differentiation (Stewart et al., 
2003). More specifically, the well-established NTera-2/cl.D1 (NT2) lineage, 
which has been derived from a human testicular cancer, offers a 
convenient and robust model for studying the commitment of human EC 
stem cells to the neural lineage and their subsequent differentiation into 
neurons (Andrews, 1984). Upon treatment with retinoic acid (RA), the NT2 
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cells can be induced to differentiate into postmitotic neurons (NT2-N) that 
express many neuronal markers (Pleasure et al., 1992). Using specific 
culture conditions these NT2-N neurons form functional synapses (Hartley 
et al., 1999) and express a variety of neurotransmitter phenotypes 
(Pleasure et al., 1993; Yoshioka et al., 1997; Guillemain et al, 2000). This 
cell line has also been used in several transplantation studies including 
engraftments in experimental animals (Ferrari et al, 2000; Watson et al., 
2003) and in human patients (Kondziolka et al., 2001). 
Although techniques have been developed to produce and purify NT2-N 
neurons from other contaminating cell types, these methods are laborious, 
yield relatively few neurons per culture, and are thus time consuming. 
Therefore, the last 2 years have witnessed an increase in experiments 
aimed at improving culture systems for enhanced neuronal productivity and 
reduced differentiation time (Durand et al., 2003; Horroks et al., 2003). 
These studies are focused on the cultivation of free floating cell spheres 
(neurospheres) under suspension conditions, using non-adherent Petri 
dishes. However, these static culture systems have several limitations that 
affect culture productivity, scalability and specially reproducibility. To 
overcome these limitations novel culture systems for proliferation and 
differentiation of NT2 cells are needed. So far, due to their characteristics 
and wide use, stirred culture systems, including fully controlled bioreactors, 
appear as promising candidates, as they are hydrodynamically well 
characterized, easy to scale-up, enable better homogeneity of cultures, 
reproducible experimental conditions and allow easy sampling. Within the 
field of stem cell expansion and differentiation several reports have been 
published using stirred tank bioreactors (Collins et al., 1998a; Collins et al., 
1998b; Sen et al., 2002; Youn et al., 2005; Cameron et al., 2006). However, 
these are previous approaches and more innovative strategies need to be 
explored. Up to now, the biggest restriction is still the low efficiency of the 
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stem cell differentiation process and this limitation is very critical when 
aiming towards scaleable protocols.  
The present work describes a novel culture system that enables the 
improvement of expansion and differentiation of NT2 cells. Herein, for the 
first time, a strategy was established to obtain neuronal differentiated from 
non-neuronal EC cells using stirred suspension conditions. Thus, culturing 
the NT2 cells as 3D aggregates (neurospheres) permitted increased yields 
of differentiated NT2-N neurons to be obtained in a shorter process time. 
The improvement of the culture system described here opens new 
perspectives for hESC technology field, by allowing promising strategies for 
stem cell proliferation and differentiation, a bottleneck for the expansion of 
this science and technology area. 
  
2. MATERIAL AND METHODS 
2.1. Cell culture 
Undifferentiated NT2 cells were routinely cultivated in standard tissue 
culture flasks (T75 culture flasks from Nunc) and maintained in OptiMEM 
medium (Gibco) supplemented with 5% (v/v) of fetal bovine serum (FBS, 
Hyclone) and 100 U/mL penicillin- streptomycin (P/S, Gibco).  
2. 2. Systems for NT2 neuronal differentiation 
In order to evaluate the effectiveness of the culture strategy developed 
herein (stirred conditions) protocols for culturing and differentiation NT2 
cells in static conditions reported in the literature were also performed. A 
brief description of both methodologies is summarized in Table 3.1. 
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Table 3.1. Comparison of neuronal differentiation protocols in static and stirred culture 
conditions for NT2 cells. 
 
 
 
2.2.1. Experiments in static conditions  
Control experiments of NT2 differentiation were done according to the 
procedure described in Pleasure et al 1992. Briefly, NT2 precursor cells 
were cultured in standard tissue culture flasks (T75 culture flasks from 
Nunc) and differentiated in Dulbecco’s Modified Eagle’s Medium (DMEM)-
High Glucose (HG) (Gibco) with 10% (v/v) FBS, 100 U/mL P/S and 10 μM 
retinoic acid (RA, Sigma) for five weeks into postmitotic NT2-N neurons. 
This cell culture was then trypsinized and replated at a lower density (total 
cells collected from one T75 culture were equally divided by two T175) and 
cultured in DMEM-HG with 5% (v/v) FBS containing 100 U/mL of P/S and 
mitotic inhibitors (1 μM cytosine arabinoside, AraC, 10 μM 
fluorodeoxyuridine, Fudr, and 10 μM uridine, Urd) (Sigma) for 12 days in 
order to obtain a NT2-N culture with maximum purity. After this period of 
culture in T175 culture flasks, NT2-N neurons were selectively trypsinized 
using a 1:3 diluted trypsin solution (Trypsin-EDTA 1X, liquid 0.05% Trypsin, 
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Gibco) in DMEM-HG medium. Subsequently, the cells were counted and 
transferred to plates/slides coated with PDL and MG (PDL-MG) for further 
experiments, including culture characterization using immunocytochemistry 
tools. 
2.2.2. Experiments in stirred suspension conditions  
This protocol was designed into three sequential steps where only the first 
one is performed in stirred suspension conditions. 
Step 1 - NT2 proliferation and differentiation in spinner vessels: NT2 cells 
were inoculated in a 125 ml spinner vessel (from Wheaton, Techne, NJ) 
equipped with ball impeller, at a density of 5x105 cell/ml. Throughout this 
step, cells were cultured in stirred suspension conditions for 16 days. 
Growth Period: During the first two days, undifferentiated NT2- cells were 
cultured in 80 ml of DMEM-HG medium (Invitrogen)) supplemented with 
10% (v/v) FBS (Hyclone) and 100 U/mL of P/S (Invitrogen)).  
Differentiation Period: From the third day onwards every 2-3 days (i.e, three 
times per week), retinoic acid (RA, Sigma) was added to the medium to 
yield a final concentration of 10 M in 100 ml of culture volume. Since 
sedimentation of neurospheres (similar to earlier published work described 
in Moreira et al, 1994) was too slow, yielding necrotic centers and dramatic 
loss of viability, another strategy was attempt; transferring half of culture 
supernatant to centrifuge tubes. After centrifugation at 200 g for 10 min, the 
collected cells/aggregates were ressuspended in new culture medium 
containing RA. Then, the cell suspension obtained was added to the 
remaining cell suspension in the spinner vessel to yield a final volume of 
100 mL. The agitation rate was increased during cultivation in order to 
avoid aggregate clumping and to control neurosphere size (Day 1 to Day 9 
– 60 rpm, Day 10 to Day 14 – 80 rpm, Day 15 upwards – 100 rpm). 
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Step 2 – Neurosphere Harvesting: After 16 days of culture, corresponding 
to 2 weeks of differentiation time, the NT2 neurospheres were collected. 
After that, both intact and dissociated neurospheres were plated (cell 
density 1-3x105cells/cm2) on T75 culture flasks (Nunc) coated with poly-D-
lysine (PDL, Sigma) and Matrigel (MG, Becton-Dickinson), and cultured 
under mitotic inhibitory conditions: DMEM-HG (Invitrogen)) supplemented 
with 5% (v/v) FBS (Hyclone), 100 U/mL of P/S (Invitrogen)), 1 M Ara C, 10 
M FudR and 10 M Urd (Sigma); the culture medium was partially (50%) 
replaced every 2 days.  
Step 3 – Selecting NT2-N neurons: After 7 days of culture in T75 culture 
flasks, NT2-N neurons were selectively trypsinized using a 1:3 diluted 
trypsin solution (Trypsin-EDTA 1X, liquid 0.05% Trypsin, Invitrogen)) in 
DMEM-HG medium. Subsequently, the cells were counted and transferred 
to plates/slides coated with PDL and MG (PDL-MG) for further experiments, 
including culture characterization using immunocytochemistry tools. 
2.3. Aggregates dissociation test  
Five protocols were compared for the dissociation of NT2 neurospheres 
obtained after cultivating aggregates in spinner vessel for 16 days, 
including mechanical and enzymatic methods. The same cell concentration 
was used for each dissociation protocol. In the mechanical assay, NT2 
aggregates were dissociated using a fire narrowed Pasteur pipette. In the 
enzymatic protocols, neurospheres were disrupted using four different 
solutions: TrypLe Select (Invitrogen), Trypsin-EDTA (1X) (liquid 0.05% 
Trypsin, Invitrogen), Accutase (Chemicon) and Accumax (Chemicon). For 
all assays a similar procedure was used: 1 mL of cell suspension was 
collected for each protocol and after centrifugation (200 g, 10 min) the 
neurospheres were incubated with 200 L of dissociation enzyme at 37ºC 
during 2 min. Then, 800 L of serum supplemented medium were added to 
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each sample. In all procedures cell density and viability were evaluated 
after dissociation. Cell density was assessed using a hemacytometer and 
viability was determined using the standard Trypan Blue exclusion test. The 
experiments were performed in triplicate.  
The different cell suspensions were then plated on 6-well plates (Nunc) 
precoated with PDL-MG and cells were cultured for up to 7 days under 
mitotic inhibitory conditions. All cultures were monitored daily using an 
inverted microscope (Leica, DM IRB). 
2.4. Aggregate size 
The aggregate size in each culture sample was measured using a 
micrometer coupled to an inverted microscope (Leica, DM IRB). The 
average diameter was calculated by measurement of two perpendicular 
diameters of a minimum of 15 aggregates. Aggregates less than 20 m in 
diameter (generally single cells or doublets) were not considered. 
2.5. Immunofluorescence microscopy 
Cell culture slides and cell aggregates: Aggregates and cell culture grown 
on glass coverslips were rinsed in phosphate-buffered saline (PBS) with 
0.5mM MgCl2 and fixed 20min in 4% (w/m) paraformaldehyde (PFA) 
solution in PBS with 4% (w/v) saccarose. After fixation cells were washed 2 
times with PBS and then incubated with permeabilization solution, TritonX-
100, 0.3% (w/v) diluted in PBS, during 20 min. Consequently, cells were 
washed again with PBS and kept in blocking solution composed of bovine 
serum albumine (BSA) 1% (w/v), and TritonX-100 0.1% (w/v) in PBS, for 1 
h. Cells were then incubated with primary antibodies diluted in PBS 
containing 0.1% (w/v) of TritonX-100, for 2 h at room temperature; the 
coverslips were washed 3 times with PBS and overlayed with secondary 
antibodies for 1 h at room temperature. After 3 washes with PBS, samples 
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were mounted in ProLong medium, supplemented with DAPI (Molecular 
Probes), for nucleus staining. Primary antibodies and dilutions used were: 
anti-Nestin (Nestin, 1:200, Chemicon), anti-Tubulin beta III isoform (-
TubIII, 1:10, Chemicon), anti-Neurofilament, light chain (NF-L, 1:200, 
Chemicon), anti-Neurofilament, heavy chain (NF200, 1:200, Chemicon), 
anti- Microtubule associated protein-2 (MAP2a&b, 1:100, Chemicon), anti-
Glial fibrillary acidic protein (GFAP, 1:200, Chemicon) and anti- 
Oligodendrocyte marker O4 (O4, 1:200, Chemicon). The secondary 
antibodies and dilutions used were: anti-mouse Alexa 488 (1:200) and anti-
rabbit Alexa 594 (1:500) from Molecular Probes. Cells were visualized 
using a fluorescence microscope (Leica DMRB).  
 
3. RESULTS  
3.1. NT2 neurospheres cultured in spinner vessel  
The ability to consistently and reproducibly grow large numbers of human 
neural cells in vitro is often limited by complex and demanding protocols. 
Since NT2 cells have been reported to successfully proliferate and 
differentiate on non-adhesive substrates as cell clusters (Durand et al., 
2003; Horroks et al., 2003), herein the challenge was to cultivate the NT2 
neurospheres in scalable and robust culture systems.  
Therefore, NT2 precursor cells were inoculated in a spinner vessel, at a 
density of 5x105 cell/mL. During the following 2 days of culture (Growth 
Period) the agitation rate was set up to low values in order to promote NT2 
cell aggregation. Under these conditions the NT2 precursor cells 
proliferated with a two-fold increase in cell concentration (results not 
shown) and successfully aggregated into small cell aggregates ranging 
from 50 to 100 m (average diameter 60.1  7.6 m) (Figure 3.1A).  
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Neuronal differentiation was induced by addition of RA two days after cell 
inoculation (Differentiation Period). Initially such aggregates had a ragged 
appearance (Figure 3.1B) but, as differentiation progressed their size 
diameter increased (ranging from 100 to 300m – average diameter 160.0 
 78.6m) and their structure stabilized forming solid and spherical 3D 
aggregates- neurospheres (Figure 3.1C, D). Here, an essential parameter 
that needs monitoring control is the aggregate/neurosphere size, which 
should be minimized in order to avoid detrimental diffusion gradients and/or 
decrease the differentiation potential of the culture. As reported previously 
(Moreira et al., 1994; Kallos et al., 2003), the agitation rate in suspension 
systems should be sufficient to control the diameter of neurospheres. 
Therefore, in this study, the rate of agitation was increased during culture 
time in order to ensure a homogenous neurosphere culture and avoid 
necrotic and apoptotic cells within the neurospheres.  
 After two weeks of RA treatments neurospheres were characterized in 
terms of cell composition using immunofluorescence microscopy. Figure 
3.1E shows that, at this time, neurospheres were composed by both nestin 
positive cells (undifferentiated stem cells and neural progenitor cells) and 
tubIII positive cells (NT2-N neurons). 
3.2. Neurospheres harvesting 
At day 16, neurospheres were collected and two different strategies were 
tested in order to evaluate the best method to recover the NT2-N neurons. 
On both strategies the cells were seeded into PDL-MG coated surfaces and 
cultured under mitotic inhibitory conditions for one week. 
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Figure 3.1. Phase contrast photographs of NT2 cells cultured in stirred conditions 
(spinner). Small cell aggregates ( 50 m) were observed at day 2 (A). Afterwards these 
neurospheres grew in number (B- day 5) and in size (C- day 10), yielding an average 
diameter of approximately 300 m at day 15 (D). (E) Immunofluorescence image of NT2 
neurospheres collected at day 16: double labelling with b-TubIII (green) and nestin 
(red).Scale bar: 100m (A,B,C,D); 50m (E).  
 
Chapter 3. Novel strategy for neuronal differentiation of human stem cells 
 90 
On the first strategy, neurospheres were dissociated using five different 
protocols (including enzymatic and mechanical methods). In order to 
investigate and select the best procedure, these results were compared in 
terms of final single cell concentration and viability after each specific 
dissociation procedure. As shown in Figure 3.2, enzymatic methods led to 
higher cell viabilities (> 90% in all protocols) than the mechanical 
procedure. In addition, higher amounts of cell debris were present in 
mechanical dissociated cultures. These findings suggest that the 
mechanical procedure is very aggressive for NT2 neurosphere dissociation. 
When the enzymatic dissociation protocols were compared for final single 
cell concentration, the highest value was observed for samples dissociated 
with Trypsin, which was also the method that enhanced better neurosphere 
dissociation, when monitored by microscopic inspection (Figure 3.3, Day 0). 
The remaining enzymatic dissociation assays (TrypLE Select, Accutase 
and Accumax) were less efficient as several cell aggregates were detected 
in each cell suspension following the dissociation procedure (Figure 3.3, 
Day 0). Moreover, the values of final cell concentration were lower when 
compared to the samples dissociated with Trypsin (Figure 3.2).    
 
Figure 3.2. Effect of neurosphere dissociation protocol in concentration of viable 
(white bars) and non viable (grey bars) cells.  
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Figure 3.3. Phase contrast micrographs showing the neurosphere dissociated 
cultures obtained immediately after each dissociation procedure and following 7 
days of culture under mitotic inhibitory conditions. The column in the right 
corresponds to a 4-fold magnification of the corresponding culture shown in the 
centre column. Scale bar: 50m.
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After 7 days of culture, it was observed that Trypsin dissociated cultures 
assured better NT2-N neuron preservation (Figure 3.3) as they yielded 
higher fractions of NT2-N neurons (quantified by cell counting after 
selective trypsinization, see Materials and Methods) from the total number 
of NT2 cells at neurosphere harvesting. This percentage of neuronal 
differentiation was higher on Trypsin dissociated cultures (approximately 
6.8%) than on the others dissociated cultures (less than 1%), where smaller 
amounts of NT2-N neurons were detected on PDL-MG coated surfaces 
(Figure 3.3). Therefore, Trypsin digestion was selected as the best method 
for neurosphere dissociation since it promoted higher recovery of NT2-N 
neurons. 
On the second strategy, non-dissociated neurospheres were directly plated 
into PDL-MG coated surfaces. After 7 days of culture, no cell aggregates 
were detected in the cultures plates. Besides that, higher amounts of NT2-
N neurons with extensive neuritic networks were covering the entire 
surface. Here, the fraction of NT2-N cells achieved from the initial 
neurosphere harvesting was 12.3%, approximately 2 times higher than 
those reached in the trypsin dissociated cultures. These results suggested 
that harvesting non-dissociated neurospheres is the best strategy to 
recover NT2-N neurons. 
Neurospheres and trypsin dissociated NT2 cells were also plated directly 
on uncoated tissue cultures flasks at harvesting time. However neither 
neurospheres nor dissociated cells attached to those untreated surfaces 
(results not shown). 
3.3. NT2-N selection and characterization 
Following neurospheres harvesting to coated surfaces, non-dissociated 
neurospheres cultures were further characterized in order to describe the 
changes and evolution of the cultures. 
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Figure 3.4. Characterization of NT2-N cultures. (A) Non-dissociated NT2 neurospheres 
adhered well on PDL-MG coated surfaces after 1 day of neurosphere platting. At this 
time, neurospheres sprout large numbers of non neuronal cells and also some neurons. 
(B) Immunofluorescence image of NT2 cultures after 1 day of neurosphere harvesting: 
Double labelling with -TubIII (green) and nestin (red). (C) After 7 days, the culture 
became enriched into well differentiated NT2-N neurons. (D) Immunofluorescence 
images of NT2 cultures after 7 days of neurosphere harvesting: Double labelling with b-
TubIII (green) and nestin (red). Nuclei are labelled with DAPI (blue). (E) Pure cultures of 
NT2-N neurons obtained upon selection. (F-I) Immunofluorescence images in pure NT2-
N cultures: NT2-N neurons labelled with FTubIII, (G) NF-L, (H) MAP2a&b and (I) 
NF200. Scale bar: 50m.  
 
After 1 day of neurosphere platting, non-dissociated NT2 neurospheres 
adhered well on PDL-MG coated surfaces. During the first days, 
neurospheres sprout large numbers of non neuronal cells and also some 
NT2-N neurons; at this time, cultures are composed by stem cells, neural 
progenitor cells and differentiated cells as detected by phase-contrast 
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microscopy (Figure 3.4A). This observation was confirmed by double 
staining the cell cultures using antibodies specific for either the 
undifferentiated and neural progenitor NT2 cells (rabbit anti-nestin) or NT2-
N neurons (mouse anti-TubIII) (Figure 3.4B). Incubation with mitotic 
inhibitory conditions led to an elimination of proliferating NT2- cells and the 
cultures gradually became enriched into differentiated NT2-N neurons and 
extensive neuritic networks. After 7 days of treatment, it was detected that 
95% of the cells present in culture plates were NT2-N neurons; the rest of 
the cell population appeared as flat cells with extensive cytoplasms (Figure 
3.4C,D). At this point, no cell aggregates were detected in the culture 
plates.  
To further enrich for neurons, these cells were selectively dislodged (see 
Material and Methods) and plated into new culture dishes coated with PDL 
and MG. As shown in Figure 3.4E, pure cultures of NT2-N neurons with 
extensive neuritic networks covering the entire surface were obtained upon 
selection. 
The identity of those final pure cultures was confirmed by positive staining 
for the neuronal markers NF-L, NF200, -TubIII and MAP2a&b (Figure 
3.4E-I). By the end of the culturing strategy, the cells were also stained for 
neural precursor cell (Nestin) and glial markers (GFAP for astrocytes and 
O4 for oligodendrocytes). Neither Nestin nor GFAP and O4 positive cells 
were detected in the final cultures of NT2-N cells (not shown).  
3.4. Expansion and differentiation apparent rates of NT2 cells in 
stirred and static cultures  
To assess the level of functionality of this novel NT2 differentiation process, 
the apparent rate of expansion (i.e. the rate of cell expansion obtained after 
RA treatment period – 35 days in static and 16 days in stirred culture) and 
the apparent rate of differentiation (i.e. the rate of cell differentiation 
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achieved during the RA treatment period- 35 days in static and 14 in 
stirred) were compared for the static and stirred suspension culture. For 
this, it was assumed that no NT2-N cells were present at inoculation day 
(day 0) and that differentiation occurs during incubation with RA. 
Subsequent steps for neurons selection and recover were not considered 
at the apparent differentiation rates calculation. 
Figure 3.5 shows that the lengthy static adherent culture protocol promotes 
higher apparent rate of expansion (5.6×103 cell.mL-1.h-1) compared to cells 
cultured in stirred suspension vessels (2.5×103 cell.mL-1.h-1). Concerning 
the apparent ratio of differentiation the highest value was achieved in 
stirred suspension culture (5.4×102 NT2-N cell.mL-1.h-1 comparing to 
1.9×102 NT2-N cell.mL-1.h-1 obtained in static culture). These findings 
suggest that higher amounts of contaminant cells are produced in static 
cultures.  
 
 
Figure 3.5. Apparent rates of NT2 cell expansion (white bars) and 
neuronal differentiation (grey bars) obtained by static and stirred (spinner 
culture) differentiation protocols.   
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Due to the specific limitations of each culture system (surface area in static 
system and minimal cell concentration in stirred culture) different cell 
inoculation densities were used, approx. 2×105 cell/mL and 5×105 cell/mL 
for static and stirred culture, respectively. Therefore the apparent 
differentiation rates results suggest that the neuronal differentiation 
potential of both culture strategies was practically similar. 
3.5. Neuronal differentiation of NT2 cells in stirred and static 
cultures 
At the end of each neuronal differentiation strategy, the final concentrations 
of NT2-N neurons were calculated. Table 3.2 shows that higher 
concentrations of NT2-N neurons were achieved by the stirred culture 
strategy in 23-28 days (1.8×105 cells/mL). In the lengthy static culture 
protocol the final concentration of NT2-N neurons was about 1.6×105 
cell/mL, after 47-53 days of culture. 
Table 3.2. Comparison of static and stirred culture conditions for NT2 neuronal 
differentiation. 
 Static Culture Stirred Culture 
Differentiation Time 47 days 23 days 
NT2-N final concentration 1.6×10
5
 cell/mL 1.8×10
5
 cell/mL 
Differentiation Efficiency 3.2 ± 0.8 % 13.6 ± 1.8 % 
Laborious Yes No 
Scalable No Yes 
 
Neuronal differentiation efficiency was also compared by analyzing the ratio 
between the number of reached NT2-N neurons and the total amount of 
NT2 cells harvested after RA treatment period (Table 3.2). For this, three 
experimental trials were evaluated for each differentiation 
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system.Reproducible results showed that the lowest value of differentiation 
efficiency was achieved by the static culture protocol (3.2 ± 0.8 %) which 
was shown to be about four times less efficient than the stirred culture 
protocol (13.6 ± 1.8%).  
 
4. DISCUSSION 
Several static culture protocols used for NT2 differentiation have been 
proposed to date. However, they were found to be time consuming, 
extremely laborious, to produce low yields of neurons per culture and not to 
be scalable (Pleasure et al., 1992; Durand et al., 2003; Horroks et al., 
2003). Herein, a novel strategy to expand, accelerate and enhance the 
neuronal differentiation process of NT2 cells was developed, overcoming 
those process limitations. Therefore, the challenge was to improve the 
proliferation and differentiation steps, by culturing NT2 cells as 3D 
aggregates in the presence of RA, using suspension stirred bioreactors, 
without compromising their differentiation potential.  
Culturing NT2 cells in spinner flasks yielded neurospheres with 
homogenous morphology (Figure 3.1) and avoided neurosphere clumping, 
resulting in a more efficient NT2 population than found in static cultures 
(Pleasure et al., 1992; Durand et al., 2003).  
Moreover, the protocol developed drastically improves neuronal 
differentiation efficiency as compared with static cultures; a 4-fold increase 
of NT2 cells expressing several neuronal markers together with a reduced 
time required for the differentiation process is achieved (Table 3.2, Figure 
3.5). The finding that NT2 differentiation is faster and more efficient in 
suspension than in adherent systems agrees with the results previously 
reported by Durand et al (2003). Although the studies reported by Durand 
et al. were performed in static conditions the authors clearly show that both 
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cell-cell contacts (within the neurospheres structures) and RA contribute to 
a more rapid neuronal differentiation process than in the conventional 
protocol using cell monolayer culture (Pleasure et al., 1992).  
The decrease in the NT2 apparent expansion rate obtained for the 
suspension stirred system does not compromise the differentiation potential 
of NT2 precursors, suggesting that the proposed culturing protocol directs 
more efficiently the neuronal differentiation process reducing the 
percentage of contaminant cells (Figure 3.5). These are important 
achievements towards the development of scaleable protocols for stem cell 
differentiation; i.e. significant improvement of differentiation process 
efficiency and, ultimately  reaching higher concentrations of Human 
Neurons, one of the current drawbacks of stem cell technology (revised in 
Kallos et al., 2003 and Ulloa-Montoya et al., 2005).  
After NT2 expansion and differentiation, an efficient neurosphere 
harvesting process is required to assure a good recovery of differentiated 
neurons.  Several protocols for NT2 cells and neurosphere dissociation 
have been proposed to date (Pleasure et al., 1992; Sen et al, 2004). 
However, due to the sensibility of neuronal cells and neurosphere 
complexity, the preservation of NT2 neurons after each dissociation 
procedure could be compromised. In the present study, both mechanical 
and enzymatic methods were evaluated, trypsin digestion being selected as 
the best strategy for neurosphere dissociation and NT2-N preservation. 
Nevertheless, the highest recovery of NT2-N neurons was achieved when 
non-dissociated neurospheres were collected directly to treated surfaces 
(with PDL-MG). This result indicates that both neurosphere dynamics and 
the matrix surfaces (PDL-MG) are sufficient to provide an optimal system 
for NT2-N neuron selection in a second step to optimize the neuronal 
differentiation process.      
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Overall, this study demonstrates that culturing human NT2 cells in stirred 
tank bioreactors increase by 4-fold culture differentiation efficiency. 
Furthermore, the possibility to include an additional period for precursor 
cells proliferation is also of great advantage, as it brings flexibility in what 
concerns the possibility to expand precursor NT2 cells before induction of 
neuronal differentiation, yielding higher numbers of final NT2-N cells per 
volume of culture. Static systems do not allow this design as culture surface 
limits the NT2 neuronal differentiation potential.  
In conclusion, this culture method is promising for NT2 proliferation and 
differentiation, assuring a robust, easy to operate, scalable and 
reproducible system to culture NT2 pluripotent cells under a fully controlled 
environment.  
Studies on bioprocess optimization (including the effect of several process 
parameters such as pO2, medium composition, growth factor 
concentrations, feeding strategies, agitation rate) are ongoing aiming for 
further improvement of NT2 differentiation yields. Hopefully, the knowledge 
gained using this cell model will allow for a more straightforward application 
for the culture of human ES cells in bioreactors, a challenge of stem cells 
bioengineering.   
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CHAPTER 4 
INTEGRATING STEM CELL EXPANSION AND 
NEURONAL DIFFERENTIATION  
 
 
 
 
This chapter was based on the following manuscript: 
Serra, M., Brito, C., Costa, E.M., Sousa, M.F. and Alves, P.M., 2009. Integrating human 
stem cell expansion and neuronal differentiation in bioreactors. BMC Biotechnol. 9, 82. 
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ABSTRACT  
Human stem cells are cellular resources with outstanding potential for cell 
therapy. However, for the fulfillment of this application, major challenges 
remain to be met. Of paramount importance is the development of robust 
systems for in vitro stem cell expansion and differentiation. In this work, we 
successfully developed an efficient scalable bioprocess for the fast 
production of human neurons.  
The expansion of undifferentiated human embryonal carcinoma stem cells 
(NTera2/cl.D1 cell line) as 3D-aggregates was firstly optimized in spinner 
vessel. The media exchange operation mode with an inoculum 
concentration of 4x105 cell/mL was the most efficient strategy tested, with a 
4.6-fold increase in cell concentration achieved in 5 days. These results 
were validated in a bioreactor where similar profile and metabolic 
performance were obtained. Furthermore, characterization of the expanded 
population by immunofluorescence microscopy and flow cytometry showed 
that NT2 cells maintained their stem cell characteristics along the 
bioreactor culture time.  
Finally, the neuronal differentiation step was integrated in the bioreactor 
process, by addition of retinoic acid when cells were in the middle of the 
exponential phase. Neurosphere composition was monitored and neuronal 
differentiation efficiency evaluated along the culture time. The results show 
that, for bioreactor cultures, we were able to increase significantly the 
neuronal differentiation efficiency by 10-fold while reducing drastically, by 
30%, the time required for the differentiation process.  
The culture systems developed herein are robust and represent one-step-
forward towards the development of integrated bioprocesses, bridging stem 
cell expansion and differentiation in fully controlled bioreactors. 
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1. INTRODUCTION  
Many neurodegenerative disorders, such as Parkinson’s disease, are 
caused by the impairment or death of neurons in the central nervous 
system (Storch and Schawarz, 2002). In the future, it is hoped that large 
numbers of stem cell-derived neurons will be produced in culture with the 
purpose of being used in clinical applications (Jones and Thomson, 2000). 
Hampering the faster implementation of the ambitious stem cell therapy 
technology, there is still the need of efficient, robust and scalable 
bioprocesses for cell expansion and/or differentiation in vitro.  
During the last five years, substantial progress has been made towards this 
goal (King and Miller, 2007; Ulloa-Montoya et al 2005). Stirred suspension 
systems have been pioneered, by others and ourselves, as a promising in 
vitro system for stem cell expansion (Serra et al., 2009; Cormier et al., 
2006), embryoid body cultivation (Niebruegge et al., 2009; Cameron et al., 
2006) and stem cell differentiation into specific cell types (Serra et al., 
2007). These systems offer attractive advantages of scalability and relative 
simplicity; stirring provides a more homogenous culture environment and 
allows the measurement and control of extrinsic factors such as nutrient 
and cytokine concentration, pH and dissolved oxygen (pO2) (Zandstra and 
Nagy, 2001).  
Aiming to improve the yields of specific stem cell stages, several culture 
parameters have been optimized, including the agitation rate, cell inoculum 
concentration and medium composition (King and Miller, 2007; Ulloa-
Montoya et al., 2005; Zhao and Ma, 2005), and different culturing 
approaches have been developed such as the use of microcarrier supports 
(Serra et al., 2009) and cell encapsulation (Zhao and Ma, 2005). Perfusion 
and frequent feeding operation modes have been shown to increase the 
expansion of mesenchymal stem cells (Zhao and Ma, 2005), embryonic 
stem cells (Fong et al., 2005; Come et al 2008) and mammary epithelial 
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stem cells (Youn et al., 2006), without compromising their stem cell 
performance.  
Computer-controlled bioreactors are particular advantageous for process 
development by allowing the online monitoring and control of specific 
culture parameters (temperature, pH and pO2), ensuring a fully controlled 
environment for stem cell cultivation. Oxygen-controlled bioreactors have 
been used for culture of mouse and human ESC-derived cardiomyocytes 
(Niebruegge et al., 2009; Bauwens et a., 2005). Gilbertson et al (Gilbertson 
et al., 2006) were the first group to use controlled conditions for neural 
precursor cell culture as aggregates; the authors report the successful 
expansion of mouse neural stem cells in 500 mL bioreactors (temperature, 
pH and pO2 control) while retaining the cell multilineage potential 
(Gilbertson et al., 2006). More recently, this system was applied to the 
culture of human neural precursor cells (Baghbaderani et al., 2008). The 
expansion of various human stem cell types in bioreactors under defined 
and controlled conditions remains to be addressed. Future challenges also 
include the combination of expansion and directed differentiation steps in 
an integrated bioprocess that will ultimately result in scale-up of well 
differentiated cells to clinically relevant numbers.  
Within this context, the present work focused the development of a 
reproducible scalable system for the production of human neurons derived 
from expanded and differentiated stem cells. The human embryonal 
carcinoma cell line NTera-2/cl.D1 (NT2) was the cellular system used 
because it is a valuable model for both undifferentiated human embryonic 
stem cells (hESCs) (Andrews, 2002) and human neuronal differentiation in 
vitro (Przyborski et al., 2004). In addition, the neurons derived from this cell 
line have been successfully used in transplantation studies in several 
mouse models and in human stroke patients (Kondziolka and Wechsler, 
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2008), providing also promising material for cell therapy investigations in 
central nervous system. 
Herein, undifferentiated NT2 cells were cultivated as 3D-aggregates in 
controlled stirred suspension conditions. In order to improve the yields of 
stem cells, two parameters were studied: (i) the inoculum concentration, as 
it has been shown to be critical in enhancing cell aggregation and culture 
profile (Cormier et al., 2006), and (ii) the culture operation mode, since it 
has been demonstrated that the feeding strategy affects cell metabolism 
and consequently could improve cell culture performance (Zhao and Ma, 
2005; Bauwens et al., 2005; Xie and Wang, 2006). At the end, the 
expansion of undifferentiated NT2 cells, followed by directed neuronal 
differentiation were integrated in stirred bioreactors with temperature, pH 
and pO2 control, in an effort to develop a promising model system for the 
production of human stem cell derivatives. 
  
2. MATERIAL AND METHODS 
2.1. Cell culture 
NTERA-2/cl.D1 cells (NT2) were obtained from the CNDR, University of 
Pennsylvania School of Medicine. Undifferentiated NT2 cells were routinely 
cultivated in standard tissue culture flasks (Nunc) and maintained in 
OptiMEM medium (Invitrogen) supplemented with 5% (v/v) of fetal bovine 
serum (FBS, Hyclone) and 100 U/mL of penicillin- streptomycin (P/S, 
Invitrogen), according to method described at Brito et al.(Brito el al., 2007).  
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2.2. Stirred Suspension Culture 
2.2.1. Undifferentiated NT2 cell expansion in spinner vessels 
Undifferentiated NT2 cells (passage 60-62) were cultured as 3D-
aggregates in 125-mL spinner vessels (Wheaton) equipped with a ball 
impeller and maintained at 37ºC and 5% CO2 for up to 7 days.  The 
agitation rate was increased during cultivation in order to avoid aggregate 
clumping and to control aggregate size (day 0 to 2 – 60 rpm, day 2 to 3 – 
70 rpm, day 3 to 4 – 80 rpm, day 4 upwards – 90 rpm). Two independent 
experiments were performed for each expansion strategy. 
Inoculum Concentration Experiments – Cells were cultured in a batch 
operation  mode in Dulbecco’s Modified Eagle’s Medium- High Glucose 
(DMEM-HG, 25 mM glucose) (Invitrogen) supplemented with 10% (v/v) 
FBS and 100 U/mL of P/S (complete DMEM-HG). The cell inoculum 
concentrations evaluated were: 0.4x105, 1x105 and 4x105 cell/mL; for an 
easier reading the nomenclature used was SP-0.4B, SP-1B and SP-4B, 
respectively. In SP-0.4B and SP-1B, cells were cultured in 75 mL of 
medium at 50 rpm during the first 4-8 h, to promote cell aggregation.  
Culture Operation Mode Experiments – Glucose fed-batch and medium 
exchange culture operation modes were performed using an inoculum cell 
density of 4x105 cell/mL; the nomenclature used for these experiments 
were SP-4FB (SP- spinner, FB- fed-batch) and SP-4ME (SP- spinner, ME- 
media exchange), respectively. In SP-4FB, the culture medium was DMEM-
Base (Sigma) supplemented with 10% (v/v) FBS, 4mM of glutamine 
(Invitrogen), 100 U/mL P/S and 1.4 mM of glucose (Merck). During culture 
time, glucose concentration was monitored twice a day and maintained at 
lower levels (<1.4 mM); refeeds were performed accordingly to the 
consumption rates (calculated from 2 consecutive samples).  SP-4ME was 
cultured in similar conditions to those described for SP-4B, except that 
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medium was partially exchanged daily from the day 3 onwards as follows: 
fifty percent of culture media was collected in sterile conditions and 
centrifuged at 200x g for 5 min; the supernatant was discarded and the 
recovered cell aggregates gently resuspended in an equivalent volume of 
pre-warmed complete DMEM-HG.  
For all spinner cultures, sampling (2.5 mL) was performed 4 h after 
inoculation and daily from then on. Cell aggregates were monitored under 
an inverted microscope (Leica DM IRB). Cell concentration, metabolite 
concentration and lactate dehydrogenase activity were analyzed as 
described below.  
2.2.2. NT2 culture in a fully controlled bioreactor 
To ensure fully controlled cell culture environment, a stirred tank bioreactor 
(Santos et al., 2005) equipped with ball impeller and pH and dissolved 
oxygen (pO2) measuring probes (Mettler-Toledo) was used for the 
expansion and differentiation of  NT2 cells. The pH was kept at 7.2 by 
injection of CO2 and addition of base (NaOH, 0.2 M). The pO2 was 
maintained at 25% via surface aeration. The temperature was kept at 37ºC 
by water recirculation in the vessel jacket controlled by a thermocirculator 
module. Data acquisition and process control were performed using 
MFCS/Win Supervisory Control and Data Acquisition (SCADA) software 
(Sartorius-Stedim, Germany).  
NT2 cell expansion – The SP-4ME experiment was reproduced in the 
bioreactor system, using undifferentiated NT2 cells with 60-62 passages in 
static conditions. Moreover, cells used for the inoculum (day 0) and at days 
3 and 6 of cultivation in the bioreactor, were characterized using 
immunofluorescence tools and the neuronal differentiation potential 
evaluated (see below).  
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NT2 neuronal differentiation – Undifferentiated NT2 cells with up to 62 
passages in static conditions were expanded in the bioreactor, in complete 
DMEM-HG, using an inoculum concentration of 4x105 cell/mL. 
Differentiation was initiated in the middle of the exponential phase (day 3), 
following the differentiation protocol developed by Serra et al (Serra et al., 
2007). Briefly, neuronal differentiation was induced by addition of retinoic 
acid (RA, Sigma) to the culture media, at a final concentration of 10 µM. A 
50% media exchange was performed 3 times a week on a regular basis for 
up to 24 days. Two bioreactor independent experiments were performed. 
Samples were collected from the bioreactor at 3 time points: day 9, 16 and 
23 (corresponding to 1, 2 and 3 weeks of differentiation process). Cell 
concentration and neurosphere size were determined and culture was 
characterized using immunofluorescence microscopy. Neurospheres 
harvested at the referred time points were transferred to coverslips or 
culture flasks (5x104 cell/cm2) coated with poly-D-lysine (PDL, Sigma) and 
Matrigel (MG, Becton-Dickinson) and cultured for up to 7 days in mitosis 
inhibitor (MI) medium: DMEM-HG supplemented with 5% FBS, 100 U/mL of 
P/S, 1 µM cytosine arabinosine (Sigma), 10 µM fluorodeoxyuridine (Sigma) 
and 10 µM uridine (Sigma). Neurons were selectively trypsinized (22,23) 
using  a 0.015% Trypsin-EDTA solution (prepared from Trypsin-EDTA 1X, 
liquid 0.05% Trypsin, Invitrogen), counted and transferred to coverslips 
coated with PDL and MG for characterization by immunocytochemistry. 
Neuronal differentiation efficiency was defined as the ratio between the 
number of neurons obtained after 7 days of culture in MI medium and the 
total amount of cells harvested at the 3 different harvesting times.  
Figure 4.1 summarizes the experimental outline used for expansion and 
differentiation processes. 
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2.3. Analytical methods 
2.3.1. Cell concentration determination  
Cell aggregates were dissociated by a 2 min incubation with Trypsin-EDTA 
(0.05%) at 37ºC followed by cell resuspension in complete DMEM-HG. Cell 
density was assessed using a Fuchs-Rosenthal haemocytometer (Brand, 
Wertheim, Germany) and cell viability estimated by the standard trypan 
blue exclusion test. 
2.3.2. Aggregate diameter 
Aggregate size in each culture sample was determined using a micrometer 
coupled to an inverted microscope (Leica, DM IRB). Two perpendicular 
diameters of a minimum of 15 aggregates were measured and the average 
diameter was calculated. Aggregates less than 20 µm in diameter 
(generally cell doublets or triplets) were not considered for calculations as 
they represent a small percentage of the total cell number in culture. 
2.3.3. Lactate dehdrogenase activity 
Lactate dehydrogenase (LDH) activity from the culture supernatant was 
determined as an indirect way of assessing cell death. LDH activity was 
determined by following spectrophotometrically (at 340 nm) the rate of 
oxidation of NADH to NAD+ coupled with the reduction of pyruvate to 
lactate.The specific rate of LDH release (qLDH, U.day
-1.cell-1) was calculated 
for every time interval using the following equation: qLDH = ΔLDH/(Δt ΔXV), 
where ΔLDH (U) is the change in LDH activity over the time period Δt (day) 
and ΔXv (cell) is the average of total cells during the same time period. 
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Figure 4.1. Experimental outline for NT2 cell sampling and characterization during 
expansion (A) and differentiation (B) in fully controlled bioreactors. (A) In expansion 
runs, cells were harvested from days 0 (inoculum), 3 and 6 and immediately 
characterized by flow cytometry. Harvested cells were plated on glass coverslips 
and processed for immunofluorescence microscopy analysis after 2 days or plated 
in tissue culture flasks for induction of neuronal differentiation. For this, cultures 
were treated with retinoic acid (RA) for 5 weeks, splitted and further cultured in 
mitosis inhibitory (MI) conditions. After 12 days in MI, the neurons were harvested, 
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identified by immunofluorescence microscopy using neuronal markers and neuronal 
differentiation efficiencies were calculated. (B) In differentiation runs, the addition of 
RA was initiated at day 3 of bioreactor culture and prolonged for 3 weeks. 
Neurospheres were harvested at day 9, 16 and 23. The latest were analyzed by 
cryosection immunofluorescence microscopy. All neurosphere harvested were 
plated in static culture flasks and cultured in MI conditions. After 3 days, cultures 
were characterized by immunofluorescence microscopy and after 7 days and 
neuronal differentiation efficiencies were calculated.   
 
The cumulative value qLDHcum was estimated by qLDHcum i+1 = qLDH i + qLDH i+1. 
The fold increase of the specific LDH release rates achieved throughout 6 
days of cultivation were determined by calculating the ratio between the 
values of qLDHcum obtained at day 6 and day 0. These values indirectly 
represent the fold increase in cell lysis obtained within 6 days of culture. 
2.3.4. Metabolite analysis 
Glucose (GLC), lactate (LAC) and glutamine (GLN) concentrations in the 
culture medium were analyzed using an YSI 7100MBS (YSI Incorporated, 
USA). Ammonia was quantified enzymatically using a commercially 
available UV test (Roche, Germany). 
The specific metabolic rates (qMet., mol.day
-1.cell-1) were calculated using 
the equation: qMet. = ΔMet/(Δt ΔXv), where ΔMet (mol) is the variation in 
metabolite concentration during the time period Δt (day) and ΔXv (cell) the 
average of adherent cells during the same time period.  
2.3.5. Apparent growth rate and fold increase in cell expansion  
Apparent growth rates and fold increase parameters were calculated for all 
expansion cultures. Apparent growth rates (, day-1) were calculated using 
a first order kinetic model for cell expansion: dX/dt = X, where t (day) is 
the culture time and X (cell) is the value of viable cells for a specific t. The  
values were estimated applying the model to the slope of the curves during 
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the exponential phase. The fold increase in cell expansion (FI) was defined 
as the ratio XMAX/X0, where XMAX is the peak cell density (cell/mL) and X0 is 
the inoculation cell density (cell/mL).  
2.4. Differentiation potential 
To assess the neuronal differentiation potential along the expansion 
assays, 2.3x106 cells were collected from the suspension cultures and 
plated in a T75 flask (Nunc). NT2 cells were differentiated into post-mitotic 
neurons according to Pleasure et al (Pleasure et al., 1992). Briefly, cells 
were cultured for 5 weeks in complete DMEM-HG supplemented with 10 
µM RA. Cells were splitted at 1:4.5 ratio and cultured in MI medium for 12 
days. After this period, neurons were selectively trypsinized, as described 
above, counted and transferred to coverslips coated with PDL and MG for 
characterization by immunocytochemistry. Neuronal differentiation 
efficiency was defined as the ratio between the number of neurons 
obtained after culture in MI medium and the total amount of cells harvested 
after RA treatments. 
2.5. Immunofluorescence microscopy 
In expansion cultures, cell aggregates were collected at day 3 and 6, 
dissociated using Trypsin-EDTA (0.05%) at 37ºC followed by cell 
resuspension in complete DMEM-HG, and transferred to glass coverslips. 
Three days after plating, cultures were characterized. In differentiation 
assays neurospheres were harvested from the bioreactor cultures at day 9, 
16 and 23, and processed for cryosection or transferred to coverslips 
coated with PDL and MG (see Figure 4.1).  
Cells in coverslips were washed in PBS with 0.5 mM MgCl2 and fixed in 4% 
(w/v) paraformaldehyde solution in PBS with 4% (w/v) sucrose, for 20 min. 
For cryosection, neurospheres were washed in PBS, transferred to a tissue 
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protecting compound (Tissue Teck, OCT™ Compound) and frozen at -
80ºC. Ten µm sections, obtained using a cryostat (Leica), were rehydrated 
with PBS and fixed in methanol, at -20ºC, for 10 min. After fixation, the 
same procedure was followed for cryosections and coverslips. 
For staining intracellular epitopes, cells were permeabilized with 0.1% (w/v) 
Triton X-100 (TX-100) in PBS, for 15 min. After 1 h in blocking solution 
(0.2% (w/v) fish skin gelatin in PBS), cells were incubated with primary 
antibody for 2 h. The coverslips were washed 3 times with PBS and 
overlaid with secondary antibody for 1 h. Primary and secondary antibodies 
were diluted in 0.125% (w/v) fish skin gelatin in PBS with 0.1% (w/v) TX-
100. Samples were mounted in ProLong mounting medium (Molecular 
Probes), supplemented with DAPI for nucleus staining. For surface 
epitopes staining, cells were not permeabilized with TX-100. Samples were 
visualized using a fluorescence microscope (Leica DMRB).  
Primary antibodies used were: mouse anti-tumor related antigen-1-60 (Tra-
1-60) (Santa Cruz Biotechnology), mouse anti-stage specific embryonic 
antigen-4 (SSEA-4) (Santa Cruz Biotechnology), mouse anti-Oct-4 (Santa 
Cruz Biotechnology), mouse anti-nestin (Chemicon), mouse anti-type III β-
tubulin (βIII-Tub) (Chemicon), mouse anti-microtubule associated protein 
2A and 2B (MAP2) (Chemicon). The secondary antibodies were goat anti-
mouse IgM-AlexaFluor488, goat anti-mouse IgG-AlexaFluor 594, goat anti-
mouse IgG-AlexaFluor 488 and rabbit anti-mouse IgG-AlexaFluor 594 
(Invitrogen).  
2.6. Flow cytometry 
Cells used for the inoculum (day 0) and from day 3 of the bioreactor 
expansion culture were dissociated into single cells and analyzed by flow 
cytometry. Samples were fixed in CytofixCytoperm reagent (BD Pharmigen) 
for 10 min, blocked with 1% BSA in PBS at 4ºC for 30 min and, in the case 
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of intracellular antigens, permeabilized with 1% TX-100 for 10 min. Primary 
antibodies were mouse anti-Tra-1-60 and anti-Oct-4. Secondary antibodies 
were anti-mouse IgM-AlexaFluor488 and anti-mouse IgG-AlexaFluor488. 
Ten thousand events were registered per sample with a CyFlowspace 
(Partec) instrument, using the appropriate scatter gates to avoid cellular 
debris and aggregates. A cell was considered to be positively stained if the 
measured fluorescence intensity exceeded the signal obtained by cells 
incubated with an isotype control antibody (Santa Cruz Biotechnology).  
2.7. Statistical analysis 
For each spinner and bioreactor assays, two independent experiments 
were performed. The results were expressed as the mean  standard 
deviation. The statistical test used, One-way ANOVA, was performed in 
SPSS 13.0 for Windows for a level of confidence of 95% (a=0.05) followed 
by the Scheffé multiple comparison test.  
 
3. RESULTS  
With the goal of developing a robust and scalable system for NT2 neuronal 
differentiation, both expansion and differentiation steps were integrated in a 
fully controlled bioreactor process. Firstly, different strategies for expansion 
of undifferentiated NT2 cells as 3-D aggregates were screened in stirred 
spinner vessels; two parameters were studied (i) the inoculum 
concentration and (ii) the culture operation mode, i.e., medium replenishing 
strategies.  Having the expansion of pluripotent NT2 cells optimized and 
well characterized, the neuronal differentiation strategy previously 
developed by our group (Serra et al., 2007), was integrated and the overall 
bioprocess combined in the bioreactor.  
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3.1. Effect of inoculum concentration in NT2 cell expansion 
Three different cell inoculum concentrations were tested in batch culture 
mode, using 125 mL spinners: 0.4, 1 and 4 x105 cell/mL (SP-0.4B, SP-1B 
and SP-4B, respectively).  
During the first 24 h of SP-1B and SP-4B cultures, cells assembled into 
small 3D-aggregates (Figure 4.2A) ranging from 40 to 65 µm. After this 
period, cells started to divide and aggregate size increased up to 150 µm. 
The growth curve and the calculated apparent growth rates are shown in 
Figure 4.2B and Table 4.1, respectively. SP-1B exhibited a high apparent 
growth rate (0.51  0.01 day-1) and the highest FI in cell concentration (7.14 
 0.86).  Nevertheless, maximum cell density 6.64 ( 1.57) × 105 cell/mL 
was only reached 6 days after inoculation, whereas in SP-4B, a maximum 
of 8.48 ( 0.11) × 105 cell/mL was achieved at day 3. From day 4 onwards 
of SP-4B culture, cells started to detach from the aggregates (Figure 4.2A), 
resulting in cell death (data not shown). Similar behavior was observed for 
SP-1B culture upon day 7 of cultivation. Concerning the SP-0.4 culture, cell 
aggregates were rare and small throughout cultivation time (Figure 4.2A). 
In fact, no effective cell growth was observed (Figure 4.2B) and cell viability 
was low (data not shown). 
Aiming to develop an efficient bioprocess for the fast production of human 
neurons, cell number and culture time were the parameters preferentially 
used to select the best strategy. For SP-4B, the time needed to achieve 
Xmax was 2 times lower than for SP-1B, reaching similar Xmax values (Table 
4.1). Based on these results, SP-4B was chosen to be further optimized 
and integrated with the neuronal differentiation step. 
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Figure 4.2. Effect of inoculum concentration in NT2 cell expansion as 3D-aggregates. 
Cells were cultured in spinner vessels with inoculum concentrations of 0.4 (SP-0.4B, 
squares), 1 (SP-1B, circles) and 4 (SP-4B, triangles) x10
5
 cell/mL. Phase contrast 
photomicrographs of cultures samples visualized by day 1, day 3 and day 6 of 
cultivation. Scale bar: 100 µm (A). Growth curves expressed in terms of cell 
concentration; error bars denote standard deviation of average from 2 independent 
experiments (B). 
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Table 4.1. Growth kinetics of NT2 cell expansion as 3D-aggregates using different culture 
strategies. Apparent growth rate (), fold increase (FI) and maximum cell concentration 
values (Xmax)of NT2 cells cultured in spinner vessel (SP) or in bioreactor (BR); with inoculum 
densities of 0.4x10
5
 (SP-0.4) 1x10
5
 (SP-1) or 4x10
5 
cell/mL (SP-4, BR-4); in batch (B), fed-
batch (FB) and media-exchange (ME) culture operation mode.  
Strategy μ (day
-1
) FI Xmax (10
5
 cell/mL) 
SP-0.4B n. a. n. a. 0.63  0.11 * 
SP-1B 0.51  0.01 7.14  0.86 * 6.64  1.57 
SP-4B 0.39  0.02 2.12  0.03 8.48  0.11 
SP-4FB 0.52  0.06 4.30  0.33 * 17.19  1.30 * 
SP-4ME 0.41  0.06 4.56  0.04 * 18.25  0.18 * 
BR-4ME 0.37  0.03 4.10  0.41 16.25  0.16 
Apparent growth rate () and fold increase (FI) values are expressed as mean  SEM from n=2 
independent experiments. n. a. – not applicable. *Indicates significant statistical difference (p-value < 
0.05) from the SP-4B mean values of µ, FI and Xmax by the one-way ANOVA analysis with a Scheffé 
post-hoc multiple comparison test.    
 
3.2. Impact of operation mode in NT2 cell expansion  
In all batch cultures there was a rapid decrease in cell density after the 
culture reached its maximum concentration value (Figure 4.2A). Although 
no complete depletion of neither glucose nor glutamine was observed 
(Figure 4.3A,C), this profile could be correlated to the exhaustion of other 
essential nutrients and/or the progressive accumulation of toxic metabolic 
waste products such as lactate and ammonia (Figure 4.3B,D). In SP-4B, by 
the 4th day of cultivation, the lactate and ammonia concentrations were 
already 21.9 mM and 3.1 mM, respectively (Figure 4.3B,D). In SP-1B, 
these values were also high at day 7 of culture (27.2 mM and 4.2 mM for 
lactate and ammonia concentration, respectively).  
Aiming at prolonging the exponential growth phase and improve the cell 
expansion, two additional operation modes were tested. The first strategy 
consisted of a glucose fed-batch operation mode (SP-4FB). In this strategy, 
culture was initiated at low concentration of glucose (1.4 mM) and the 
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feeding was performed twice a day assuring the maintenance of low levels 
of glucose throughout cultivation time (see Methods section). The second 
strategy (SP-4ME) was designed to simulate a perfusion system, in which 
cells are kept in culture and the media is renovated regularly. This was 
achieved by performing a daily partial media exchange (50%) from the 3rd 
cultivation day onwards, as this time point corresponded to the growth peak 
in the batch culture (Figure 4.2B, SP-4B).  
For SP-4ME and SP-4FB cultures, the exponential growth phase was 
extended until day 5 (Figure 4.3F), with a significant increase in Xmax, when 
compared to SP-4B (Table 4.1). These differences are also reflected in cell 
metabolism, as shown by the nutrient consumption and metabolite 
production profiles (Figure 4.3E). The SP-4FB culture presented the lowest 
specific rates of glucose consumption and lactate production. The lower 
accumulation of lactate (16.5 mM at day 6, Figure 4.3B) in SP-4FB 
contributed to the high apparent growth rate of this strategy (0.520.06   
day-1, Table 4.1). Nevertheless, there was still a steeply decrease in cell 
concentration after day 6 (Figure 4.3F) that may result from the 
accumulation of other toxic metabolites, such as ammonia, which reached 
values as high as in SP-4B (4.0 mM and 4.2 mM for SP-4FB and SP-4B 
cultures, respectively, at day 6 of cultivation, Figure 4.3D). 
Cell viability was calculated in term of cell lysis, translated by the specific 
release rates of the intracellular enzyme LDH (qLDH). For SP4-ME, the qLDH 
achieved were lower (fold increase of 9.1) than those obtained for SP-4B 
and SP-4FB (fold increase of 20.5 and 19.4, respectively) throughout 6 
days of cultivation, indicating that a lower percentage of cell lysis occurred 
in the SP-4ME culture. Despite no complete depletion of either glucose or 
glutamine was observed in the strategies tested, cells in SP4-ME were not 
continuously subjected to the accumulation of toxic metabolites, which 
probably had a positive effect on cell viability (Figure 4.3A-D). 
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Figure 4.3. Effect of culture operation mode on NT2 cell expansion as 3D-
aggregates. Cells were cultured in spinner vessels (SP) or in bioreactors (BR), with 
inoculum concentration of 4x10
5
 cell/mL, using different operation modes: batch 
(SP-4B, black line and triangles), fed-batch (SP-4FB, dashed line and white 
triangles) and media exchange (SP-4ME, dashed line and black triangles, and BR-
4ME, grey line and triangles). Concentrations of glucose (A), lactate (B), glutamine 
(C) and ammonia (D) presented in media during culture time. Specific rates of 
glucose consumption and lactate production shown over the course of exponential 
growth phase (E) (day 2- white bars, day 3- grey bars, day 4-striped bars, day 5- 
black bars). Growth curves expressed in terms of cell concentration; error bars 
denote standard deviation of average from 2 independent experiments (F). 
 
3.3. Expansion and characterization of undifferentiated NT2 cells in 
a bioreactor 
From the results shown above, SP-4ME was the most promising culture 
strategy for expansion of undifferentiated stem cell. The next step was the 
implementation of this strategy in a fully controlled 125 mL bioreactor, BR-
4ME.  
The growth curve obtained for the bioreactor run BR-4ME was comparable 
to the one obtained for the medium exchange operation mode in spinner 
SP-4ME; similar apparent growth rates and maximum concentrations were 
obtained (Figure 4.3F, Table 4.1). NT2 cells expanded in the bioreactor for 
6 days were characterized in terms of pluripotency, undifferentiated 
phenotype and differentiation potential. The expression of stem cell 
markers (Oct-4, TRA-1-60, SSEA-4) and nestin, an intermediate filament 
protein associated with undifferentiated phenotype of NT2 cells (Pleasure 
and Lee, 1992), was detected during exponential growth phase (day 3) and 
at day 6  (Figure 4.4A). This labeling pattern was similar to the cell 
inoculum (day 0).  
Moreover, in addition to the expression of stem markers analysis, the 
expanded cells ability to differentiate into neurons was also confirmed. For 
that purpose, cells were collected at 3 time points (day 0, 3 and 6) and 
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induced to differentiate into neurons  using the standard static 
differentiation protocol (Pleasure et al., 1992). After treatment with RA and 
further cultivation in MI medium, the neuronal differentiation efficiency 
(defined as the ratio between the number of neurons obtained and the 
number of cells harvested from the bioreactor, see Methods section) was 
similar for all culture samples, presenting values in the range typically 
obtained for the static differentiation protocol (3.3±0.2%) (Serra et al., 
2007). The differentiated neurons were identified by βIII-Tub and MAP2 
positive staining (Figure 4.4B).  
3.4. Integrating expansion and neuronal differentiation of NT2 cells 
in the bioreactor 
Once the expansion of pluripotent NT2 cells was adapted and 
characterized in the bioreactor system, we further integrated the neuronal 
differentiation step according to Serra et al (Serra et al., 2007). Neuronal 
differentiation was induced by RA addition when cells achieved the middle 
of the exponential growth phase at day 3 (Figure 4.3C). Flow cytometry 
analysis of cell populations showed that the levels of Oct-4 (94.8% positive 
cells) and Tra-1-60 (88.7% positive cells) obtained for the inoculum were 
kept at day 3 of the bioreactor culture (97.2% and 94.6% Oct-4 and Tra-1-
60 positive cells, respectively), confirming that the stem cell population was 
maintained at this time point.  
Throughout differentiation, the aggregate size increased, reaching average 
diameters of 150 ± 40, 309 ± 94 and 458 ± 44 µm after 1, 2 and 3 weeks of 
RA treatment, respectively (Figure 4.5A,B,C, Table 4.2). The aggregate 
shape became uniform, forming compact and spherical structures (Figure 
4.5B,C).  
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Figure 4.4. Characterization of NT2 cells expanded as 3D-aggregates.  
Immunofluorescence images of cells from the inoculum (day 0) and collected from the 
bioreactor culture (day 3 and day 6). Immunolabeling of Oct-4, TRA-1-60, SSEA-4 
(green) and nestin (red). Nuclei are labeled with DAPI (blue) (A). Immunofluorescence 
images of differentiated cultures derived from the inoculum (day 0) and from the 
bioreactor culture (day 3 and day 6). Neurons labeled with βIII-Tub and MAP2 (green) 
(B). Nuclei were stained with DAPI (blue). Scale bars: 100 µm. 
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Table 4.2. Characterization of NT2 neurospheres cultured in a fully controlled bioreactor.  
Neurospheres  
Time of harvesting (day) 9 16 23 
Duration of RA  treatment (week) 1 2 3 
Neurosphere size (µm) 150 ± 40 309 ± 94 458 ± 44 
Differentiation efficiency 0.13 ± 0.06 17.2 ± 2.2 37.4 ± 0.9 
Neurosphere size and neuronal differentiation efficiency are expressed as mean  SEM 
from n=2 independent bioreactor experiments 
 
Immunofluorescence microscopy of aggregate cryosections showed that 
these were neurospheres, composed of precursors (nestin-positive) and 
differentiated neurons (βIII-Tub-positive), the latest distributed preferentially 
at the surface (Figure 4.5C1). After 9, 16 and 23 days of bioreactor culture 
(1, 2 and 3 weeks of neuronal differentiation, respectively), neurospheres 
were harvested and cultured for 7 days, on PDL-MG coated flasks, in MI 
medium, to allow cell migration and inhibit cell proliferation. One day post-
seeding, the presence of neurites surrounding the neurospheres was more 
pronounced on cultures harvested at day 23 (Figure 4.5F), while on 
neurospheres harvested earlier, cells with flattened morphology 
predominated (Figure 4.5D). Three days post-seeding, the cell culture 
composition was analyzed by immunofluorescence microscopy (Figure 
4.5G,H,I). Cultures derived from neurospheres harvested at day 23 were 
richer in neurons (βIII-Tub-positive staining) and presented more developed 
neuritic networks than the neurospheres harvested at day 16 (Figure 
4.5H,I). A reduced number of βIII-Tub-positive cells was detected in 
cultures derived from neurospheres collected at day 9, in which nestin-
positive cells predominated (Figure 4.5G).  
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Figure 4.5. Neuronal differentiation of NT2 cells in a fully controlled bioreactor. Neuronal 
differentiation was induced by addition of retinoic acid (RA) from day 3 onwards (RA 
treatments). Phase contrast photomicrographs of neurospheres harvested at day 9 (A), 
day 16 (B) and day 23 (C) of the bioreactor culture. By day 23, neurosphere composition 
was analyzed by cryosection immunofluorescence microscopy - double labeling of nestin 
(red) and βIII-Tub (green) (C1). Harvested neurospheres were further cultured in mitotic 
inhibitory (MI) conditions, on poly-D-lysine and Matrigel-coated surfaces. Cultures were 
visualized by phase contrast microscopy 1 day after plating (D,E,F) and characterized by 
immunofluorescence microscopy 3 days after plating (G,H,I). Double labeling of nestin 
(red) and βIII-Tub (green). Phase contrast and immunofluorescence images of cultures 
derived from neurospheres harvested at day 9 (D,G), day 16 (E,H) and day 23 (F,I). 
Scale bars: 100m. 
 
The estimated neuronal differentiation efficiency was 0.13 ± 0.06 % and 
17.2 2.2% for cultures derived from neurospheres harvested at day 9 and 
16, respectively (Table 4.2). The results obtained until day 16 were similar 
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to the ones described for the spinner culture (Serra et al., 2007), both in 
culture profile and differentiation efficiency, proving that the integrated 
culture strategy was successfully implemented in the bioreactor. Moreover, 
by extending the RA treatments for an additional week, a significant 
increase in the yield of neuronal differentiated cells was obtained (neuronal 
differentiation efficiency of 37.4 ± 0.9%, Table 4.2). 
 
4. DISCUSSION 
To fully fulfill the expectations raised by cell therapy it is urgent to develop 
robust and totally controlled culture systems, specially designed for the 
production of high numbers of differentiated and well characterized cells, 
expanded as fast and pure as possible. In the present study, we 
successfully developed a bioprocess for the rapid production of human 
neurons using fully controlled stirred tank bioreactors (125 mL). This was 
accomplished by integrating human NT2 cell expansion and differentiation 
in a two-step bioprocess. 
In this particular study, an ideal expansion strategy should assure the fast 
production of high numbers of stem cells without compromising their 
potential. We demonstrated that, along expansion as 3-D aggregates, NT2 
cells maintained their pluripotent and undifferentiated phenotype as well as 
the ability to differentiate into neurons. Different bioreaction parameters, 
including cell inoculum concentration and culture operation mode were 
studied. The results indicate 4x105 cell/mL as the most adequate inoculum 
strategy to be integrated with the differentiation step, as it allowed higher 
cell densities in less culture time contributing to a fast overall process. 
However, the feasibility of starting the cultures with inoculum 
concentrations as lower as 1x105 cell/mL looks promising for specific 
clinical applications in which the starting material is a limiting factor. 
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Although lower inoculation concentrations have been used to expand 
undifferentiated murine embryonic stem cells as aggregates (Cormier et al., 
2006; zur Nieden et al., 2007), NT2 cell proliferation could not be achieved 
when 4104 cell/mL were used. This difference in cell behavior may reflect 
the distinct cell origins, as NT2 are pluripotent human embryonal carcinoma 
stem cells, derived from teratocarcinomas (Pleasure et al., 1992), that 
closely resemble the human embryonic stem cells derived from the 
blastocyst inner cell mass (Henderson et al., 2002).  
By using a fed-batch strategy, where low levels of glucose were maintained 
in culture, it was possible to enhanced glucose metabolism efficiency with a 
concomitant improvement of the FI in cell concentration and increase of 
culture lifespan. This strategy may have minimized the toxicity effect 
associated with lactate accumulation, as reported previously for several 
animal cell cultures (Xie and Wang, 1994; Cruz et al., 2000). Nevertheless, 
the accumulation of other toxic metabolites, including ammonia, resulted in 
an increase in cell death. The possible depletion of nutrients (others than 
glucose and glutamine) as well as the exhaustion of essential small 
molecules, namely growth factors, not replenished in the glucose fed-batch 
strategy, may have contributed to arrest cell growth.  The media exchange 
mode overcame these drawbacks, being the most efficient strategy to 
enhance undifferentiated stem cell cultivation, as shown by the higher cell 
densities and higher culture viability obtained throughout the cultivation 
time. Therefore this strategy was chosen for implementation in the 
controlled bioreactor in which stem cell expansion was successfully 
reproduced, confirming the robustness of the process. Media exchange and 
perfusion strategies have been used previously for adult stem cell 
cultivation (King and Miller, 2007; Serra et al., 2007) and human embryoid 
bodies (Come et al., 2008). In order to achieve higher expansion ratios, as 
those obtained for the expansion process as aggregates of murine 
Chapter 4. Integrating stem cell expansion and neuronal differentiation 
 130
embryonic stem cell (Cormier et al., 2006; zur Nieden et al., 2007) and 
human neuronal precursor cell (Burjghhghg et al., 2008), serial passage 
with addition of fresh media can be further included.   
By incorporating both expansion and differentiation steps in an integrated 
bioprocess, this strategy also assures the feasibility of expanding human 
differentiated neurons derived from a continuous source of pluripotent stem 
cells. The system described herein allows for obtaining well differentiated 
neurons after 2 weeks of differentiation, as well as higher yields of neurons 
for a later culture time. Importantly, when compared to well established 
static differentiation protocols, this methodology drastically enhanced the 
neuronal differentiation efficiency of NT2 cells and reduced the time needed 
for differentiation process; for a differentiation time of 23 days in the 
bioreactor culture a 10-fold improvement in yield was observed over the 
static culture protocols lasting 35 days (Pleasure at al., 1992).  
In this work, the expansion and differentiation of NT2 cells was successful 
validated in computer-controlled bioreactors. In future, further optimizations 
can be attempted aiming to determine the optimal conditions (pH, pO2 and 
temperature) to grow and differentiate NT2 cells. So far, some studies have 
demonstrated that low pO2 decreases the rate of stem cell differentiation 
and enhances stem cell proliferation (Gibbons et al., 2006). Nieruebuegge 
et al. also reported a significant increase in final cell number as well as an 
improvement of cardiac–enriched genes in hEBs cultures under hypoxic 
conditions (pO2= 4%) (Nieruebuegge et al., 2009). A recent study reports 
that rat mesenchymal stem cell differentiation is enhanced at lower 
temperatures (32ºC) than in 37ºC conditions (Stolzing and Scutt, 2006).  
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5. CONCLUSION 
In this work, a scalable and efficient two-step bioprocess for the generation 
of human NT2-derived neurons was developed in a fully controlled 
bioreactor, allowing continuous monitoring, non-invasive sampling and 
characterization. By integrating a fast expansion step with an efficient 
differentiation process, this strategy significantly reduced the time and 
improved the yields of the neuronal differentiation, when compared to the 
standard static differentiation protocols.   
The controlled bioprocess developed herein can be adaptable to other cell 
types, including hESCs and iPSCs, representing a strong and promising 
starting point for the development of novel technologies for the production 
of differentiated derivatives from pluripotent cells. 
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CHAPTER 5 
IMPROVING EXPANSION OF PLURIPOTENT 
HUMAN EMBRYONIC STEM CELLS IN PERFUSED 
BIOREACTORS THROUGH OXYGEN CONTROL 
 
 
 
This chapter was based on the following manuscript: 
Serra, M., Brito, C., Sousa, M.F., Jensen, J., Tostões, R., Clemente, J., Strehl, R., 
Hyllner, J., Carrondo, M.J. and Alves, P.M., 2010. Improving expansion of pluripotent 
human embryonic stem cells in perfused bioreactors through oxygen control. J 
Biotechnol. 148(4), 208-15 
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ABSTRACT  
The successful transfer of human embryonic stem cell (hESC) technology 
and cellular products into clinical and industrial applications needs to 
address issues of automation, standardization and the generation of 
relevant cell numbers of high quality. In this study, we combined 
microcarrier technology and controlled stirred tank bioreactors, to develop 
an efficient and scalable system for expansion of pluripotent hESCs.  
We demonstrate the importance of controlling pO2 at 30% air saturation to 
improve hESCs growth. This concentration allowed for a higher energetic 
cell metabolism, increased growth rate and maximum cell concentration in 
contrast to 5% pO2 where a shift to anaerobic metabolism was observed, 
decreasing cell expansion threefold. Importantly, the incorporation of an 
automated perfusion system in the bioreactor enhanced culture 
performance and allowed the continuous addition of small molecules 
assuring higher cell concentrations for a longer time period. The expanded 
hESCs retained their undifferentiated phenotype and pluripotency. 
 Our results show, for the first time, that the use of controlled bioreactors is 
critical to ensure the production of high quality hESCs. When compared to 
the standard colony culture, our strategy improves the final yield of hESCs 
by 12-fold, providing a potential bioprocess to be transfered to clinical and 
industrial applications.  
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1. INTRODUCTION  
hESCs can provide a renewable source of cellular material for regenerative 
medicine, drug screening and in vitro toxicology (Davila et al., 2004; Jensen 
et al., 2009; Jones et al., 2000). However, the development of bioprocesses 
for production of hESCs or their progeny in large quantities will be 
necessary for their translation to these fields.  
Expansion of undifferentiated hESCs typically requires adherence to a 
surface. Although the majority of culture methods available are still based 
on 2D surfaces (Ellerstrom et al., 2007), the use of microcarriers to support 
stem cell growth has been explored; recent studies showed the successful 
use of spinner vessels to expand hESCs on microcarriers, attaining higher 
cell concentrations than standard static cultures (Fernandes et al., 2009; 
Lock et al., 2009; Nie et al., 2009; Oh et al., 2009; Phillips et al., 2008; 
Kehoe et al., 2009). However, the impact of specific operating conditions 
upon expansion of pluripotent hESCs remains to be addressed. Oxygen is 
a critical factor in hESCs culture (Placzek et al., 2009) and there is 
emerging evidence suggesting that reducing oxygen concentration towards 
low levels (Fischer et al., 1993; Ottosen et al., 2006) is beneficial for the in 
vitro maintenance of pluripotent hESCs (Forsyth et al., 2006; Ezashi et al., 
2005; Prasad et al., 2009). Additionally, perfusion mode is known to 
improve stem cell expansion assuring the renewal of nutrients and other 
factors and removal of metabolic byproducts (Bauwens et al., 2005; Serra 
et al., 2009a).  
Herein, we demonstrated that microcarrier technology and controlled stirred 
bioreactors in perfusion mode, where scalability, automation, 
straightforward operation and tight control of the culture environment are 
combined, can be used to improve the expansion of pluripotent hESCs. 
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2. MATERIAL AND METHODS 
2.1. Cell culture 
hESCs cells (SCEDTM461, Cellartis AB) were routinely propagated in static 
conditions in standard culture medium (KO) (DMEM-KO supplemented with 
20% (v/v) KOSR, 1% (v/v) MEM-NEAA, 0.1mM 2-mercaptoethanol, 2mM 
glutamax, 1% (v/v) Pen/Strep, 0.5% (v/v) gentamycin (all from Invitrogen) 
and 10ng/mL bFGF (Perprotech)) as previously reported (Ellerstrom, et al., 
2007). For spinner and bioreactor cultures, hESCs were used at low 
passage numbers (6-8).  
2.2. Spinner cultures  
hESCs were inoculated at 1.5, 3 and 4.5 ×105cell/mL into 125mL spinner 
vessels (Wheaton) containing Cytodex3TM microcarriers (3g/L, GE 
Healthcare) coated with MatrigelTM (BD Biosciences) [5,8]. Cells and beads 
were inoculated in 25mL of mouse embryonic fibroblasts conditioned 
medium (KO-CM) supplemented with 10µM Rock Inhibitor (Merck), and the 
spinner vessels were placed inside an incubator (37ºC, 5%CO2) under 
intermittent  stirring (vessels were agitated gently for 1 min every 30 min). 
After 6h fresh KO-CM was added to cultures and agitation rate set to 
24rpm. By day 3, the volume was completed to 100mL; 50% of medium 
was replaced daily.  
2.3. Bioreactor cultures 
hESCs were cultivated in computer-controlled stirred tank bioreactors 
(BIOSTAT® Qplus, Germany), equipped with low shear stress marine 3-
blade impellers, under defined conditions (working volume-300mL; pH-7.2; 
temperature-37ºC; pO2-5% and 30% air saturation; surface aeration rate-
0.1vvm; agitation rate-50-65rpm). Data acquisition and process control 
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were performed using Multiple Fermenter Control System for Windows 
Supervisory Control and Data Acquisition software (Sartorius Stedim, 
Germany). Cells (4.5×105 cell/mL) were seeded on microcarriers placed 
inside glass bottles and, after colonization (6-8h), transferred to bioreactor 
vessels. Semi-continous cultures were carried out by replacing 50% of the 
medium daily (1 pulse/day). Perfusion experiments were performed with a 
probe adapted to the bioreactor cap using automated gravimetric control 
(D= 0.5 day-1, 30 pulses/day). 
2.4. Cell growth and metabolism 
Cell concentration, viability and microcarrier colonization were evaluated 
according to (Lock, et al., 2009). Lactate dehydrogenase activity, glucose 
and lactate concentrations in supernatants were measured as described 
before (Serra et al., 2009b). Growth kinetics and metabolic performance 
were determined according to (Serra, et al., 2009a). Briefly, apparent 
growth (µ) and death (kd) rates were estimated using a simple first order 
kinetic model dX/dt = µX and dX/dt = kdX respectively, where t (days) is the 
culture time and X (cells) is the value of viable cells for a specific t. µ and kd 
were estimated using this model applied to the slope of the curves during 
the exponential and death phase, respectively.  The specific metabolic 
rates (qMet., mol.day
-1.cell-1) were calculated using the equation: 
qMet. = ΔMet/(Δt ΔXv), where ΔMet (mol) is the variation in metabolite 
concentration during the time period Δt (day) and ΔXv (cell) the average of 
viable cells during the same time period.  
2.5. Immunocytochemistry 
Immunocytochemistry was performed as described previously (Serra, et al., 
2009b) and samples analyzed using a fluorescence microscope (DMI6000, 
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Leica). Primary antibodies used were: Tra-1-60, SSEA-4, Oct-4, Ki67, (all 
Santa Cruz Biotechnology), and hESCellectTM (Cellartis AB).   
2.6. Flow cytometry 
For flow cytometry analysis, cells were dissociated with TrypLE Select 
before labeling. Ten thousand events were registered per sample with a 
CyFlowspace (Partec) instrument as reported elsewhere [19]. Primary 
antibodies used were: Tra-1-60, SSEA-4, and isotype control antibodies (all 
Santa Cruz Biotechnology). 
2.7. qRT-PCR  
Total RNA was extracted from cells using RNeasy PLUS Mini kit (Qiagen) 
and cDNA synthesized with High Capacity cDNA synthesis kit (Applied 
Biosystems). PCR was performed using ABI7500 Real-Time PCR System, 
primers and probes from TaqMan Assays-on-Demand Gene Expression 
Products (Applied Biosystems).  
2.8. Alkaline phosphatase analysis 
Histological staining for alkaline phosphatase activity was carried out using 
a commercially available kit (Chemicon) following the manufacturer’s 
instructions.  
2.9. In vitro pluripotency test 
hESCs were dissociated, transferred to non-adherent petri dishes 
(5×105cell/mL) and cultured in KO medium without bFGF. After 7 days, 
embryoid bodies (EBs) were transferred to gelatin coated plates and 
cultured for 14 days. Differentiated cells were identified using 
immunocytochemistry. Primary antibodies used were: α-smooth muscle 
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actin (α-SMA, DAKO), Forkheadbox A2 (FOX A2, Santa Cruz) and β tubulin 
type III (βIII-Tub, Chemicon).  
2.10. In vivo pluripotency test 
For teratoma formation, 1×106 cells expanded in bioreactors, were injected 
into the testis of 6-8 weeks old nude mice (6 mice used per sample). Eight 
weeks after injection the mice were sacrificed and the resulting teratomas 
examined histologically as described in (Oh et al., 2009).  
 
3. RESULTS AND DISCUSSION  
In this study we investigated the optimal conditions for propagation of 
pluripotent hESCs (SCEDTM461) in controlled stirred tank bioreactors.  
Different inoculation conditions were firstly evaluated in spinner flasks. The 
best conditions to promote hESCs attachment were achieved by combining 
matrigel-coated Cytodex3TM microcarriers (Lock, et al., 2009; Phillips, et al., 
2008) in mEF conditioned culture medium  supplemented with Rock 
inhibitor (Figure 5.1A).  Additionally, an inoculum concentration of 
4.5x105cell/mL was selected to be used in next bioreactor studies as it 
allowed higher cell yields and a more efficient microcarrier colonization 
(>90%) during culture time while maintaining constant the levels of SSEA-4 
positive cells (Figure 5.1B-E). It is important to highlight that, the long lag 
phases of 5-7 days presented in all strategies could be a result of cell 
adaptation to new culture conditions (feeder-free conditions, microcarriers, 
stirring) 
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Figure 5.1.  Effect of inoculum concentration in the expansion of hESCs adherent to 
microcarriers. Cells were inoculated at 1.5, 3 and 4.5 x 10
5
 cell/mL (SP1.5, SP3 and 
SP4.5) in spinner flasks. (A) Phase contrast images of hESC cultures 8 hours after 
inoculation with 4.5 ×10
5
 cell/mL in different culture conditions: using Cytodex
TM
3 
microcarriers without (w/o) or with (w) matrigel coating (MG) in the presence (w) or 
absence (w/o) of Rock Inhibitor (RI).  Scale bar: 100 μm. (B) Growth curve expressed 
in terms of cell number per volume of medium. (C) Profile of microcarrier colonization 
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expressed in percentage of colonized beads; error bars represent SEM of 3 replicates. 
(D) Viability analysis of hESC cultures at day 11 stained with fluoresceine diacetate 
(FDA- live cells, green). Scale bar: 100 μm. (E) Flow cytometry analysis of the 
expanded cell population in SP4.5: percentage of SSEA-4 positive cells at day 0 and 
day 13. 
 
The cultivation of hESCs as 3D cell-microcarrier aggregates allowed for 
higher cell densities than standard static culture (approximately 6.4-fold 
improvement, Table 5.1). This can be explained by the significantly 
increased surface area available for cell growth, further facilitating the 
process scale-up (Fernandes, et al., 2009; Oh, et al., 2009; Kehoe, et al., 
2009). 
The impact of dissolved oxygen partial pressure (pO2) upon the expansion 
of hESCs grown in microcarriers was studied. Two pO2 values were tested 
using stirred controlled bioreactors operating in parallel – 5% (BR5%pO2) 
and 30% (BR30%pO2) of air saturation (corresponding to approximately 1% 
and 6% of oxygen, respectively). Our results demonstrated that BR30%pO2 
improved cell expansion; cell density reached 2.2x106 cell/mL at day 11, in 
contrast to BR5%pO2 where expansion was 3 times lower (Figure 5.2A-D, 
Table 5.1); this lowest pO2 condition produced a metabolic change to 
anaerobic metabolism of glucose (Kallos et al., 1999); while similar glucose 
consumption profiles were observed in both bioreactors, higher lactate 
production were achieved in BR5%pO2 (Figure 5.3A,B). In addition oxygen 
depletion could occur in BR5%pO2, especially within microcarrier 
aggregates where the availability of oxygen is limited. The higher energetic 
metabolism observed in BR30%pO2 correlated with higher growth rate 
(Table 5.1), underscoring the importance of using bioreactors with fine 
control of pO2 to manipulate hESC metabolism and, consequently, cell 
growth, without compromising their undifferentiated phenotype (Figure 
5.2E).   
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Figure 5.2. Effect of pO2 in the expansion of hESCs in bioreactors. Cells were 
inoculated at 4.5 x 10
5 
cell/mL and cultured in spinner flasks (SP4.5) or in bioreactors at 
30% (BR30%pO2) and 5% (BR5%pO2) of pO2.  (A) Growth curve expressed in terms of 
cell number per volume of medium. (B) Maximum cell yield and (C) fold increase in cell 
density obtained in static and stirred cultures. (D) Phase contrast and fluorescence 
images of hESC cultures at day 2 and 11 of both bioreactor experiments. Viability 
analysis of cultures stained with fluoresceine diacetate (FDA-live cells, green) and 
propidium iodide (PI- dead cells, red). Scale bar: 100 μm. (E) Flow cytometry analysis of 
the expanded population: percentage of SSEA-4 and TRA-1-60 positive cells at day 10 
and 13 in relation to the inoculum population; error bars represent SD of 2 
measurements.   
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In uncontrolled spinner vessels, placed inside of incubators (where 20% of 
oxygen is available), the fold increase in cell concentration was 2.5 times 
lower (Figure 5.2C, Table 5.1), suggesting that the operating conditions of 
pO2 were not adequate for optimal hESC expansion. Additionally, the 
decrease in pH to values that compromised cell viability (pH=6.5), might 
have contributed to the lower cell yields obtained. In standard 2D systems, 
where diffusion and availability of oxygen is often limited, it has been 
demonstrated that physiological levels (1.5-8% oxygen) support self-
renewal and reduce spontaneous differentiation (Ezashi, et al., 2005; 
Prasad, et al., 2009) in contrast to normoxia conditions (20%). Others 
reported no advantage in the undifferentiated phenotype when hESCs are 
cultured at 5% of oxygen instead of 20% (Chen et al., 2009). Using pO2-
controlled bioreactors, this work contributed to clarify the impact of low 
oxygen levels upon hESC growth performance. 
Moreover, when an automated continuous perfusion system was 
incorporated in the bioreactor apparatus, hESCs showed an even more 
efficient energetic metabolism, expressed by higher oxygen consumption 
and lower lactate production (Figure 5.3B,C), as well as faster cell growth. 
In this culture, lag phase was reduced and maximum cell density were 
achieved earlier (day 10) (Figure 5.4A, Table 5.1), confirming that culture 
performance was enhanced.  
When compared to semi-continuous mode, continuous perfusion reduces 
the fluctuations in the concentration of medium components, such as 
glucose and lactate (Figure 5.4C-D), which contributes to enhance cell 
metabolism and growth (Bauwens, et al., 2005; Serra, et al., 2009a). 
Additionally, the automated strategy assures an efficient operation 
management, overcoming the main drawbacks of the laborious semi-
continuous procedure requiring repeated manipulation.  
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Figure 5.3.  Metabolic performance of hESCs cultured in bioreactors. 
Specific rates of (A) glucose consumption (qGLC), (B) lactate production (qLAC) 
and (C) oxygen consumption (qO2) of hESCs cultured in bioreactors at 1% 
(BR5%pO2) and 6% of pO2, operating in semi-continuous (BR30%pO2) or in 
perfusion mode (BR30%pO2 per).  
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Taking advantage of the implemented perfusion system, supplementation 
with Rapamycin was tested since it has been reported to enhance hESC 
viability (Krawetz et al., 2009). This effect was validated in bioreactors 
where higher cell densities were maintained for a longer period (Figure 
5.4A); cell viability was improved as lower LDH release and death rate (kd) 
values were obtained (Figure 5.4B, Table 5.1). 
Importantly, hESCs expanded in bioreactors retained their undifferentiated 
phenotype and pluripotency, evaluated by immunofluorescence 
microscopy, flow cytometry, qRT-PCR and detection of alkaline 
phosphatase activity (Figure 5.5A-C). Moreover, these cells presented in 
vitro and in vivo pluripotency (Figure 5.5D-E). 
 
 
 
Figure 5.4. Impact of perfusion culture on hESC expansion in bioreactors. Cells were 
cultured in bioreactors at 30% of pO2 using different re-feed strategies: semi-
continuous (BR30%pO2) and perfusion with (BR30%pO2 perf+Rap) or without 
(BR30%pO2 perf) Rapamycin supplementation. (A) Growth curves expressed in terms 
of cell concentration per volume of medium. (B) Cumulative values of specific rates of 
LDH release during culture time. Error bars denote SD of 2 measurements. (C-D) 
Profiles of glucose (C) and lactate (D) concentration in culture supernatants. 
Chapter 5. Improving expansion of hESC in bioreactors through oxygen control 
150 
 
 
 
Process engineering of stem cells for clinical application 
151 
      
Chapter 5. Improving expansion of hESC in bioreactors through oxygen control 
152 
Figure 5.5. Characterization of hESCs expanded in perfused bioreactors. Cells 
were cultured in bioreactors at 30% of pO2, operating in continuous perfusion with 
(BR30%pO2 perf+Rap) or without (BR30%pO2 perf) Rapamycin. (A-C) Analysis of 
hESCs phenotype before inoculation (day 0), during cell growth (days 7, 10 and 14), 
and after expansion in bioreactors. (A) Immunofluorescence images of ki67, Oct-4, 
SSEA-4, TRA-1-60, hESCellect
TM
 labeling and phase contrast pictures of alkaline 
phosphatase (AP) activity staining. Nuclei were labeled with DAPI (blue). Scale bar: 
100 μm. (B) Flow cytometry analysis of the expanded population: percentage of 
SSEA-4 and TRA-1-60 positive cells at days 7 and 14 in relation to the inoculum 
population; error bars represent SD of 2 measurements.  (C) Relative expression 
levels of oct-4 before (day 0) and after (day 14) expansion. For each sample the 
expression level was normalized to the CREBBP expression and each sample were 
normalized to the expression levels at day 0 by using the comparative C t methods 
for relative quantification (ΔΔ Ct method); error bars represent SD of at least 2 
measurements. (D) In vitro pluripotency analysis. hESCs derived from the bioreactor 
were able to form embryoid bodies (EBs) in non-adherent conditions which  
differentiated into cells from all three germ layers. Phase contrast micrograph of 
human embryoid bodies and fluorescence images of differentiated cultures labeled 
for α–SMA (α smooth muscle actin, mesoderm), FOX-A2 (Forkheadbox A2, 
endoderm) and βIII-Tub (β tubulin type III, ectoderm). Nuclei were stained with DAPI 
(blue). Scale bar: 100 μm.  (E) hESCs expanded in bioreactors formed teratomas in 
nude mice. Low magnification photograph showing teratoma on the capsule of testis 
(a). Typical differentiated tissues form the three germ layers are shown: 
neuroepithelium (ectoderm) (b), smooth muscle (mesoderm) (c), glandular 
epithelium and vessels (endoderm) (d). 
We are currently applying this technology to other stem cell lines, including 
human iPS cells, as well for the production of human stem cell derivatives 
by integrating the differentiation step. It is important to highlight that the 
bioreactor protocol developed herein could be easily adapted to other 
culture strategies. Recently, some reports demonstrated the successful 
expansion of undifferentiated hESC and human iPSC lines as 3D 
aggregates (Amit et al., 2010; Singh et al., 2010; Steiner et al., 2010), 
without feeders or microcarriers. In aggregates culture, where the limited 
diffusion of nutrient/gases within the aggregate could promote spontaneous 
differentiation, the control of specific bioreactor parameters, including 
dissolved oxygen, will be critical to preserve the self-renewal ability and 
further increase the expansion yields. 
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4. CONCLUSION 
Our findings show the importance of controlling pO2 conditions (30%), 
achieved in 300mL stirred tank bioreactors, for the efficient production of 
pluripotent hESCs on microcarries. A 12-fold improvement in the final cell 
yield was obtained when compared to static 2D cultures, yielding almost 
7×108 hESCs per run. The use of continuous perfusion systems further 
enhances hESC metabolic performance, ultimately facilitating bioprocess 
optimization including culture adaptation to xeno-free conditions. The 
technology developed herein can be translated to clinical and industrial 
settings, assuring the scalable production of cell-based products in a 
robust, controlled and automated manner.  
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CHAPTER 6 
MICROENCAPSULATION TECHNOLOGY: A 
POWERFUL TOOL TO INTEGRATE EXPANSION 
AND CRYOPRESERVATION OF HUMAN 
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ABSTRACT  
The successful implementation of human embryonic stem cells (hESCs)-
based technologies requires the production of relevant numbers of well 
characterized cells and their efficient long-term storage. In this study, cell 
microencapsulation in alginate was used to develop an integrated 
bioprocess for expansion and cryopreservation of pluripotent hESCs. 
Different three-dimensional (3-D) culture strategies were evaluated and 
compared: microencapsulation of hESCs as single cells, cell aggregates 
and cells immobilized on microcarriers. Aiming to establish a scalable 
bioprocess, hESC-microcapsules were cultured in stirred tank bioreactors.  
The combination of cell microencapsulation and microcarrier technology 
resulted in an optimum protocol for the production and storage of 
pluripotent hESCs. This strategy ensured high expansion ratios 
(approximately 20-fold increase in cell concentration) and high cell recovery 
yields after cryopreservation. When compared to non-encapsulated cells, 
an improvement of up to three-fold in cell survival post-thawing was 
obtained without compromising hESC characteristics.  
Microencapsulation also improved the culture of hESC aggregates by 
protecting cells from the hydrodynamic shear stress and through aggregate 
size control, assuring the maintenance of cell pluripotency for up to two 
weeks. 
This work demonstrates, for the first time, that microencapsulation 
technology is a powerful tool to integrate expansion and cryopreservation of 
pluripotent hESCs. The 3-D culture strategy developed represents a 
significant breakthrough towards the translation of hESCs to clinical and 
industrial applications. 
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1. INTRODUCTION  
The discoveries on human stem cells, including embryonic stem cells 
(hESCs) and induced pluripotent stem cells (hiPSCs), are dynamic and 
fascinating research fields. The inherent capacity of these cells to grow 
indefinitely (self-renewal) and to differentiate into all mature cells of the 
human body (pluripotency) makes them extremely attractive for 
regenerative medicine, tissue engineering, drug discovery and toxicology 
(Davila et al., 2004; Jensen et al., 2009; Krtolica et al., 2009; 
Nirmalanandhan et al., 2009).  However, the establishment of effective and 
robust protocols for large-scale expansion, storage and distribution of 
hESCs is imperative for the development of high quality therapeutic 
products or functional screening tools. 
 The hESCs are routinely cultured in two-dimensional (2-D) systems, 
namely Petri dishes, well-plates and tissue culture flasks (Ellerstrom et al., 
2007). Over the last years, we have been witnessing a constant 
inadequacy of these 2-D systems in providing the microenvironments that 
occur in stem cell niches (Lund et al., 2009). Indeed, the inherent variability, 
lack of environment control and low production yields associated with these 
culturing approaches are the main drawbacks hampering the development 
of efficient, scalable and cost-effective stem cell expansion (reviwed in 
(Placzek et al., 2009)). The low cell recovery yields and the high rates of 
uncontrolled differentiation obtained after cryopreservation (Heng et al., 
2007; Heng et al., 2006; Hunt et al., 2007) also limits their use in clinical or 
industrial applications.   
Many efforts have been put on the development of more efficient hESC 
culture systems, namely by combining a strategy for 3-D cell organization 
with a bioreactor-based system where scalability, straightforward operation 
and homogeneous culture environment are guaranteed (Kehoe et al., 2009; 
Krawetz et al., 2009; Oh et al., 2009; Serra et al., 2010). Recent studies 
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show the successful use of stirred tank bioreactors (spinner vessels and 
environment controlled stirred tank bioreactors) to expand hESCs as 
aggregates (Dang et al., 2004) or immobilized on microcarriers (Lock et al., 
2009; Nie et al., 2009; Oh, et al. 2009; Phillips et al., 2008; Serra, et al. 
2010). From a clinical/industrial perspective, these systems still require 
further improvements in order to increase cell expansion yields and ensure 
efficient bioprocess integration with cryopreservation protocols. In fact, 
stirred culture vessels often apply mechanical forces (mixing and eventually 
perfusion) to the cells, that can ultimately compromise cell viability, 
morphology, gene expression and differentiation potential (Sargent et al., 
2010). The excessive aggregate/microcarrier clumping observed during 
culture is another concern since it may cause the formation of necrotic 
centers and/or promote spontaneous differentiation, reducing cell 
expansion yields.  Moreover, the development of effective cryopreservation 
protocols capable of assuring efficient cell banking after large-scale 
expansion is still lacking.  Although Nie et al reported a new method for the 
cryopreservation of hESCs adherent on microcarriers (Nie, et al. 2009),  
this protocol needs further optimization in order to remove animal feeder 
cells and improve cell attachment/survival after thawing.  
Cell microencapsulation technology is an attractive approach to overcome 
these bioprocessing challenges since it provides cell protection from 
hydrodynamic shear and prevents excessive aggregates agglomeration 
while allowing efficient diffusion of nutrients, growth factors and gases due 
to the pore size (Hwang et al., 2009; Zimmermann et al., 2007). Several 
hydrogels have been used to enhance the culture of hESCs including 
alginate (Siti-Ismail et al., 2008), poly (lactic-co-glycolic acid)/poly(l-lactic 
acid) scaffolds (Levenberg et al., 2003) and hydrogels of agarose (Dang, et 
al. 2004), chitosan (Li et al., 2010) and hyaluronic acid (Gerecht et al., 
2007). Alginate is the most common encapsulation material (Chayosumrit 
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et al., 2010; Jing et al., 2010; Siti-Ismail, et al. 2008) due to its intrinsic 
properties including biocompatibility, biosafety and permeability (Orive et 
al., 2003). The production of alginate cell-microcapsules can be performed 
under safe and physiological conditions (e.g. physiological temperature and 
pH, use of isotonic solutions instead of cytotoxic solvents) (de Vos et al., 
2006) and using good manufacturing practice (GMP) guidelines (Schwinger 
et al., 2002), conditions that potentiate the use of this technology in cell-
based therapies. Indeed, it was already reported that alginate 
microcapsules have great potential for transplantation of Langerhans’ islets 
and other factor-secreting cells and tissues (Freimark et al., 2010; 
Zimmermann et al., 2005).  
Cell microencapsulation in alginate has been adopted by our group and 
others to improve the viability and functionality of primary hepatocytes 
(Miranda et al., 2010; Tostões et al., 2010) and to enhance the 
differentiation of stem/progenitor cells into different cell types (Bauwens et 
al., 2005; Delcroix et al., 2010; Goldstein et al., 2001; Kuo et al., 2006; Lee 
et al., 2009; Liu et al., 2005; Maguire et al., 2007; Maguire et al., 2006; 
Nieponice et al., 2008; Wang et al., 2009) in bioreactors. In addition, we 
recently demonstrated that cell encapsulation in alginate is also a valuable 
strategy to improve cell viability and the integrity of cell monolayers and 
neuroshperes after freeze/thawing, since cells are protected against 
mechanical damages during ice crystallization and the risk of disrupting 
cell‐cell and cell-matrix contacts are reduced through immobilization within 
the hydrogel (Malpique et al., 2009; Malpique et al., 2010). Despite the 
success in many (stem) cell types, studies describing the 
microencapsulation of hESCs are rather limited (Chayosumrit, et al. 2010; 
Jing, et al. 2010; Siti-Ismail, et al. 2008). 
In this work, we report for the first time an efficient integrated bioprocess for 
expansion and cryopreservation of hESCs, using cell microencapsulation in 
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alginate. Different strategies were evaluated and compared: 
microencapsulation of single cells, cell aggregates and cells immobilized on 
microcarriers. The rationale behind the selection of these strategies was 
based on the fact that each 3-D approach allows different cell-cell and cell-
matrix interactions. Microcapsules containing hESCs were cultured in 
stirred tank bioreactors (spinner vessels) and, after expansion, 
cryopreserved in cryovials, aiming at developing a scalable and 
straightforward bioprocess. 
 
2. MATERIAL AND METHODS 
2.1. hESCs culture on feeder layer 
hESCs (SCEDTM461, Cellartis AB, Göteborg, Sweden) were routinely 
propagated as colonies in static systems (6 well-plates) on a feeder layer of  
human foreskin fibroblasts (hFF, ATCC collection), inactivated with 
mitomycin C (Sigma‐ Aldrich, Steinheim, Germany), in DMEM-KO culture 
medium (KnockoutTM-DMEM supplemented with 20% (v/v) Knockout-Serum 
Replacement (KO-SR), 1% (v/v) MEM non-essential amino acids (MEM-
NEAA), 0.1 mM 2-mercaptoethanol, 2 mM Glutamax, 1% (v/v) Pen/Strep, 
0.5% (v/v) Gentamycin (all from Invitrogen, Paisley, UK)) and 10 ng/mL 
basic fibroblast growth factor bFGF (Neuilly‐ Sur‐ Seine, France, 
Peprotech), as previously described (Ellerstrom, et al. 2007).  Every 10-12 
days, i.e. when approximately 75-85% of the surface area of the culture 
well was covered by hESC colonies, the colonies were digested with 
TrypLETM Select (Invitrogen, Paisley, UK), for 6‐ 8 minutes, and the single 
cell suspension was transferred to fresh inactivated hFF feeders (at splitting 
ratios between 1:4 and 1:24). Culture medium was replaced with fresh 
medium every 1–3 days. 
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2.2. Preparation of mEFs conditioned medium 
For the production of conditioned medium (mEF-CM), mouse embryonic 
fibroblast (mEFs, Millipore, Billerica, MA, USA) were mitotically inactivated 
and replated on gelatin-coated in T-flasks (Nunc, Roskilde, Denmark) at 
5.5×104 cell/cm2 in DMEM-KO medium without bFGF (0.5 mL/cm2). Briefly, 
inactivated mEF were cultured at 37ºC with 5% (v/v) CO2 (in air) and 
conditioned media were collected daily for a total of 10 days per batch. 
Before feeding hESC cultures, mEF-CM was filtered and supplemented 
with 10 ng/mL bFGF and 0.1 nM Rapamycin (Sigma, Steinheim, Germany).  
2.3. Microencapsulation of hESCs 
Alginate: Ultra Pure MVG alginate (UP MVG NovaMatrix, Pronova 
Biomedical, Oslo, Norway) was prepared at a concentration of 1.1% (w/v) 
in 0.9% (w/v) NaCl solution (Chayosumrit, et al. 2010).  
Microcapsules formation: Microcapsules were prepared by passing the 
alginate-cells mixture using 1 mL syringe through an air‐ jet generator 
(kindly provided by Fraunhofer-IBMT, Germany), as described in detail 
elsewhere (Zimmermann et al., 2001), at an air flow rate of 2-3.5 L/min and 
an air pressure of 1 bar. These encapsulation conditions yielded 
microcapsules with a diameter of approximately 400-700 µm. For 
cross‐ linkage of the UP MVG alginate, a 100 mM CaCl2/10 mM HEPES 
solution adjusted to pH 7.4 was used. Alginate microcapsules were washed 
twice with 0.9% (w/v) NaCl solution and once with DMEM-KO medium 
before being transferred to culture systems.  
Alginate microcapsules dissolution: Ca2+-UP MVG alginate was dissolved 
by incubating the microcapsules with a chelating solution (50 mM EDTA 
and 10 mM HEPES in PBS) for 5 min at 37ºC (Chayosumrit, et al. 2010). 
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2.4. Three-dimensional (3-D) hESC cultures  
A schematic diagram describing the main steps of the 3-D culture 
strategies developed herein is outlined in Figure 6.1.  
 
Figure 6.1. Schematic workflow of the main steps of the microencapsulated 3-D 
culture strategies developed for expansion and cryopreservation of hESCs.  
Encapsulation of single cells: Before detachment from 2-D static cultures, 
hESCs colonies were pre-treated for 1 h with 5 µM Y-27632, a selective 
Rho kinase (ROCK) inhibitor (ROCKi, Calbiochem Nottingham, UK). The 
single cell suspension, obtained after colony dissociation with TrypLE 
Select, was immediately encapsulated at different concentrations in 
alginate (0.75, 2 and 3 x106 cell/mL alginate). hESCs-microcapsules were 
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then inoculated into 125 mL Erlenmeyer (Corning, Corning, NY, USA) and 
cultured in 15 mL mEF-CM supplemented with 10 µM ROCKi, at 37ºC and 
5% CO2 in an orbital shaker with an agitation of 70 rpm. In all conditions 
tested, cells were inoculated at 1.5 ×105 cell/mL. 
Encapsulation of hESC aggregates: hESCs were dissociated from the 2-D 
static cultures and inoculated as single cells at 1.5 ×105 cell/mL into 
Erlenmeyer (Corning, Corning, NY, USA). Cells were cultured in 50 mL 
mEF-CM supplemented with 10 µM ROCKi, at 37ºC and 5% CO2, using an 
orbital agitation of 70 rpm. Encapsulation was performed at day 2; 
aggregates were pre-treated with 5 µM ROCKi for 1 h and then transferred 
to 15 mL tubes to allow their deposition and culture medium removal. After 
addition of alginate, aggregates were encapsulated, transferred to 125 mL 
spinner vessels (Wheaton, Techne, NJ, USA) equipped with paddle 
impellers and cultured in 100 mL of mEF-CM at 45 rpm for additional 16 
days. Culture medium was partially replaced three times a week. This was 
done by stopping agitation (to induce microcapsules deposition), removing 
50% of the medium and feeding with 50% of fresh medium. Cultures of 
non-encapsulated aggregates were also performed in parallel and used as 
control. Both cultures were monitored in terms of cell viability, metabolic 
activity, aggregate size, concentration and composition during time. For 
flow cytometry analysis, aggregates were transferred to gelatin coated 
surfaces, in mEF-CM, where cells were able to migrate. After 2-3 days, 
cells were dissociated using TrypLE Select and processed for flow 
cytometry analysis using the protocol described below. 
Encapsulation of hESCs immobilized on microcarriers: hESCs were 
inoculated at 4.5 ×105 cell/mL into 125 mL spinner vessels with paddle 
impellers containing Cytodex3TM microcarriers (2 g/L, GE Healthcare, 
Uppsala, Sweden). The microcarriers were prepared and sterilized 
according to the manufacture’s recommendation and coated with Matrigel 
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(BD Biosciences, Bedford, MS, USA) as described in the literature (Lock 
and Tzanakakis 2009). Cells were cultured in 25 mL of mEFs-CM 
supplemented with 10 µM ROCKi, and the spinner vessels were placed at 
37ºC, 5% CO2 under intermittent stirring. After 6 h, fresh mEFs-CM was 
added to cultures and agitation rate set to 24 rpm. By day 3, more media 
was added for a final volume of 100 mL. The encapsulation was performed 
at day 6; empty microcarriers (1 or 2 g/L) coated with Matrigel were added 
to the cultures 1 h before encapsulation. Within this period, cultures were 
treated with 5 µM ROCKi. After encapsulation, hESCs were transferred to 
spinner vessels and cultured in the same conditions for additional 13 days. 
Medium was partially (50%) replaced daily. Cultures of non-encapsulated 
cells-microcarriers were also performed and run in parallel as a control. 
Both cultures were monitored in terms of cell concentration, viability and 
culture composition during time.  
At the end of the expansion process of both cell aggregates and hESC-
microcarriers cultures, microcapsules were dissolved and hESC clumps 
were dissociated and plated on a top of a monolayer of inactivated hFF for 
further characterization studies to assess cell pluripotency.  
2.5. Cell cryopreservation 
Cultures of non-encapsulated and encapsulated hESCs were harvested 
from the spinner vessels and cryopreserved using the slow freezing rate 
method (Malpique, et al. 2010). The hESC-microcarriers and hESCs 
aggregates were collected at day 13 and 14 of culture, respectively (Fig. 1), 
and all samples were pre-treated with 5 µM ROCKi for 1 hour before being 
cryopreserved. 
Freezing: At the moment of freezing, after deposition of the microcapsules, 
culture medium was removed and cryopreservation medium (90% KO-SR, 
10% (v/v) DMSO (Sigma, Steinheim, Germany), 5 µM ROCKi) was added. 
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Cell suspensions obtained were then transferred to cryovials (Nunc, 
Roskilde, Denmark) (1 mL/vial). The cells were allowed to equilibrate in the 
cryopreservation medium for 20 minutes at 4ºC. Samples were frozen to -
80ºC in an isopropanol-based freezing system, (“Mr. Frosty”, Nalgene, NY, 
USA) at a rate of 1ºC per minute, and stored in the gas phase of a liquid 
nitrogen reservoir until their thawing. 
 Thawing: Following storage, cells were quickly thawed by placing the 
cryovials in a 37ºC water bath; a stepwise dilution (1:1, 1:2, 1:4) in mEF-CM 
was performed immediately after thawing in order to dilute the DMSO while 
reducing the osmotic shock (Malpique, et al. 2010). Cells-microcapsules 
were transferred to Petri-dishes and cultured for 9 days in mEF-CM 
supplemented with 5 µM of ROCKi. Media exchange was performed daily. 
At day 9, microcapsules were dissolved and hESC clumps were 
dissociated with TrypLE Select; hESCs were transferred to a monolayer of 
inactivated hFF and maintained in culture for several passages for 
post‐ thaw studies of growth and pluripotency. 
Assessment of hESCs survival after thawing: The percentage of hESCs 
survival/recovery after thawing was determined by calculating the ratio 
between the number of viable hESCs after cryopreservation and the 
number of initially frozen viable hESCs, counted using a  Fuchs‐ Rosenthal 
haemocytometer chamber (Brand, Wertheim, Germany) and the Trypan 
Blue (Invitrogen, Paisley, UK) exclusion method.  
2.6. Evaluation of cell viability 
Three methods were used to estimate cell viability. 
Cell membrane integrity assay: The qualitative assessment of the cell 
plasma membrane integrity during culture was done using the enzyme 
substrate fluorescein diacetate (FDA; Sigma-Aldrich, Steinheim, Germany) 
and the DNA-dye propidium iodide (PI; Sigma-Aldrich, Steinheim, 
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Germany) as described in the literature (Lock and Tzanakakis 2009). 
Briefly, cells/microcapsules were incubated with 20 µg/mL FDA and 10 
µg/mL PI in PBS for 2-5 min and then visualized using fluorescence 
microscopy (Leica Microsystems GmbH, Wetzlar, Germany). 
Trypan Blue exclusion method: The total number of viable cells was 
determined by counting the colorless cells in a Fuchs‐ Rosenthal 
haemocytometer chamber after incubation with Trypan Blue dye (0.1% (v/v) 
in PBS).  
Lactate dehydrogenase (LDH) activity: LDH activity from the culture 
supernatant was determined by monitoring the rate of oxidation of NADH to 
NAD+ coupled with the reduction of pyruvate to lactate at 340 nm. The 
specific rate of LDH release (qLDH) was calculated for each time interval 
using the following equation: qLDH= (LDH)/( t×Xv), where LDH  is 
the change in LDH activity over the time period t, and Xv is the average 
of the total cell number during the same period. The cumulative value 
qLDHcum was estimated by qLDHcum i+1 = qLDH i + qLDH i+1. 
2.7. Evaluation of metabolic activity 
AlamarBlueTM assay: hESCs metabolic activity was assessed using the 
metabolic indicator alamarBlue following the manufacture’s 
recommendation (Paisley, UK, Invitrogen). Briefly, 2 mL of hESC culture 
were incubated overnight with fresh medium containing 10% (v/v) 
alamarBlue. Fluorescence was measured in 96-well plates using a 
microwell plate fluorescence reader (FluoroMax-4, Horiba Jobin Yvon). 
2.8. Evaluation of cell growth  
Apparent growth rate (µ): µ was estimated using a simple first-order kinetic 
model for cell expansion: dX/dt = µX, where t (day) is the culture time and X 
(cell) is the value of viable cells for a specific t. The value of µ was 
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estimated using this model applied to the slope of the curves during the 
exponential phase. 
Expansion ratio or fold increase (FI) in cell concentration: FI was evaluated 
based on the ratio XMAX/X0, where XMAX is the peak of cell density (cell/mL) 
and X0 is the lowest cell density (cell/mL). 
 2.9. Characterization of hESCs 
For all culture samples, microcapsules were dissolved prior to analysis. The 
undifferentiated status of hESCs was evaluated by analyzing the activity of 
alkaline phosphatase (AP) and by detecting the expression of specific stem 
cells markers using immunocytochemistry and flow cytometry analysis.  
Alkaline Phosphatase (AP) staining: Cultures were stained using an AP 
activity detection kit (Millipore, Billerica, MA, USA) according to the 
manufacturer’s instructions and observed using an inverted phase contrast 
microscope (Leica Microsystems GmbH).  
Immunocytochemistry: Cultures of hESC were fixed in 4% (w/v) 
paraformaldehyde (PFA) in PBS for 20 minutes, permeabilized (only for 
detection of intracellular marker Oct-4) for 5 minutes in 0.1% (w/v) Triton 
X‐ 100 (Sigma‐ Aldrich, Steinheim, Germany) in PBS  and subsequently 
incubated with primary antibody overnight at 4°C. Cells were washed three 
times in PBS and then incubated with secondary antibodies during 1 h at 
room temperature in the dark. After three washing steps with PBS, cell 
nuclei were counterstained with 4,6‐ diamidino‐ 2‐ phenylindole (DAPI, 
Sigma‐ Aldrich, Steinheim, Germany). Cells were visualized using spinning 
disk confocal (Nikon Eclipse Ti-E, confocal scanner: Yokogawa CSU-x1) 
and inverted (Leica Microsystems GmbH) fluorescence microscopy. In 
samples of hESC aggregates, an additional permeabilization step was 
performed before the addition of primary antibodies; cells were incubated 
with 0.2% fish skin gelatine and 0.1% TX-100 in PBS for 2 h at room 
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temperature. Primary antibodies used were: Tra-1-60, and Oct-4 (all from 
Santa Cruz Biotechnology, Santa Cruz, CA, USA). Secondary antibodies 
used were: goat anti-mouse IgM-AlexaFluor488 and goat anti-mouse IgG-
AlexaFluor 488 (all from Invitrogen, Paisley, UK).  
Flow cytometry: cell clumps were dissociated with TrypLE Select and the 
single cell suspension was resuspended in washing buffer (WB) solution 
(5% (v/v) FBS in PBS). After two washing steps, cells were incubated with 
primary antibody for 1 h at 4ºC, washed three times in WB and then 
incubated with the secondary antibody for additional 30 min at 4ºC. After 2 
washing steps with WB, cells were analyzed in a CyFlow® space (Partec 
GmbH, Münster, Germany) instrument as reported elsewhere [16]. Ten 
thousand events were registered per sample. Primary antibodies used 
were: Tra-1-60, SSEA-4, SSEA-1 and isotype control antibodies (all Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) and hES-CellectTM (Cellartis 
AB, Göteborg, Sweden). Secondary antibodies used were: goat anti-mouse 
IgM-AlexaFluor488 and goat anti-mouse IgG-AlexaFluor 488 (all from 
Invitrogen, Paisley, UK).  
2.10. In vitro pluripotency  
The cells’ pluripotent potential was evaluated in vitro via embryoid body 
(EB) formation and spontaneous differentiation. hESCs were dissociated, 
transferred to non-adherent Petri dishes (5 ×105 cell/mL) and cultured in 
suspension for 1 week in DMEM-KO medium without bFGF. EBs formed 
during this time were harvested and cultured in gelatin‐ coated plates for 
further 2 weeks (medium was changed three times a week). Differentiated 
cells were identified using immunocytochemistry as described above. 
Primary antibodies used were: α-smooth muscle actin (DAKO, Glostrup, 
Denmark), Forkhead box A2 (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) and β tubulin type III (Chemicon, Temecula, CA, USA). Secondary 
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antibodies used were: goat anti-mouse IgG-AlexaFluor488 and donkey 
anti-goat IgG-AlexaFluor594 (all from Invitrogen, Paisley, UK). 
 
3. RESULTS  
Results previously reported by our group and others demonstrate that it is 
possible to expand hESCs as aggregates or immobilized on microcarriers 
in stirred tank bioreactors [13-18]. Aiming to increase further the cell 
expansion yields, different 3-D cell microencapsulation strategies were 
evaluated (Figure 6.1). The most promising strategies were selected to 
evaluate the impact of microencapsulation on cell cryopreservation, with 
the final goal to implement an integrated bioprocess for the robust 
expansion and storage of pluripotent hESCs. In this work, calcium 1.1% 
(w/v) UP MVG alginate microcapsules were used since previous studies 
reported that the properties of this matrix fulfill the main requisites 
(permeability, stability and elasticity) to support an efficient hESCs culture 
(Chayosumrit, et al. 2010). 
3.1. Expansion of microencapsulated hESC as single cells 
In a first approach we investigated the hypothesis of expanding single 
hESCs in alginate microcapsules. Cells were encapsulated at different 
concentrations, 0.75, 2 and 3 ×106 cell/mL alginate, and inoculated at 1.5 
×105 cell/mL in stirred culture systems. For all conditions tested, cell 
viability decreased significantly from approximately 95% to 5% after 7 days 
of cultivation (data not shown). In high cell density microcapsules (3 ×106 
cell/mL alginate), some cells remained viable, proliferated and formed small 
clusters, however the percentage of populated microcapsules was very low 
(<10%, data not shown). These results indicate that the microencapsulation 
of single cells is not a suitable strategy to expand hESCs. 
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3.2. Expansion of microencapsulated hESC aggregates in stirred 
tank bioreactors 
On the second strategy, hESCs were induced to form small cell aggregates 
after single cell enzymatic dissociation (Figure 6.1). By day 2, aggregates 
ranging from 30-60 μm were encapsulated to generate approximately 1 
aggregate per microcapsule, and transferred to spinner vessels.  
The results show that the microencapsulation of aggregates enhanced the 
culture performance of hESCs when compared to the microencapsulation 
of single cells. Aggregates of hESC presented high cell viability and a 
spherical shape during culture time (Figure 6.2A). After 2 weeks of culture, 
an increase in aggregate size (5-fold, Table 6.1) and metabolic activity (2-
fold, Figure 6.2B) was observed, indicating that hESCs proliferated inside 
alginate microcapsules. Overall, a significant improvement in cell viability 
and expansion was obtained when compared to non-encapsulated cultures 
where aggregates clumped together and formed large (> 1mm in size) 
irregular structures with necrotic centres (Figure 6.2A). In fact, the 
pronounced decrease in metabolic activity and the high values of 
cumulative LDH release confirm that the culture of non-encapsulated hESC 
aggregates in spinner vessels resulted in an accentuated cell death (Figure 
6.2C).  
Aggregates collected after microcapsules dissolution maintained their 
integrity and high cell viability (not shown), thus ensuring an efficient cell 
characterization. The results show that hESCs expanded as encapsulated 
3-D aggregates retained their undifferentiated phenotype during 2 weeks of 
culture in spinner vessels, as evaluated by immunofluorescence 
microscopy and flow cytometry (Figure 6.2D-F). By day 7, the percentages 
of SSEA-4 and TRA-1-60 positive cells were high (94.6% and 89.2%, 
respectively) indicating that the majority of cells had an undifferentiated 
character (Figure 6.2D,E).  
Chapter 6. Microencapsulation technology to integrate expansion and cryopreservation of hESC 
174 
 
 
 
D 
E 
Process engineering of stem cells for clinical application 
175 
 
Figure 6.2. Effect of alginate microencapsulation on the expansion of hESC as 
aggregates. hESC aggregates were encapsulated at day 2 and cultured in spinner 
vessels. (A) Phase contrast and fluorescence images of encapsulated and non-
encapsulated cultures at days 3, 7 and 9. Viability of hESC aggregates was assessed 
by staining with fluoresceine diacetate (FDA-live cells, green) and propidium iodide 
(PI- dead cells, red). Scale bar:  100 µm. (B-C) Cell growth performance of both 
Chapter 6. Microencapsulation technology to integrate expansion and cryopreservation of hESC 
176 
encapsulated (purple) and non-encapsulated (grey) cultures. (B) Cumulative values 
of specific rates of LDH release with time. (C) Metabolic activity measured by 
alamarBlue test on the day after microencapsulation (day 3) and at day 15; error bars 
denote SD of 3 measurements. (D-H) Characterization of encapsulated hESC 
aggregates expanded in spinner vessels. (D) Confocal images of aggregates labeled 
for Oct-4 and TRA-1-60 at day 16 of 3-D culture. Scale bar: 50µm. (E-F) Flow 
cytometry analysis of the expanded population. (E) Percentage of SSEA-4, TRA-1-60 
and SSEA-1 positive cells at days 7 (purple bars) 14 (pink stripes bars) and 21 (grey 
stripes bars); error bars represent SD of 2 measurements. (F) Histograms obtained in 
flow cytometry analysis of SSEA-4 and TRA-1-60 positive cells at day 7 of culture. 
(G) Immunofluorescence images of Oct-4 and TRA-1-60 labeling and phase contrast 
pictures of alkaline phosphatase (AP) activity, staining after expansion (2-D culture). 
Nuclei were labeled with DAPI (blue). Scale bars: immunofluorescence images - 200 
μm, AP image -1mm. (H) In vitro pluripotency analysis. Microcapsules were dissolved 
and hESCs were transferred to a monolayer of inactivated hFF. At confluence, 
colonies were dissociated and hESCs were able to form embryoid bodies (EBs) in 
non-adherent conditions and differentiated into cells from all three germ layers. 
Fluorescence images of differentiated cultures labeled for α–SMA (α smooth muscle 
actin, mesoderm), FOX-A2 (Forkheadbox A2, endoderm) and βIII-Tub (β tubulin type 
III, ectoderm). Nuclei were stained with DAPI (blue). Scale bar: 100 μm.. 
Additionally, in all culture time points the percentages of SSEA-1 positive 
cells were always below 10% (Figure 6.2D). At day 18, a significant 
decrease in SSEA-4 and TRA-1-60 positive cells was observed (Figure 
6.2D); the presence of EB-like structures (aggregates with irregular shape 
and cystic cavities) detected at this time point (data not shown), indicates 
that hESCs were differentiating. 
After alginate dissolution, microencapsulated hESC aggregates expanded 
in the bioreactor were able to form undifferentiated colonies on top of a 
monolayer of inactivated hFF (Figure 6.2G). Moreover, these cells 
differentiated spontaneously in vitro, via EB formation, into cells from the 
three germ layers (Figure 6.2H), confirming that they maintained their 
pluripotent potential. 
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3.3. Expansion of encapsulated hESC immobilized on 
microcarriers in stirred tank bioreactors 
In the third strategy evaluated, hESCs were immobilized on Matrigel-coated 
Cytodex 3 microcarriers (3g/L) (Serra, et al. 2010) and encapsulated in 
alginate. Firstly, the microencapsulation step was tested at different culture 
time points: 8h (day 0), 1, 3 and 6 days; day 6 was selected since it allowed 
a higher percentage of microcarriers and microcapsules colonization (data 
not shown). Preliminary experiments also demonstrated that the addition of 
empty supports (1g/L) on cell-microcarrier cultures (cells immobilized on 
microcarriers, 2g/L) immediately before microencapsulation, enhanced 
further microcapsules colonization and cell expansion yields (data not 
shown).  
Encapsulated hESCs immobilized on microcarriers were cultured for 19 
days in spinner vessels (Figure 6.1). The results show that the 
microencapsulation of cell-microcarriers in alginate markedly enhanced cell 
viability and expansion when compared to non-encapsulated cultures 
(Table 6.1, Figure 6.3A,B). By day 19, the fold increase in cell 
concentration was higher in encapsulated (10.7±0.8%) than in non-
encapsulated (7.8±0.3%) cultures, which supports that alginate 
microcapsules protect the cells from the hydrodynamic shear stress, 
enhancing cell migration and further proliferation on microcarriers. 
Moreover, no differences were observed in the apparent growth rates 
(Table 6.1), indicating that the alginate matrix did not compromise the 
hESCs proliferation potential. 
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Table 6.1. Expansion and cryopreservation of encapsulated and non-encapsulated 
hESC cultures. 
Culture Strategy             hESC aggregates 
Alginate Microencapsulation No Yes 
EXPANSION   
Fold increase in metabolic activity (2weeks) 0 2.4±0.2 
Initial aggregate size (day 2) (µm) 53±16 53±16 
Final aggregate size (day 15) (µm) - 257±61 
CRYOPRESERVATION   
% cell survival  0% 0% 
Culture Strategy hESCs immobilized on microcarriers 
Alginate Microencapsulation  No  Yes  Yes  
Microcarrier Concentration  3g/L  3g/L  4g/L  
EXPANSION        
Initial cell concentration  
(×10
5
 cell/mL) 
 1.7±0.3  1.8±0.1  1.5±0.6  
Maximum cell concentration  
(×10
5
 cell/mL) 
 12.7±0.5  19.0±2.4  28.2±3.8  
Expansion ratio/Fold increase 
related to initial cell concentration 
 7.7±0.2  10.7±0.8  19.2± 1.8  
Apparent growth rate, µ (day
-1
)  0.14± 0.03 
(R
2
=0.99) 
 0.15± 0.07 
(R
2
=0.99) 
 0.16± 0.02 
(R
2
=0.94) 
 
CRYOPRESERVATION        
% cell survival: 
Immediately after thawing 
1 day after thawing 
  
53.2±1.1% 
23.8±4.5% 
  
100.5±14.0% 
68.8±4.3% 
  
- 
- 
 
 
Aiming to improve further cell expansion yields, we increased the 
concentration of microcarriers: 2 g/L of empty supports were added before 
microencapsulation, yielding a final concentration of 4 g/L. The increase in 
the surface area available for cell growth contributed to increase the final 
cell concentration (2.9 × 106 cell/mL corresponding to a 19.2±1.8 of 
expansion ratio, Table 6.1). Within microcapsules, cells migrated and 
colonized most of the microcarriers, presenting higher viability during time 
(Figure 6.3C). It is important to highlight that, using these conditions, the 
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exponential growth phase was prolonged until day 19 (Figure 6.3A). The 
culture was aborted at this time point because cells’ overgrowth was 
observed in some microcapsules (data not shown). 
After being expanded as encapsulated cell-microcarrier aggregates, hESCs 
retained their undifferentiated phenotype (Figure 6.3D-F). When compared 
to non-encapsulated cultures, results were very similar with the exception 
of TRA-1-60 where higher levels of positive cells were registered in 
encapsulated cultures (Figure 6.3D). The percentage of SSEA-1 positive 
cells was higher in non-encapsulated (13.0±0.4%) than in encapsulated 
cultures (7.8±0.3%) (Figure 6.3E), indicating that, at the end of the 
expansion process, more cells in an early differentiated state were present 
in the formers. 
Encapsulated cells maintained their capacity to form undifferentiated 
colonies in 2-D standard monolayer systems (Figure 6.3G) and presented 
in vitro pluripotency; cells were able to form EBs and spontaneously 
differentiate into cells from the three embryonic germ layers (Figure 6.3H).  
3.4. Cryopreservation of hESCs using 3D microencapsulated 
culture strategies 
Since hESCs can be successfully expanded in microcapsules as cell 
aggregates or adherent to microcarrier surface, we evaluated the possibility 
of cryopreserving these 3-D structures.. Cells were harvested from the 
bioreactor cultures at specific culture time points (day 13 and 14 for hESCs-
microcarriers and aggregates cultures, respectively) (Figure 6.1) and 
cryopreserved using a slow rate freezing protocol. 
Our results show that alginate microencapsulation did not prevent cell 
death of cryopreserved hESC aggregates immediately after thawing (Figure 
6.4A).  
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Figure 6.4. Post-thawing survival of non-encapsulated and encapsulated hESCs. 
Non-encapsulated and encapsulated hESCs were cryopreserved as aggregates or 
immobilized on microcarrier using slow freeze rate method. (A) Phase contrast and 
fluorescence images of cryopreserved hESC immediately, 1, 3 and 7 days after 
thawing. Viability analysis of hESCs stained with fluoresceine diacetate (FDA-live 
cells, green) and propidium iodide (PI- dead cells, red). Scale bar: 200 μm. (B-G) 
Post-thawing characterization of non-encapsulated (grey) and encapsulated (purple) 
hESCs immobilized on microcarriers. (B) Percentage of cell survival immediately and 
one day after thawing; error bars denote SD of 2 measurements.  (C) Metabolic 
activity measured by alamarBlue test before cryopreservation and 1 and 9 days after 
thawing. Error bars denote SD of 3 measurements. (D) Cumulative values of specific 
rates of LDH release of cryopreserved hESCs after thawing. 
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On the contrary, microencapsulated hESCs immobilized on microcarriers 
presented high cell viability and cell recoveries post-thawing (Figure 6.4A). 
When compared to non-encapsulated cultures, the results are very 
promising; immediately and one day after thawing, the percentage of cell 
survival was higher in encapsulated (day 0=103.7±8.8%, day 1= 
71.0±5.0%) than in non-encapsulated cells (day 0= 55.7±4.6%, day 1= 
24.9±2.8%) (Figure 6.4B, Table 6.1). Although some cell death occurred in 
the first days post-thawing, microencapsulated hESCs recovered faster 
their proliferative and metabolic activity (Figure 6.4C). In non-encapsulated 
cultures, cells were prone to detach from the microcarriers after thawing 
resulting in a pronounced cell death (Figure 6.4A); in fact, cells did not 
reestablish their metabolic activity and the values of LDH were higher than 
in encapsulated cultures at all time points (Figure 6.4C-D).  
To examine if microencapsulated hESCs immobilized on microcarriers 
maintained their pluripotent characteristics after cryopreservation, cells 
were characterized 9 days post-thawing and during 5 additional passages 
on a top of inactivated hFF monolayers. The results confirmed that hESCs 
maintained their undifferentiated phenotype (Figure 6.5A-C) and the ability 
to differentiate in vitro into cells from the three germ layers (Figure 6.5D).  
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Figure 6.5. Post-thawing characterization of encapsulated hESCs immobilized on 
microcarriers. Phenotype analysis of encapsulated hESC immobilized on Matrigel 
coated Cytodex3 microcarriers (A) 9 days post‐thawing (P0) and (B) after 2 and 5 cell 
passages in 2-D culture systems (P2 and P5, respectively); confocal images of Oct-4, 
and TRA-1-60 labeling and phase contrast pictures of alkaline phosphatase (AP) 
activity. Nuclei were labeled with DAPI (blue). Scale bars: (A) 100 μm and (B) 200 μm 
for immmunofluorescence images; (A, B) 1mm for phase contrast images. (C) Flow 
cytometry analysis; percentage of SSEA-4, hES-Cellect
TM
 (hES) and SSEA-1 positive 
cells after 2 and 5 cell passages post‐thawing (P2 and P5, respectively); error bars 
represent SD of 2 measurements. (D) In vitro pluripotency analysis. Microcapsules 
were dissolved and hESCs were detached from the microcarriers and transferred to a 
monolayer of inactivated hFF. At confluence, colonies were dissociated and hESCs 
were able to form embryoid bodies (EBs) in non-adherent conditions and differentiated 
into cells from all three germ layers. Phase contrast micrograph of human embryoid 
bodies and fluorescence images of differentiated cultures labeled for α–SMA (α 
smooth muscle actin, mesoderm), FOX-A2 (Forkheadbox A2, endoderm) and βIII-Tub 
(β tubulin type III, ectoderm). Nuclei were stained with DAPI (blue). Scale bars: 100 
μm.   
 
4. DISCUSSION 
Efficient culture strategies are urgently needed to accelerate the transition 
of hESCs to the clinic and industry. The aim of this study was to develop an 
integrated bioprocess for expansion and cryopreservation of pluripotent 
hESCs; our approach consisted in obtaining 3-D culture strategies using 
cell microencapsulation in alginate. The results obtained show that the 
combination of cell microencapsulation and microcarrier technology is an 
optimum protocol for the production and storage of pluripotent hESCs in 
high quality and relevant quantities. 
Cell microencapsulation in alginate proved to be a valuable strategy to 
improve cell expansion in stirred tank bioreactors, since it ensured a shear 
stress free microenvironment and avoids excessive clustering of 
microcarriers or aggregates in culture. This strategy is extremely attractive 
for use in large-scale bioprocesses, by enabling tighter control of the 
culture and higher cell expansion yields than non-encapsulated cultures.  
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Our results show that the microencapsulation of hESCs immobilized on 
microcarriers is a very efficient system for the long-term culture of 
undifferentiated stem cells with high cell viability, overcoming the main 
limitations of both single cells and aggregate cultures. In agreement with 
other studies confirming  that cell-cell and cell-matrix interactions affect 
significantly stem cell fate decisions (apoptosis, self-renewal, 
differentiation) (Azarin et al., 2010; Chayosumrit, et al. 2010; Sommar et 
al., 2010; Wang, et al. 2009), our results show that these interactions cause 
the improvement of stem cell bioprocesses. In fact, hESCs loose drastically 
their viability when encapsulated as single cells, even after treatment with 
Y-27632, a selective ROCK inhibitor known to prevent apoptosis of hESCs 
after single cell enzymatic dissociation (Chayosumrit, et al. 2010; 
Watanabe et al., 2007). Moreover, the cultivation of microencapsulated 
aggregates promotes spontaneous differentiation after 2 weeks of culture. 
This profile can be explained by the increase in aggregate size (>250 µm), 
which may limit the diffusion of growth factors and gases within aggregates 
thereby inducing the formation of EB-like structures and reducing cell 
proliferation capacity. In a previous study, Siti-Ismai et al. reported the long-
term feeder‐free culture of hESC aggregates in large (approximately 1 mm) 
calcium alginate capsules, confirming that cells retained their 
undifferentiated state and pluripotent characteristics for up to 260 days 
(Siti-Ismail, et al. 2008). This difference in cell behavior may reflect the 
distinct hESC line and/or culture conditions (alginate matrix, culture 
medium) used. Nevertheless, the culture of microencapsulated hESC 
aggregates could be adopted for the production of human stem cell 
derivatives, by inducing directed differentiation at the second week of 
culture (when stem cell population is still pluripotent), and bypassed the EB 
formation step in a controlled manner.  There are several studies reporting 
the use of this strategy to differentiate mouse and/or human ESCs into 
pancreatic insulin-producing cells (Wang, et al. 2009), hepatocytes 
Process engineering of stem cells for clinical application 
187 
(Maguire, et al. 2007; Maguire, et al. 2006), definitive endoderm 
(Chayosumrit, et al. 2010), cardiomyocytes (Bauwens, et al. 2005; Jing, et 
al. 2010) and osteoblasts (Hwang, et al. 2009). High expectations are 
posed in these culture strategies to potentiate hESCs towards cell therapy 
and tissue engineering applications (revised in (Murua et al., 2008)).  
Another advantage of microcarrier technology in cell expansion processes 
is the flexibility to adjust easily the area available for cell growth, which 
further facilitates the process scale-up. From clinical/industrial perspectives, 
this feature has a tremendous impact in reducing the costs of cell 
manufacturing by reducing the amount of media, growth factors and other 
expensive supplements required in stem cell cultivation (Fernandes et al., 
2009; Krtolica, et al. 2009). By increasing the concentration of microcarriers 
we were able to achieve up to 3x106 cell/mL, which corresponds to 
approximately 15-fold increase in final cell yields when compared to 
standard 2-D protocols (Serra, et al. 2010).  Although performed at small 
lab scale spinner vessels, the evolved strategies can be easily up-scaled to 
environment controlled stirred tank bioreactors where scalability, 
automation and accurate control of culture environment are guaranteed. 
Indeed, our group has recently demonstrated that the expansion of 
pluripotent hESCs is improved in stirred tank bioreactors with controlled 
pO2 and continuous perfusion (Serra et al., 2010).  
This study also demonstrated that the microencapsulation of hESCs 
immobilized on microcarriers results in an efficient protocol for the 
cryopreservation of hESCs. Such protocol allows for the recovery of hESCs 
with high viabilities and undifferentiated levels, and the maintenance of their 
pluripotent characteristics over several passages in standard culture 
conditions, enabling their use for further applications. The presence of 
components of the extracellular matrix on microcarrier cultures (e.g. 
collagen, laminin) may have contributed to enhance cell survival during 
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freezing and thawing (Ji et al., 2004; Kim et al., 2004), by reducing post-
thaw apoptosis (Heng, et al. 2006; Ji, et al. 2004). In contrast, 
microencapsulated aggregates showed high cell death immediately after 
thawing. The limitations in heat and mass (water and cryoprotectant) 
transfer within aggregates may result in different cryoprotection gradients, 
possibly leading to cryodamage (Karlsson et al., 1996; Malpique, et al. 
2010). In the future, more fundamental studies on the physico-chemical and 
biophysical phenomena occurring during freezing/thawing of 
microencapsulated hESC aggregates will allow for a further improvement of 
this process.  
It is important to highlight that, the cryopreservation of hESCs immobilized 
on microcarriers has already been reported by Nie et al (Nie, et al. 2009). 
The advantage of our strategy is that higher cell recovery yields can be 
achieved without the use of feeder cells. In fact, the alginate microcapsule 
allows further improvement of post-thaw cell viability, enhancing cell 
survival (up to 3-fold) compared to non-encapsulated cultures. Although the 
underlying mechanisms are still unclear, several studies indicate that 
maintaining cell-cell contact improves hESC recovery following 
cryopreservation (Hunt 2007; Ji, et al. 2004). Cell entrapment within 
alginate microcapsules may help protect hESCs from the adverse effects of 
cryopreservation not only by preventing the disruption of cell-cell and cell-
matrix contacts (Malpique, et al. 2010; Zimmermann, et al. 2005) but also 
by decreasing exposure to cryoprotectants and preventing the damage 
caused by intracellular ice formation and propagation (via gap junctions) 
(Murase et al., 1997; Toner et al., 1993). 
To our knowledge this is the first study reporting the successful expansion 
and cryopreservation of pluripotent hESCs on microcarriers inside alginate 
microcapsules. More importantly, we describe for the first time an 
integrated bioprocess which may be used for efficient production, banking 
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and distribution of hESC in a scalable and straightforward manner. 
Hopefully, the integrated strategy developed herein will potentiate the 
translation of hESCs towards a wide range of applications. If hESC can be 
harvested from the microcapsules they could have immediate use for in 
vitro applications demanding high number of cells, e.g. in high-through-put 
screening of pharmaceutical compounds. However, from a clinical 
perspective, further improvements are still required including the adaptation 
to defined xeno-free culture conditions. The presence of microcarriers 
within the microcapsules is a major concern, demanding the incorporation 
of an additional step to release cells from the microcapsules and separate 
them from the microcarriers before cell transplantation. As an alternative, a 
biodegradable clinical approved microcarrier could be used. In fact, gelatin 
and pharmacologically active microcarriers (PAMs) have been used 
successfully in adult cell therapy for brain neuronal damage and cartilage 
engineering (revised in (Delcroix, et al. 2010; Hernandez et al., 2010)). 
Although the type of alginate used in this study has never been tested in 
clinical studies, it is manufactured in compliance with current GMP and 
presents low levels of endotoxins (≤100 EU/g), conditions that may boost 
the use of this matrix in transplantation experiments. 
  
5. CONCLUSION 
This study shows that cell microencapsulation in alginate is a powerful tool 
to integrate expansion and cryopreservation of pluripotent hESCs. 
Moreover, the combination of cell microencapsulation with microcarrier 
technology promotes cellular interactions that are essential for the efficient 
production and storage of hESCs without compromising their viability, self-
renewal and pluripotency. The 3-D culture strategy we have developed 
represents an important step forward in facilitating the translation of hESCs 
for a broad spectrum of applications in regenerative medicine, tissue 
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engineering and in vitro toxicology. Future studies will include the 
incorporation of a differentiation step and the development of a fully 
integrated bioprocess for the expansion, differentiation and storage of 
hESC derivatives. 
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1. DISCUSSION  
Recent advances in stem cell biology and biotechnology have sparked 
hope that stem cell-based therapies will soon be available to treat 
devastating maladies such as Parkinson’s disease, Type I diabetes and 
cardiovascular diseases. The successful translation of stem cells to this 
field requires the development of robust bioprocesses for the production of 
stem cells and/or their progeny in quantities and qualities that satisfy 
clinical demands.  
The work developed in this thesis aimed at overcoming critical challenges 
in stem cell expansion and differentiation bioprocesses. Distinct case 
studies were investigated and novel culture strategies were developed and 
further optimized. Moreover, several analytical tools were established to 
monitor stem cell characteristics along culture and also to assess 
bioprocess yields and end product’s purity, quality and quantity. Each 
presented case faces unique challenges and shows that there is no 
“optimal/universal” stem cell-based bioprocess capable of embracing all the 
applications of these cells. Nonetheless, the knowledge gained in the 
quantitative characterization of expansion and differentiation processes 
provides important insights for the implementation of, at least, more 
universal and robust stem cell production platforms.  
1.1. Process engineering of stem cells for clinical application  
The successful production of stem cell-based products relies on robust 
bioprocesses that should be designed according to the cell type and 
characteristics, the needs of the application, and the method requirements 
(Figure 1.1, page 7). 
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In this thesis, different culture strategies were developed for three stem cell 
types, chosen for their unique features and potential applications: adult 
stem cells isolated from pancreas (rPSC), with the capacity for multilineage 
differentiation (Chapter 2); human teratocarcinoma stem cells (NT2), which 
differentiate into neurons after treatment with retinoic acid (Chapters 3 and 
4); and pluripotent human embryonic stem cells (hESC) (Chapters 5 and 6). 
These stem cell types share important characteristics (self-renewal ability 
and the potential to differentiate into specific cell types) and similar 
bioprocessing challenges.  
 An important requirement for the cultivation of these stem cell lines is, in 
fact, the need for maintaining cell‐cell and cell‐matrix interactions as well as 
monitoring specific environmental factors that affect stem cells’ fate 
decisions, in order to better control the culture outcome and boost stem cell 
bioprocess yields. In this thesis, the development of culturing strategies for 
3-D cell organization (cell aggregates, cells immobilized on microcarriers, 
cell microencapsulation in alginate) combined with the use of bioreactor-
based system (where the necessary conditions for cells to guide their fate 
are “perfectly tuned”) demonstrated to be a promising approach to improve 
stem cell expansion and differentiation yields and to facilitate bioprocess 
integration.  
A schematic representation of the main focus of this thesis is summarized 
on Figure 7.1. Overall, the following outcomes were achieved: 
- Implementation of a robust and scalable protocol for the expansion 
of undifferentiated rPSCs (Chapter 2) and hESCs (Chapter 5) in 
environmentally controlled stirred tank bioreactors; 
- Development of a robust strategy for the efficient and rapid 
production of human neurons derived from NT2 cells using stirred 
tank bioreactors (Chapter 3);       
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- Development of a scalable and integrated bioprocess for the expansion 
and neuronal differentiation of NT2 cells (Chapter 4); 
‐ Development of a novel and integrated bioprocess for expansion and 
cryopreservation of hESCs using cell microencapsulation technology 
(Chapter 6). 
 
 
Figure 7.1. Schematic view of the focus and outcomes of the work developed in thesis. 
(DIFF: differentiation; EXP: Expansion; CRYO: cryopreservation) 
 
These outcomes represent a significant step towards the translation of 
stem cells from lab scale to clinical trials and larger scales required for 
industrial applications. 
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1.1.1. Stirred tank bioreactor: a powerful culture system to 
potentiate stem cell bioprocessing 
An important requirement for the exploitation of stem cells in regenerative 
medicine is the ability to derive sufficient numbers of cells of a consistent 
quality in a cost-effective and straightforward manner. Stirred tank 
bioreactors are an attractive approach for the culture of stem cells. These 
bioreactors have been heavily utilized in the biotechnology industry for the 
production of antibodies, enzymes, vaccines and viruses, where nominal 
volumes of 25 mL to 200L are typically utilized (revised in (Birch et al., 
2006; Chu et al., 2001; Kretzmer, 2002)). Hence, stem cell bioprocesses 
developed in this bioreactor type may be easier to translate to a 
clinical/industrial production setting than entirely novel designs.  
Stirred tank bioreactors are scalable and hydrodynamically well 
characterized systems with simple design and operation. The main 
characteristic of these bioreactors is the possibility of culturing cells in a 
dynamic stirred environment, overcoming the mass and gas transfer 
limitations of static and other bioreactor systems. Another important feature 
of these bioreactors is the feasibility to perform non-invasive sampling thus 
enabling the continuous monitorization/characterization of the stem cell 
culture status/performance which is critical for process optimization.  
In particular, environmentally controlled stirred tank bioreactors allow the 
on-line monitoring and control of critical culture variables (e.g. temperature, 
oxygen, pH) known to affect stem cell self-renewal and directed 
differentiation (revised in Chapter 1). In this thesis, we addressed the 
importance of controlling the dissolved oxygen and the impact of operation 
mode to improve the culture of stem cells.  
Finally, it is also demonstrated that stirred tank bioreactors can be easily 
adapted to different 3-D culture strategies (cell aggregates, microcarriers, 
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microencapsulated cells) and different processes (expansion and 
differentiation). This versatility makes them appealing “universal culture 
systems” for use with different stem cell types (including iPS cells) and 
applications.  
 1.1.1.1. Control dissolved oxygen to enhance stem cell 
expansion 
All cells of the developing embryo are exposed to oxygen levels in vivo 
(1.5-8%) far below that of atmospheric oxygen levels (approximately 20%), 
and they differentiate and undergo organogenesis in a low oxygen 
environment. Therefore, the effects of low oxygen on self-renewal and 
differentiation of embryonic stem cells have been examined in a number of 
studies, trying to maximize and control stem cell expansion and/or 
recapitulate specific differentiation pathways. It has been demonstrating 
that physiological levels of oxygen support self-renewal of hESCs (Ezashi 
et al., 2005; Prasad et al., 2009) but also reduce pluripotency gene 
expression of mESCs (Millman et al., 2009), although some reports are 
conflicting. Others showed no advantage in the undifferentiated phenotype 
when hESCs are cultured at 5% of oxygen instead of 20% (Chen et al., 
2009). Similar disparities are reported for proliferation rates and 
differentiation efficiencies. One major problem in the field is the lack of 
recognition that the oxygen experienced by the cells (pO2cell) is often 
different from the oxygen in the gas phase (pO2gas), which makes 
interpretation of the literature difficult. In fact, pO2cell can differ drastically 
from pO2gas, as it depends on the cell density, culture system (static, stirred, 
suspension), cellular oxygen consumption rate and oxygen transfer rate in 
the culture. Knowledge of pO2cell is necessary for interpreting the results of 
studies and comparing them to data from other studies.  
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Using environmentally controlled stirred tank bioreactors, the work 
presented in Chapter 5 contributed to clarify the impact of low pO2cell on 
hESC growth performance. Although further studies are required to select 
the best pO2cell condition for maximizing hESC expansion, the results 
presented in this thesis suggested that 30% of air saturation (which 
corresponds to approximately 6% of pO2cell) enhances the metabolic 
performance of hESCs, ultimately improving cell expansion yields without 
compromising stem cell characteristics such as undifferentiated phenotype 
and pluripotency. Indeed, more efforts to estimate (Powers et al., 2010) or 
control pO2cell are essential for rational advance of this field.    
 1.1.1.2. Culture operation mode to streamline stem cell 
bioprocessing 
Stirred tank bioreactors are highly flexible as they can be handled in 
different culture operation modes, according to the desired culture 
outcome. The fed-batch strategy is very suitable for tuning and optimizing 
cell metabolism (Xie et al., 1994); by providing nutrients in a rational 
manner, their uptake and consumption are energetically more efficient 
leading to reduced accumulation of toxic metabolites in culture supernatant 
(Chapter 4). However, the main disadvantage of this approach is the 
possibility of depletion of growth factors and/or excessive accumulation of 
metabolic byproducts and paracrine factors. Thus, perfusion mode was 
preferentially adopted aiming at improving stem cell bioprocess yields, 
since it assures the continuous renewal of nutrients and other factors (e.g. 
Rapamycin) as well as the continuous removal of metabolic byproducts 
(Chapters 4 and 5). 
Within this context, more knowledge regarding the in vivo stem cells 
microenvironment is needed, i.e. take into consideration the existence of 
concentration gradients in stem cell niches will help to understand their 
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impact on stem cells’ fate decisions. Although not tackled in this thesis, the 
development of high-throughput technologies combined with the 
implementation of genomic and proteomic characterization tools will be an 
important approach to test different identities/combinations/relative levels of 
nutrients/factors and to analyze the resulting effects on cell phenotype and 
function (Kirouac et al., 2009; Liu et al., 2009; Bushway et al., 2006). Such 
combined approach may pave the way for further improvements to the 
existing expansion strategies, enhancing cellular metabolism by the 
addition of specific nutrients/aminoacids, or to differentiation processes, by 
the addition of induced factors. Using stirred tank bioreactors with 
automated perfusion, the exchange of culture media and/or addition of 
soluble factors (e.g. growth factors, cytokines and small molecules) may be 
programmed and performed in a safe operation management, respecting 
GMP guidelines. 
1.1.2. 3-D culture strategies for stem cell bioprocessing: what 
to choose? 
Given the importance of cell-cell and cell-matrix interactions on stem cell 
fate decisions (apoptosis, self-renewal, differentiation) (Azarin et al., 2010; 
Chayosumrit et al., 2010; Sommar et al., 2010; Wang et al., 2009) different 
3-D culturing strategies were explored in this thesis.  
In aggregate cultures, cells can re-establish mutual contacts and specific 
microenvironments that allow them to express a tissue-like structure, 
ultimately enhancing cell differentiation and functionality (Burdick et al., 
2009; Lund et al., 2009; Pampaloni et al., 2007). Using this 3-D approach, 
we were able to improve significantly neuronal differentiation process of 
NT2 cells by increasing the differentiation efficiency and reducing the time 
needed for differentiation process. At the end, this culturing strategy yields 
higher amounts of NT2-N neurons with increased purity, as compared with 
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those routinely obtained using static cultures (Pleasure et al., 1992) 
(Chapter 3).  
Although efficient for expansion and differentiation of NT2 cells, this 
strategy was unfeasible for the production of undifferentiated rPSCs and 
hESCs, where cells (and aggregates) clumped together and did not 
proliferate (Chapters 2 and 6). This profile can be explained by the increase 
in aggregate size, which may limit the diffusion of nutrients, growth factors 
and gases within aggregates thereby compromising cell viability and 
promoting spontaneous differentiation. Further improvements may be 
considered to better control aggregate size by employing different agitation 
rates (Cormier et al., 2006; Moreira et al., 1995), using different impeller 
designs (Singh et al., 2010) and performing repeated enzymatic 
dissociation steps (Krawetz et al., 2009; zur Nieden et al., 2007).  
One method to overcome cellular aggregation in stirred tank bioreactors is 
to utilize microcarriers to support cell growth. A vast range of microcarriers 
is currently available (composed by different materials and surface types), 
in order to allow the culture of different anchorage-dependent cell types in 
stirred suspension conditions. The selection of the microcarrier type should 
be performed according to stem cell type (size, morphology, clonal 
efficiency) and process requirements (expansion, differentiation, cell 
harvesting). Concerning rPSCs, a more efficient cell adherence and 
proliferation was obtained using Cytodex 3 microcarriers, which may be 
explained by the better adhesion of stem cells to the collagen layer that 
covers the surface of the microcarriers (Chapter 2). However, for the 
cultivation of hESCs, these microcarriers should be further functionalized 
with compounds of the extracellular matrix (presented in Matrigel, a 
complex xenogenic basement membrane matrix) to improve cell 
attachment and expansion (Chapter 5). The presence of non-defined and 
animal origin components in the Matrigel matrix, is a major concern for 
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clinical application of this technology. Future studies should be focus on the 
development of well defined, GMP compliant and xeno-free matrices for the 
cultivation of hESCs on microcarriers. 
Another advantage of microcarrier technology in cell expansion processes 
is the flexibility to adjust easily the area available for cell growth, which 
further facilitates the process scale-up. From clinical/industrial perspectives, 
this feature has a tremendous impact in reducing the costs of cell 
manufacturing by reducing the amount of media, growth factors and other 
expensive supplements required in stem cell cultivation (Fernandes et al., 
2009). However, this approach also exhibits some disadvantages, including 
harmful and unknown effects of shear stress, microcarrier clumping as well 
as additional operating cost associated to the use microcarriers and the 
incorporation of additional downstream processes to separate cells from 
the supports.   
Finally, it was also demonstrated herein that cell microencapsulation in 
alginate is a valuable strategy to improve cell expansion in stirred tank 
bioreactors, since it ensures a shear stress free microenvironment and 
avoids excessive clumping of microcarriers or aggregates in culture 
(Chapter 6). This 3-D strategy is extremely attractive for use in large-scale 
bioprocesses, enabling tighter control of the culture and higher cell 
expansion yields than non-encapsulated cultures (improvement of 50%).  
In conclusion, the results presented in this thesis show that, so far, there is 
no optimal 3-D culture strategy capable of embracing all the applications of 
these cells. Each case faces unique challenges and evaluating them prior 
processing is crucial to decide on the appropriate method to be used. 
Nonetheless, it is suggested that cell aggregates strategy should be more 
appropriated for improving directed differentiation bioprocesses to enhance 
cell differentiation potential and cell functionality, whereas the use of 
microcarriers should be more suitable for controlling expansion of 
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undifferentiated stem cells. The combination of these approaches with cell 
microencapsulation strategy could be adopted not only to improve further 
expansion and/or differentiation bioprocesses but also to potentiate hESCs 
towards stem cell transplantation and tissue engineering applications 
(revised in (Murua et al., 2008)). The main benefit of cell encapsulation 
technology is the possibility of designing the scaffold environment with 
specific biomaterials to create tailored microenvironments that mimic stem 
cell niches (Burdick et al., 2009; Lund et al., 2009). Thus, the source and 
properties of the encapsulation material (i.e. elasticity, stability, 
permeability, biocompatibility and biosafety) should be selected taking into 
account the culture outcome, the final application and safety issues. In 
addition, the inoculum cell concentration and the microcarrier type/matrix 
are important process variables that should also be optimized in the design 
of 3-D culture approaches to ensure higher stem cell expansion and/or 
differentiation yields.  
It is important to highlight that the cultivation of stem cells in a 3-D 
approach is not straightforward, requiring exquisite cell culture expertise 
and the implementation of robust and sensitive characterization tools for 3-
D cell culture monitorization, but the resulting bioprocesses and novel stem 
cell-based applications should more than justify those efforts.  
1.1.3. Developing integrated bioprocesses for stem cells: a step 
forward towards clinical application 
The optimal stem cell bioprocess should be able to yield high stem cell 
production numbers, not by embracing traditional scale-up principles (for 
example, by the use of large scale bioreactors) but through process 
intensification, specialization and, more importantly, integration. 
Specifically, the establishment of systems capable of integrating stem cell 
inoculation, expansion, differentiation, harvesting and selection would 
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ultimately result in the scale-up of well differentiated cells to clinically 
relevant numbers. In fact, when incorporating both expansion and neuronal 
differentiation steps in an integrated bioprocess, the neuronal differentiation 
efficiency of NT2 cells was enhanced drastically, while the time needed for 
differentiation process was reduced; for a differentiation time of 23 days in 
the bioreactor culture a 10-fold improvement in yield was observed over the 
static culture protocols lasting 35 days (Chapter 4). This strategy also 
assures the feasibility of expanding human differentiated neurons derived 
from a continuous source of pluripotent stem cells. This integrated 
bioprocess could upstream the application of NT2 cell derived neurons in in 
vitro toxicology, drug screening and cell therapy applications since these 
cells have been successfully used in neurotoxicity and development 
neuronal toxicity studies (Hill et al., 2008) as well as in transplantation 
experiments using mouse models and human stroke patients (Kondziolka 
et al., 2008). 
Another major challenge regarding the application of stem cells in the clinic 
is the production of stem cell banks of well‐characterized cells. Indeed, the 
development of integrated bioprocesses capable to guarantee efficient cell 
banking and distribution after large-scale expansion is still lacking. Such 
protocols must assure high cell survival, low differentiation rates and 
maintenance of pluripotency post‐thawing (Hunt et al. 2007) after 
expansion and cryopreservation. The results obtained in Chapter 6 show 
that, cell microencapsulation in alginate is a powerful tool to integrate 
expansion and cryopreservation of pluripotent hESCs. Moreover, the 
combination of cell microencapsulation with microcarrier technology 
promotes cell-cell and cell-matrix interactions that are essential for the 
efficient production and storage of hESCs without compromising their 
viability, self-renewal and pluripotency.  
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One of the main requirements in the development of integrated 
bioprocesses is to settle an appropriated culture time point for the 
incorporation of a directed differentiation or cryopreservation step. In both 
strategies developed in this thesis, cells were differentiated or 
cryopreserved at the middle of the exponential growth phase since the 
stem cell population presented high cell viabilities and high percentages of 
undifferentiated and pluripotent cells.  
Although important achievements were obtained in this thesis in what 
concerns bioprocess integration, further investigations should be 
performed. Indeed, the development of a fully integrated bioprocess for 
expansion, differentiation and cryopreservation of stem cell derivatives will 
clearly support autologous stem cell therapies where is often difficult to 
predict patient’s recovery and availability for injection. Such approach could 
also be advantageous for the development of clinically compatible iPSC 
banks for meeting cell therapy needs of the entire world population; the 
main focus of the “HaploBank project” is to collect samples from 
haplotypically homozygous donors (for HLA-A, -B and –DR) and implement 
GMP technology for derivation of iPSC lines, cryopreservation and 
differentiation into specific therapeutically relevant cell phenotypes. 
1.2. Process and product characterization: establishing methods to 
quantify bioprocess yields and assess product’s quality  
Due to the lack of accurate, validated methods for quantitative 
characterization of stem cell expansion and differentiation processes, 
analytical tools were established for evaluation of bioprocess yield as well 
as to access end product’s quality. 
As a starting point, cell growth profiles were evaluated by determining the 
cell concentration, apparent growth rates and expansion ratios (or fold 
increase in cell concentration). The analysis of cell viability during 
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expansion process was performed through qualitative assessment of 
membrane integrity and apoptosis, and by the quantitative measure of 
metabolic activity using the alamarBlue assays which, contrary to other 
probes (e.g. MTT), allows the assessment of the same cell culture 
repeatedly over a nearly unlimited time period (Chapter 6). The specific 
consumption rate of nutrients and oxygen and the production of metabolites 
were also estimated to analyze metabolic performance of the cultures 
(Chapters 2, 4 and 5).   
The development of sensitive assays to detect residual undifferentiated and 
aberrant stem cell populations is imperative to validate reproducible stem 
cell bioprocesses. Functional assays should also be implemented to 
determine the quality and potency of the final cell products. In this thesis, 
the undifferentiated character of stem cell populations was evaluated by the 
detection of specific stem cell markers, using a combination of analytical 
tools (immunofluorescence microscopy, flow cytometry, qRT-PCR). In 
addition, the self-renewal ability of adult stem cells was confirmed by 
evaluating telomerase activity (Chapter 2).   
Further analyses were carried out to evaluate the differentiation potential of 
stem cells during and after expansion, including directed differentiation into 
adipocytes (Chapter 3) or neuronal cells (Chapter 4). Since hESCs can 
differentiate spontaneously and lose their pluripotent potential when 
cultivated in 3-D approaches, methods to evaluate the effect of the 
expansion process on hESC pluripotency were performed (via formation of 
EBs and teratomas) (chapters 5 and 6). In addition, analysis of cell 
karyotype should also be carried out to confirm maintenance of normal 
human chromosome status during long-term culture. These assays are 
currently being done in collaboration with IPO (Lisbon) as they require 
exquisite methodologies.  
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The neuronal differentiation of NT2 cells was monitored by the detection of 
neuronal markers (Chapters 3 and 4). For a better assessment of 
neurons/neurosphere functionality, studies on spontaneous electrical 
activity (Hartley et al., 1999), and synthesis, storage and release of 
neurotransmitters (Pleasure et al., 1993; Yoshioka et al., 1997; Guillemain 
et al, 2000) should also be performed. However, due to time limitations 
these techniques were not pursued further.  
In summary, a combination of assays was established to analyze stem cell 
culture status during expansion and neuronal differentiation. These were 
designed to allow the assessment of product quality and quantification of 
process yield. Moreover, the importance of evaluating proliferation, 
maintenance of cell phenotype and differentiation potential during long‐time 
culture was confirmed, which is a fundamental requirement for further 
cell‐based applications.  
The development of novel high-throughput methods allowing for a better 
characterization of metabolism, of cell genomics and proteomics and 
understood cell biology is still needed. The insufficient data available in this 
field strongly compromises and limits the application of worldwide 
recognized tools for bioprocess description and prediction - mechanistic 
models - that would be extremely useful for understanding how stem cells 
respond to specific cues with the ultimate goal of predicting key molecular 
interactions that impact cell fate (Kirouac et al., 2010).  
From an engineer point of view, the development of a fully automated and 
robust production platform requires the integration of novel technologies to 
monitor and control not only a set of process parameters (e.g. pH, pO2, 
temperature, nutrients, agitation and perfusion rate) but also cell viability, 
phenotype and functionality throughout the culture process. Therefore, 
significant benefits would derive from implementing sophisticated sensing 
and monitoring devices within the manufacturing system. The traceability, 
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efficacy, safety and quality of the process itself would be highly improved 
creating defined and robust GMP platforms to deliver safe and efficacious 
cell therapies. 
 
2. LOOKING AHEAD 
The generation of novel and more efficient 3-D culture systems are now 
more than ever, bringing stem cells to clinic and industry applications. 
Nonetheless, several hurdles are still delaying a straightforward 
implementation of these systems. 
 An important challenge in stem cell bioprocessing is to achieve sufficient 
numbers of stem cell for clinical applications. In this thesis, the expansion 
and/or differentiation of stem cells in a 3-D strategy, using stirred tank 
bioreactors, yielded cell concentrations ranging from 0.2×106 cell/mL to 
3×106 cell/mL (Table 7.1). Therefore, the production of 0.1-10 x109 cell-
based products for personalized cell therapy would require bioreactors with 
working volumes of few hundred millilitres to a few litres, although issues 
related to the respective efficiencies of differentiation and downstream 
process yields (e.g. for purification and selection of a specific cell type, for 
cell-microcarrier separation) should be considered as well. 
Table 7.1. Maximum concentration achieved for each cell-based 
product investigated in this thesis. 
Cell-based product Maximum cell concentration  
rPSCs 0.2 ×10
6
 cell/mL  (Chapter 2) 
NT2 cells 1.8 ×10
6
 cell/mL (Chapter 4) 
NT2-N neurons 0.2 ×10
6
 cell/mL (Chapter 3) 
hESCs 3.0 ×10
6
 cell/mL (Chapter 6) 
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From a clinical perspective, further improvements are still required including 
the adaptation to defined xeno-free culture conditions. There are now well 
researched chemically defined alternatives available that promise to meet 
this goal. Another concern is the persistence of undifferentiated stem cells 
that may form malignant tumors when transplanted in the host (Fujikawa et 
al., 2005). Therefore, additional efforts will be necessary for the 
implementation of more efficient methods for differentiation and purification 
of specialized cells (Brignier et al., 2010), and for the development of a fully 
integrated bioprocess for the expansion, differentiation, purification and 
storage of stem cell derivatives.  
 Finally, the complexity involved in the 3-D cultivation of stem cells in 
controlled bioreactors requires a multidisciplinary approach. By combining 
biology, engineering, physics and material sciences, stem cells-based 
products will be, for sure, more accessible in the near future. Furthermore, 
the development of mathematical models and biostatistics tools capable to 
predict the outcome of stem cell bioprocesses (yields of stem cell 
expansion/differentiation, percentage of cell contaminants, etc.) or to give 
some insights how end products’ quality and purity would impact on the 
efficacy of stem cell transplantation will be outstanding for the design of 
novel stem bioprocesses and promising cell-based therapies.   
 
3. CONCLUSIONS 
This thesis presents robust and scalable strategies for expansion and 
differentiation of challenging stem cell‐systems, some of each allowing for 
the establishment of integrated bioprocesses in which cells may be 
expanded, differentiated or cryopreserved in an efficient and 
straightforward manner. The results presented herein show that there is no 
“optimal/universal” stem cell-based bioprocess capable of embracing all the 
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applications of these cells. Nonetheless, the knowledge gained herein, in 
which the quantitative characterization of stem cell expansion and 
differentiation processes is included, provides important insights for the 
implementation of “more universal” stem cell production platforms, 
hopefully contributing to potentiate the implementation of novel stem cell-
based therapies.  
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